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i 
G -VERAL SUPZTARY 
Investigations have been carried out in three separate areas 
of research related to epilepsy. 
I. In the first of these investigations an attempt was made to 
clarify a possible role of folic acid derivatives in epilepsy. 
This investigation took the form of two self- contained studies 
involving dogs. 
A. The first study concerned the effects of anticonvulsant 
treatment on 
(a) folate activity in cerebrospinal fluid (c.s.f.). 
(b) the concentrations of 5- hydroxyindol- 3- ylacetic 
acid (5 -HIAA) and hornovanillic acid (HVA) in c.s.f. 
Routine sampling of ventricular and cisternal c.s.f. 
in the dog was achieved by the implantation of permanent 
guide tubes to the lateral ventricle and the cisterna magna. 
5 -HIAA and HVA in c.s.f. samples were estimated by fluores- 
cence assay techniques. Folate activity in c.s.f. and 
plasma samples was estimated microbiologically with a folate- 
dependent strain of 1. casei. 
In control studies the c.s.f. folate activity was found 
to be between 2 and 7 times higher than the plasma folate 
activity. A positive correlation was found between c.s.f. 
and plasma folate activities. HVA and 5 -HIAA studies con- 
firmed the concentration gradient which exists for these two 
1] - 
acids between the lateral ventricular c.s.f. and the 
cisternal c.s.f. 
Selected anticonvulsant drugs (diphenylhydantoin, 
7.5 mg/kg; phenobarbitone, 15 mg/kg; sulthiame 15 mg/kg; 
carbamazepine 15 mg /kg) were administered daily to the dogs 
for a period of five weeks. During this Period no change 
was seen in the folate activity of either c.s.f. or plasma. 
The anticonvulsants were also without effect on the concentra- 
tions of HVA and 5 -HIAA in c.s.f. 
These findings are discussed in relation to the folate 
deficiency states produced in man by chronic anticonvulsant 
therapy. 
B. The second study in the folate investigations was 
concerned with the effect of oral folic acid administration 
(a) folate activity in plasma, plasma ultrafiltrate 
and c.s.f. 
(b) the concentrations of HVA and 5 -HIAA in the c.s.f. 
During the control period of this study no correlation 
was found between c.s.f. and plasma folate activity, such as 
was found in the first study. Possible reasons to account 
for this discrepancy are discussed. Estimation of folate 
activity in plasma and plasma ultrafiltrate confirmed that 
much of the f olate activity in dog plasma is protein- bound. 
Folic acid (31 mg/kg) was administered daily to dogs 
over a 5 -week period. During this treatment period the 
mean plasma folate activity was 10 times higher than normal; 
plasma ultrafiltrate folate activity was 5 times higher the 
normal; but c.s.f. folate activity was unchanged. These 
findings were interpreted as evidence for an increased plasma 
level of a folate derivative, probably folic acid itself, 
which was more strongly bound to protein than normal plasma 
folate derivatives, and was unable to enter the c.s.f. In 
two experiments in the rabbit no evidence was found for the 
active transport of methyl -tetrahydrofolate (normally the 
predominant form of folate in the plasma) into the c.s.f. 
HVA and 5 -HIAA concentrations in the c.s.f. were unaltered 
during the period of folic acid treatment. It was concluded 
that oral folic acid administration is unlikely to have any 
significant effect on normal cerebral function. 
The implications of this study are discussed in relation 
to 
(a) the role of folic acid derivatives in epilepsy 
and mental illness. 
(b) the mechanisms responsible for the normal distri- 
bution of folate activity between c.s.f. and plasma. 
II. The second investigation concerned the effects of barbiturate 
anaesthetics and anticonvulsant drugs on the c.s.f. potassium 
fluxes of the conscious dog. 
- iv - 
A new technique was developed for "open" perfusion of the 
cerebroventricular system of the conscious dog. The dog was 
perfused from lateral ventricle to cisterna magna with artificial 
r 
c.s.f. containing inulin, and tracer amounts of 42K. K, total 
potassium and inulin assays were performed on the inflow and out - 
flow fluids. From this data it was possible to calculate, for 
each sample of outflow fluid collected, values for both the pot- 
assium efflux from, and the potassium influx into, the c.s.f. 
After a period of between 65 -100 minutes of perfusion a "steady - 
state" was reached in which the potassium fluxes, as measured by 
this technique, were relatively constant. Drugs actions were 
studied by administering the drug during the "steady- state" period 
and ascertaining the effect upon the "steady- state" potassium 
fluxes. 
It was shown that - 
(1) The barbiturate anaesthetics, sodium pentobarbitone and 
o 
sodium thipentone, in doses sufficient to induce light 
anaesthesia, may depress both potassium influx into, and 
potassium efflux from c.s.f. Both fluxes were affected 
equally on any one occasion. Flux alterations of up to 
50% were observed. 
(2) Diazepam has a consistent depressant effect on the 
potassium fluxes of the c.s.f. This effect was less marked, 
but more consistently observed, than in the case of the 
barbiturate anaesthetics. 
- v - 
(3) Diphenylhydantoin has no significant effect on potassium 
efflux from the c.s.f. but may have a slight depressant 
effect on potassium influx into the c.s.f. 
(4) Paraldehyde in a dose sufficient to induce light 
anaesthesia slightly increases the c.s.f. potassium fluxes. 
These results are discussed in relation to 
(a) previously published studies on c.s.f. potassium 
fluxes in anaesthetised animals 
(b) possible mechanisms of action of these drugs. 
The effects of the barbiturate anaesthetics and diazepam were 
interpreted as being secondary to a decrease in potassium exchange 
between brain intracellular and entracellular compartments. 
It was concluded that the anaesthetic or anticonvulsant 
action of a drug is not related to the drug's effect on c.s.f. 
potassium fluxes. 
III. The third investigation concerned the development and pre- 
liminary application of a method for the analysis of GABA and 
associated amino acids in small areas of tissue from the primary 
and secondary epileptic foci of rats with a cobalt- induced epilep- 
togenic lesion. 
The existing specific enzymic methods for GABA analysis were 
examined and found to be either too insensitive or too complex to 
act as suitable micro- methods. The standard techniques for amino 
acid analysis, involving column separation and colori_.letric esti- 
mation were also considered to be too insensitive. 
- vi - 
Reaction of the amino group of amino acids with 1- dimethyl- amno- 
napthalene-5- sulphonyl chloride (dansyl chloride) produces stable, 
highly- fluorescent derivatives which can be readily separated by 
thin -layer chromatography. 
A highly sensitive isotope dilution assay, based on the pre- 
paration of dansyl derivatives, was evolved for the estimation of 
free amino acids in brain tissue. 
The tissue was homogenised in perchloric acid and known amounts 
of 14C -amino acid standards were added to an aliquot of the per- 
chlorate extract to act as internal standards for recovery of 
amino acid through the method. The extract was then taken to pH 
9.3 - 9.8 with potassium carbonate solution, precipitating per- 
chlorate as its insoluble potassium salt. An aliquot of the 
alkaline extract was dansylated with an equal volume of H3- dansyl 
chloride in acetone. After a 30 minute reaction period the 
dansylation mixture was taken to dryness and extracted with acetone: 
glacial acetic acid solution (3:2). An aliquot of this extract 
was applied to a polyamide micro- chromatography plate which was 
then developed in two dimensions. Under u.v. light specific 
dansyl -amino acid spots were identified by their characteristic 
position on the developed plate. These spots were cut from the 
plate and counted for 3H and 14C activity in a liquid scintillation 
counter. 
The total amount of dansyl -amino acid in a spot was calculated 
from its 3H activity. Combining this figure with the 14C activity 
of the spot allowed calculation of the specific activity (w.r.t. 
1¢C) of the dansyl -amino acid in the spot. Comparison of this 
specific activity with the specific activity of the 14C -amino acid 
standard which had been added as a recovery standard gave a measure 
of the dilution of exogenous radioactive amino acid by endogenous 
non -radioactive amino acid. From this dilution factor it was 
possible to calculate the concentration of endogenous amino acid 
in the original perchlorate extract of brain tissue. Determina- 
tion of the weight of protein precipitated from the tissue sample 
by the perchloric acid extraction allowed calculation of the amino 
acid content of tissue in terms of }moles amino acid per 100 mg 
protein. 
The two dimensional chromatography did not achieve a separation 
of dansyl -glutamine and dansyl -threonine; as a result glutamine 
and threonine were estimated as the sum total of their two 
concentrations. 
The method was applied to the estimation of control values 
for GABA, glutamate, glutamine/threonine, glycine, aspartate and 
hydroxyproline levels in rat cortex. The values obtained for 
GABA, glutamate, glutamine /threonine and glycine were highly re- 
producible and in good agreement with previously published values. 
Aspartate was not satisfactorily estimated. Hyroxyproline was 
not detected in rat cortex. 
The dansylation method was applied to the analysis of brain 
tissue from three rats with 11 day -old cobalt- induced epileptogenic 
-viii - 
lesions in the frontal cortex. There was evidence that GABA and 
glutamate levels were lowered, and glutamine/threonine and glycine 
levels raised, in the region of the secondary epileptogenic 
( "mirror ") focus. This was the site from which epileptiform spike 
discharges were most frequent. 
The significance of these findings have been discussed along 
with general comments on the problems of amino acid studies in 
brain. It was concluded that disorders in amino acid metabolism 
may be involved in epileptic processes. 
1 
GENERAL INTRODUCTION 
Epilepsy has long been, and continues to be, one of the 
most challenging problems in the field of medicine. Man's 
efforts to cure this affliction may indeed date back to the 
stone age, if, as has been conjectured, evidence of successful 
trepanning in skulls from the Neolithic period indicate early 
attempts at a remedy. The first scientific work on epilepsy 
was a treatise "On the Sacred Disease" written in Greece in 
450 B.C. This early text, which has been attributed to 
Hippocrates, criticised the belief, then popularly held, that 
epilepsy was a supernatural possession of the body by devils and 
proposed that it wasyrather, a hereditary disease of the brain. 
A distinction was also drawn between epilepsy occurring in the 
absence of any particular aetiological factors, sometimes 
referred to as idiopathic epilepsy, and symptomatic epilepsy 
occurring in the presence of an obvious cause such as a head 
injury or a fever. Here also we find the first mention of the 
aura which often precedes a seizure, and of the influence of 
such factors as age and temperament upon the nature of the 
epilepsy. 
In the succeeding two thousand years little was added to 
the Hippocratic concepts of epilepsy and indeed, not until the 
work of John Hughlings Jackson in the nineteenth century do we 
find a satisfactory physiological explanation of the disease. 
After careful clinical examination of certain localised types 
- 2 - 
of seizure (now named Jacksonian), Jackson proposed that epilepsy 
resulted from occasional, sudden, excessive, rapid and local 
discharges of the grey matter of the brain. With the later 
introduction of techniques to measure the electrical activity 
of the brain (electroencephalography and depth electrode 
recording) this hypothesis has been fully confirmed. 
A modern concept of epilepsy, or more correctly the 
epílepsies, is of a symptom complex characterised by recurrent, 
paroxysmal aberrations of brain function, usually brief and 
self- -limited. These aberrations in function result from 
abnormal neuronal activity of the type proposed by Jackson, but 
the exact physiochemical mechanisms involved in the production 
of the epileptic neuronal activity are not known. It is assumed 
that the basic fault is some structural or functional pathological 
process in the brain. In many cases one can demonstrate a 
discrete epileptic focus with an organic lesion, as in epilepsy 
following haemorrhagic or ischaemic damage to the brain tissue, 
or in epilepsy due to a brain tumour. In other cases no 
obvious organic lesion can be demonstrated (cryptogenic or 
idiopathic epilepsy) but even in many of these cases an organic 
defect may be suggested by inheritance of the disease. 
From an epileptic focus of electrically unstable neurones 
the epileptic discharge can spread to normal neural tissue 
producing synchronous, paroxysmal discharges of large groups of 
neurones. When this happens a clinical seizure ensues. The 
3 
type of clinical seizure pattern which is observed depends 
little on the original cause of the epileptic focus but rather 
on the anatomical location of the focus and on its pattern of 
recruitment of normal neurones. } 
Apart from the mechanisms responsible for the generation of 
an epileptic focus there are a number of general physiological 
factors which affect the type and frequency of clinical seizure 
produced. These factors may be considered in terms of their 
producing an increase or decrease in seizure threshold. 
Genetic predisposition is an obvious factor in many types 
of human epilepsy. In animals it has been possible by 
selective breeding to produce certain strains which have a much 
reduced seizure threshold to stimuli such as flickering lights 
or loud noises. Age and cerebral maturation are also important 
factors. For instance febrile convulsions occur almost entirely 
in children below the age of five. The occurrence of petit mal 
is also linked to age, most cases occurring betweenthe ages of 
four and eight. In some laboratory animals electroshock seizure 
threshold is high at birth and decreases as the brain matures. 
The decrease in electroshock threshold correlates well with an 
increase in carbonic anhydrase activity in the brain but this is 
only one of many changes occurring during cerebral maturation. 
Seizure threshold is also highly dependent on the energy 
supply to the brain. If this is reduced, as in hypoglycaemia, 
there is a sharp decrease in seizure threshold. Hypoxia has a 
4 
similar effect. Severe anoxia on the other hand increases 
seizure threshold, presumably by limiting any kind of neuronal 
activity. 
A drop in 002 tension in the blood reduces seizure threshold 
(hyperventilation is a recognised way of stimulating seizures in 
epileptic patients) while an increase in 002 tension increases 
seizure threshold. This latter action may be responsible for 
the anticonvulsant effect of carbonic anhydrase inhibitors. 
Diet can also influence epilepsy and it has been found that 
a ketogenic diet (high in fat, low in carbohydrate) increases 
seizure threshold. Disorders in water and electrolyte balance 
produce alterations in seizure threshold, both water intoxication 
and hyponatraemia tending to induce convulsions, and water 
deprivation tending to depress them. Hormonal factors can also 
influence brain excitability. Adrenal cortical insufficiency 
decreases, while deoxycorticosterone increases,siezure threshold. 
Corticotrophin also increases seizure threshold and has been 
successfully used to alleviate some types of epilepsy. Thyroid 
hormones increase brain excitability firstly by a direct stimulant 
effect on the central nervous system and secondly by an indirect 
effect on the adrenal cortex. Many of these changes in seizure 
threshold produced by hormones may be secondary to changes in 
electrolyte and water balance. 
From this short introduction it is obvious that many 
different pathways and systems are involved in epilepsy and in 
this thesis we have attempted to isolate and study three 
5 
different mechanisms which have been implicated in the aetiology 
or control of this common disease. The three subjects studied 
were the role of folic acid derivatives in epilepsy; the effect 
of anticonvalsant drugs on potassium transport in the brain; 
and amino acid changes in a model epileptogenic focus. 
6 
SECTION I 
FOLIC ACID METABOLISM AND ANTICONVtLSANTS 
- - 
INTRODUCTION 
The Identification and Estimation of " Folate" 
Since the first recognition in the 1930's of an unidenti- 
fied growth factor which was required by animals (Wills and 
Stewart, 1935; Day, Langston and Darby, 1938; Hogan and 
Parrot, 1939; Stokstad and Manning 1938) and certain micro- 
organisms (Snell and Peterson, 1940; Mitchell, Snell and 
Williams, 1941) there has been an ever increasing awareness of 
the variety and complexity of the involvement of the folic acid 
coenzymes in general metabolism. The present state of this 
field of study has been splendidly reviewed by Stokstad and 
Koch (1967) and Chanarin (1969), and it is also the subject of 
a very comprehensive monograph by Blakely (1969). This intro- 
duction is only a brief sketch of the relevant background and 
for more detailed information the reader is directed to these 
excellent sources. 
The parent substance, folic acid (Fig. 1:1), is itself not 
biologically active and it is the dihydro or tetrahydro deriva- 
tives which actually function as coenzymes in a wide range of 
reactions, principally in the field of one -carbon transfer 
metabolism. Fig. 1:2 illustrates the various forms of folate 
which are known to occur in biological material and indicates 
some of the relationships between them. Fig. 1:2 also lists 
some of the compounds which provide one- carbon fragments for 
the folate coenzymes and some of the compounds in whose synthesis 
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FIG. 1:2 Metabolic interconversions of folic acid derivatives 
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one -carbon units from folate coenzymes have played an essential 
part. The picture presented by Fig. l:2,complex though it is, 
is further complicated by the fact that most of the folate in 
biological samples is not present in a simple form, but is 
linked, through peptide links at the ' position of the 
glutamate moiety, to further glutamate residues. Such poly - 
glutamate conjugates make up the bulk of folate derivatives in 
the liver (Noronha and Silverman, 1962; Bird, McGlahon and 
Vaitkus, 1965) and the red cell (Noronha and Aboobaker, 1963). 
The work of Wright (1958) demonstrated that in some 'in vitro' 
situations these conjugates are active while the simple deriva- 
tives are inactive. 
It is possible therefore, that in one biological sample we 
might encounter folate derivatives differing from each other in 
three separate ways. Firstly they might differ in the number 
of covalently linked Y glutamyl residues, secondly in the 
nature of the substituents, if any, on the nitrogen atoms at 
positions 5 and 10, and finally in the state of oxidation of 
the pteridine nucleus. A further complication lies in the fact 
that most of the tetrahydro derivatives of folic acid are highly 
labile and when exposed to air they may be oxidised to a relatively 
stable form such as N5- forrnyltetrahydrofolic acid, or be oxida- 
tively cleaved to form a pterin and para- aminobenzoylglutamic 
acid. In order to prevent such interconversion or destruction 
it is necessary to protect the sample with a reducing agent such 
- 11- 
as ascorbate (Noronha and Silverman, 1962; Bird et al., 1965) 
or mercaptoethanol (Copenhaver and O'Brien, 1969). Once the 
labile folate derivatives in a sample have been protected from 
oxidation there still remains the critical problem of how to 
assay them. Although folic acid and its derivatives can be 
estimated colourimetrically after a diazotisation procedure 
(Hutchings, Stokstad, Boothe, Mowat, Waller, Angier, Semb and 
Subbarow, 1948; Glazko and Wolf, 1949) this method is not 
sensitive enough to assay the nanogram amounts of folate found 
in a millilitre of c.s.f. or plasma, nor does it give any indi- 
cation which derivatives are present. Allfrey, Tepley, Geffen 
and King (1949) reported a fluorimetric method for the assay of 
folic acid in plant and animal tissues but it also is lacking in 
sensitivity and specificity. More recently Netrawali, 
Radhakrishnamurty and Sreenivasan (1964) were successful in 
using a fluorimetric method to measure the endogenous levels of 
5- formyl tetrahydrofolate in tissue. The studies of Uyeda and 
Rabinowitz (1963) would certainly suggest that once extraction 
and separation techniques have been improved there would be 
considerable potential in final fluorescence assay procedures. 
Udenfriend (1969) has recently reviewed this subject. 
At the present moment however the only assay technique with 
the necessary sensitivity and specificity is microbiological 
assay. Table 1.1 shows the various test micro -organisms which 
have been used to assay folate and their specificities in terms 




L.caseii S.faecalis P.cerevisiae 
folic acid + 
dihydrofolic acid (DHF) + + - 
tetrahydrofolic acid (THF) + + + 
5-f ormylTHF + + 
10- formylTHF + + + 
5- methylTHF + 
folylglutamate + + - 
folyldiglutamate + - - 
folylhexaglutamate - - - 
MID 
1110 411M 
+ = a response at least 50% of the maximum 
= a response less than 5% of the maximum. 
of sensitivity to the different forms of folate. Unfortunately 
the different growth responses of these bacteria to different 
folate derivatives are not of an "all or none" nature and there - 
forecannot be used for the absolute determination of one deriv- 
ative in the presence of one or more of the others. Neverthe- 
less differential assay before and after treatment of the sample 
with a 'conjugase' enzyme preparation is a technique of consider - 
ab le value; and it was by this means that Herbert, Larrabee and 
Buchanan (1962) were able to show that most of the folate 
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activity in the serum was in the form of the methyltetrahydro- 
folate derivative. The 'conjugase' treatment consists of 
treating the sample with an enzyme preparation containing Y 
glutamyl carboxypeptidase, an enzyme which is capable of 
splitting off glutamate residues from folylpolyglutamate con- 
jugates to give either simple folates or at least lower order 
polyglutamates. This is a necessary procedure prior to total 
folate assay since, as Table 1.1 indicates, the three commonly 
employed test organisms are incapable of utilising high order 
folylpolyglutamates. Wolff, Drouet and Karlin, (1949) demon- 
strated that plasma itself contained such a peptidase and it has 
been found in many other animal tissues, invertebrates, plants 
and bacteria. A detailed review of the peptidases occur,énce and 
characteristics is included in the relevant chapter of Blakely 
(1969). 
Therefore it can be seen that to estimate the total folate 
L 
content of a sample with such an organism as xactobacillus casei' 
L 
( /.casein), it is first necessary to ensure that any derivatives 
witA more than two extra glutamate residues are degraded by 'con - 
jugase' treatment to simpler forms (see Table 1.1). Further 
sophistication to examine the individual derivatives separately 
is possible by two means. Firstly, as was mentioned earlier, 
the sample may be analysed before and after 'conjugase' treat- 
ment, with the three different bacterial strains, Icase14, 
s.faecalis and p.cerevisiae. On three counts however this 
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technique is far from perfect. Firstly it gives us no inform- 
ation on the amounts of polyglutamate fractions of various 
chain lengths. Secondly the differential responses are far 
from absolute; and for some forms, e.g. formyltetrahydrofolate, 
there is no differentiation at all. Thirdly there has been a 
suspicion that some of the conjugase preparations themselves 
contain contaminating folate. 
The second way in which some sophistication can be brought 
into an examination of tissue folates is to carry out some sort 
of preliminary extraction and separation procedure. The pro- 
duction of a non- proteinaceous aqueous extract (usually by 
heating, followed by centrifugation) with the subsequent use of 
paper chromatography (Winsten and Eigen, 1950), or electrophoresis 
(Hillcoat and Blakely, 1964), or column chromatography with a 
substituted cellulose (Silverman, Law and Kaufman, 1961; Noronha 
and Silverman, 1962) has been the standard procedure. Once 
the various derivatives have been separated in this way they 
have been assayed microbiologically. These techniques however 
suffer from the disadvantage that they require relatively large 
amounts (milligrams) of folate to be present in the tissue samples 
being analysed. Copenhaver and O'Brien (1969) attempted to 
break away from the reliance on biological assay, using an ion 
exchange resin thin layer chromatographic technique followed by 
fluorimetric and colourimetric estimation procedures. 
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The final estimations however require microgram amounts of each 
derivative and it is therefore not readily applicable to assay 
of small amounts of folate, though as the authors point out it 
may be of considerable use in experiments involving radioactive 
tracer folates. 
It was against this background of complex and unsatisfactory 
assay techniques that we set out to examine in a fairly simple 
manner some aspects of folate metabolism, particularly the 
effects of anticonvulsant and folic acid therapies. 
SECTION lA: The Effect of Selected Anticonvulsants on 
(a) the Concentration of Folate in Cerebrospinal Fluid and 
Plasma and (b) the Concentration of Homovanillic Acid 
and 5- Hydroxyindol- 3- ylacetic Acid in Cerebrospinal Fluid. 
Introduction 
The first indication of a link between anticonvulsant 
therapy and folic acid metabolism came in 1952 with a report by 
Mannheimer, Pakesch, Reimer and Vetter (1952) that diphenyl- 
hydantoin might be the agent responsible for a case of megalob- 
lastic anaemia. Subsequent reports confirmed diphenylhydantoin 
therapy as the probable causal factor in certain other cases of 
anaemia (Hawkins and Meynell, 1954; Webster, 1954) and indicated 
that both primidone (Girdwood, 1956; Fuld and Moorhouse, 1956) 
and phenobarbitone therapy (Hawkins and Meynell, 1956; Hobson, 
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Selwyn and Mollin, 1956) could result in similar complications. 
From these early reports a characteristic pattern emerged. 
Serum vitamin B12 was normal in those patients in whom the test 
was done (Badenoch, 1954; Chalmers and Boheimer, 1954; Rhind 
and Varadi, 1954; Girdwood and Lenman, 1956) and the absorption 
of radioactively labelled vitamin B12 also appeared to be 
normal (Badenoch, 1954; Chalmers and Boheimer, 1954; Hawkins 
and Meynell 1958). The anaemias were, in the majority of cases 
refractory to cyanocobalamin (vitamin B12) therapy but responsive 
to oral folic acid therapy (Girdwood and Leaman, 1956; Hawkins 
and Meynell, 1958). These findings pointed to a folate defici- 
ency anaemia but surprisingly Girdwood and Lenman (1956) could 
find no evidence of malabsorption of folate after an oral dose 
of folic acid. Nor could they detect any abnormality in the 
clearance of folate from blood of the type normally found in 
folate deficiency states. They therefore suggested that an 
effective avitaminosis might be present because of competitive 
inhibition between the structurally similar anticonvulsants and 
folate coenzymes. While the exact relationship between anti - 
convulsants and folate metabolism remained a matter of speculation 
at this stage, the existence of such a link could no longer be 
doubted after the report by Hawkins and Meynell (1958). They 
found that about 40% of their patients on anticonvulsants 
displayed macrocytic changes in the red blood cells which dis- 
appeared after folic acid therapy. 
- 17 - 
The first direct evidence of an effect on folates came 
with the development of reliable serum folate assays (Baker, 
Herbert, Frank, Pasher, Hutner, Wasserman and Sabotka, 1959; 
Waters and Mollin, 1961), when low serum folates were found to 
be present in anticonvulsant induced anaemias (Kohn, Mollin and 
Rosenbach, 1961; Druskin, Wallen and Bonagura, 1962). Subse- 
quent large scale surveys of patients on anticonvulsant therapy 
(Klipstein, 1964; Reynolds, Milner, Matthews and Chanarin, 
1966) revealed sub- normal serum folates and macrocytic or 
megalob lastic changes in a substantial proportion of these 
patients. Klipstein found a correlation between macrocytosis 
and low serum folates in his group. On the basis of the 
accumulated Evidence it was proposed (Reynolds et. al., 1966) 
that the antifolate effects of the three drugs, diphenylhydantoin, 
primidone and phenobarbitone might be causally related to their 
therapeutic anticonvulsant effects, perhaps by reducing protein 
synthesis in the central nervous system. Certainly such a rela- 
tionship was in accord with the finding reported by Chanarin, 
Laidlaw, Loughridge and Mollin, (1960) of a patient with a drug - 
induced anaemia who rapidly developed 'status epilepticus' on two 
separate occasions when she was treated with folic acid. Also, a 
later report indicated an increase in fit frequency and severity in 
50% of patients on anticonvulsants who were treated with folic acid 
(Reynolds, 1967) . It should be stated that Hawkins and Meynell 
(1958) were of the opinion that folic acid had the opposite 
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effect in their group of patients. 
One effect of Reynold's hypothesis was to focus attention 
on the role of folates in the central nervous system; and in 
this context Herbert and Zalusky (1961) had reported that the 
folate activity of the c.s.f. was between one area a half and five 
times greater than that of plasma. The significance of this 
observation Jay in the fact that for many substances, the concen- 
tration in c.s.f. may closely reflect the concentration in the 
extraneuronal fluid of the brain (Dayson, 1961). If this were 
true for folate it would certainly suggest that folate was 
particularly important for normal functioning of the central 
nervous system. 
The first study on the effect of anticonvulsant therapy on 
c.s.f. folate activity, by Wells and Casey (1967), found signifi- 
cantly lowered c.s.f. folates in their group of patients but 
this finding was not confirmed by the study of Weckman and 
Lehtovaara (1969). However, independent extensive studies by 
Reynolds,Preece and Chanarin (1969) again found a convincing 
depression of c.s.f. folates in a group of patients on anti - 
convulsant therapy. 
The investigations to be reported in this section of the 
thesis were an attempt to clarify further the relationships 
between anticonvulsants and folic acid metabolism. Dogs were 
chosen as the experimental animal since, by use of techniques 
developed in this department it was possible to carry out routine 
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sampling of ventricular and cisternal c.s.f. The four different 
drugs selected for administration, diphenylhydantoin, pheno- 
barbitone, carbamazepine and sulthiame were chosen to represent 
the most important classes and structures of anticonvulsants. 
In this investigation we were also concerned to look at 
possible mechanisms by which a lowered folate concentration in 
the brain, or indeed interference with folate metabolism in 
the brain, might lead to an anticonvulsant effect. There is 
strong evidence that dopamine, noradrenaline and 5- hydroxy- 
tryptamine act as modulators of neuronal action in the central 
nervous system and it is possible that an alteration in the 
synthesis of these compounds could affect epileptic activity in 
the brain. It has been shown that both brain tyrosine hydroxylase 
and brain tryptophan hydroxylase utilise pteridine co- factors 
(Nagatsu, Levitt and Udenfriend, 1964; Gal, Armstrong and 
Ginsberg, 1966). Since these two enzymes are the rate limiting 
steps on the pathways leading to the formation of dopamine and 
5- hydroxytryptamine respectively, it is possible that any 
decrease in co- factor availability might bring about a reduction 
in synthesis of these amines. This was particularly relevant 
to the folate studies since the folates themselves are substituted 
pteridines; and Kaufman and Levenberg (1959) have demonstrated 
that, in a very similar hydroxylation system, tetrahydrofolate 
can substitute for the normal pteridine co- factor, albeit less 
efficiently. 
o- 
Another objective of the present work has therefore been 
to look at the effect of anticonvulsants on the turnover of 
dopamine and 5- hydroxytryptamine in the brain. The principal 
metabolites of dopamine and 5- hydroxytryptamine in the brain 
are respectively, homovanillic acid (HVA) and 5- hydroxyindol- 
3-ylacetic acid (5- HIAA). Since in the dog neither of these 
acid metabolites can enter c.s.f. from the blood (Ashcroft, Dow 
and Moir, 1968; Guldberg and Yates, 1968) it seems likely that 
the HVA and 5 -HIAA found in dog c.s.f. are derived from cerebral 
metabolism. More directly, in a variety of experimental situ- 
ations it has been demonstrated that the c.s.f. concentrations 
of these metabolites may reflect their concentrations in the 
brain itself (Moir, Ashcroft, Crawford, Eccleston and Guldberg, 
1970). However, c.s.f. levels of these metabolites depend not 
only on their raie of production in the brain, but also on their 
rate of transfer into the c.s.f., and on their transport from the 
c.s.f. into the blood. 
In the dog there is a gradient in the concentrations of 
both HVA and 5 -HIAA between ventricular and cisternal c.s.f. 
(Guldberg, Ashcroft and Crawford, 1966). This is caused by 
the removal of these acids from the c.s.f. by an active transport 
mechanism located probably in the 4th ventricular chiroid plexus 
(Ashcroft, Dow and Moir, 1968; Pullar, 1971 ). Any interpret- 
ation of c.s.f. data must therefore take account of the existence 
of this transport mechanism and the possible implications of 
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changes in its activity. Under conditions where the transport 
of HVA and 5 -HIAA remains unaltered, changes in the concentrations 
of these metabolites in the c.s.f. may be a simple way of 
detecting changes in the turnover of dopamine and 5- hydroxy- 
tryptamine in the brain (Moir et. al., 1970). We have there- 
fore measured these concentrations of UVA and 5 -HIGA in ventricular 
and cisternal c.s.f. of the dogs during the control p eriod and 
then during the period of administration of anticonvulsants. 
ANIMAL METHODOLOGY 
The animals used in these studies were pure bred adult 
Beagle dogs. This breed was found to be ideal from the point 
of view of both size and temperament. 
Operative Technique for the Implantation of Ventricular and 
Cisternal Guide Tubes. 
All necessary instruments, swabs and gowns were prepared 
and sterilised for the operation which was carried out under 
fully aseptic conditions. Food was withdrawn from the dog 16 
hours before the operation but water was not restricted. 
Anaesthesia was induced with an intravenous injection of 
sodium pentobarbitone (Nembutal, Abbot Laboratories) and the 
syringe and needle were taped into position to allow maintenance 
doses when necessary. The dog was then placed on the operating 
table in a prone position and a cuffed and armoured endotracheal 






A. CANNULA IN SECTION 
B. GENERAL VIEW OF CANNULA 
a.) Funnel of cannula 
b.) Stainless steel tube 
c.)Small collar 
d.) Horseshoe shaped plate 
C. VIEW OF CANNULA FROM ABOVE 
(diagramatic ) 
( Measurements in mm) 
o 25 
Fig.2 
GUIDE TUBE FOR LATERAL VENTRICLE 
IN DOG BRAIN (Sectional view ) 
a.) Part situated subcutaneously 
b.) Part screwed into skull. 
c.) Part inserted into brain,directed 
towards lateral ventricle. 
FIg.3 
LUER FITTING NEEDLE WITH SIDE 
HOLE 
a.) Stainless steel stilette. 
FIG. 1:3 Diagram of ventricular and cisternal guide tubes. 
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throughout the operation. The top of the dog's head and neck 
was then clipped and shaved and the area was swabbed, first 
with a 1% solution of cetavlon then with a dilute tincture of 
iodine. The assistant /anaesthetist then supported the dog's 
head, keeping the vault of the skull horizontal, and the 
operating area was delineated with four sterile towels. 
The first skin incision was made along the midline from a 
point 6 cm anterior to the external occipital protuberance to 
within 2 cm of the protuberance. The edges of the incision were 
retracted laterally and the temp oral muscle incised over the 
sagittal crest. With a periosteal elevator the muscle and 
connective tissue were worked away from the midline to expose 
the vault of the skull (Fig. 1:4). Two scalpel nicks were then 
made in the bone at points 8 mm out from the midline and 37 mm 
anterior to the external occipital protruberance. At each point 
in turn the bone was carefully drilled through with a hand drill 
(3 mm diam.), the hole tapped with a 3Ba tap, and the ventricular 
guide tube (Fig. 1:3) screwed firmly into place with a box 
spanner. To verify a successful placement a 21 gauge sterile 
needle was passed slowly down the guide tube until cerebrospinal 
fluid (c.s.f.) welled up into the cup of the needle (Fig. 1:4). 
This phase of the operation was completed by closing the sub- 
cutaneous fascia over the guide tubes with continuous interlocking 
suture of 3.0 chromic gut, and stitching up the skin with silk, 
using interrupted eversion mattress sutures. 
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FIG. 1 :4 Insertion of ventricular guide tubes 
(Top) Operative exposure prior to insertion of the guide tube. 
Temporal muscles retracted to expose the temporal bone. The 
notch made in the sagittal crest marks the coronal plane used. 
(Bottom) Guide tubes in place. The needle demonstrates that 
a free flow of c.s.f. can now be obtained from the lateral 
ventricle. 
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For insertion of the guide tubes to the cisterna magna 
(Fig. 1:3) the sterile towels were re -sited to expose the back 
of the skull and the neck, while the dog's nose was depressed 
by the assistant to bring the back of the head into the horizontal 
plane. An incision was then made in the skin starting 2 cm 
lateral to the midline at the level of the external occipital 
protruberance, and running caudally for 4 or 5 cm. This 
incision was retracted into the midline and the faint white 
nuchal ligament was located. This ligament and the underlying 
muscles were then incised longitudinally and retracted back from 
the midline by a self -retaining retractor. By careful blunt 
dissection the incision was deepened to expose the occipital bone 
from the external occipital protruberance right down to the 
atlanto -occipital membrane. This accomplished, the muscles and 
ligaments covering the external occipital protruberance were 
reflected with the periosteal elevator (Fig. 1:5). 
A full length cisternal guide tube was then cut back until, 
with the horse shoe- shaped plate fitting snugly round the external 
occipital protruberance, the foot of the tube, with its collar, 
just rested on the atlanto- occipital membrane at the point where 
it emerged from under the occipital bone. In some of the dogs 
the occipital bone was found to form a small lip over the membrane 
and it was necessary to drill a small hole (1 mm diam.) through 
this to allow the guide tube a direct approach to the membrane. 
When this procedure was adopted the small collar which was usually 
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FIG. 1:5 Insertion of cisternal guide tube 
(Top) Operative exposure prior to the insertion of the guide tube. 
The nuchal muscles have been split in the midline and retracted to 
expose the atlanto- occipital membrane and occipital bone. The 
occipital protuberance and adjoining region have been cleared of 
muscular attachment. 
(Bottom) Guide tube in place. The tip of the tube rests in a 
hole drilled in the lip of the occipital bone. The top bracket 
is screwed firmly to the occipital protuberance by three screws. 
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placed at the end of the tube was raised 2 mm so that it rested 
not on the membrane, but on the bone. 
After the length and positioning of the guide tube had been 
determined, it was held firmly in place by an assistant, rihile 
holes (1 mm diam.) were drilled through the plate into the bone 
of the external occipital protruberance. The holes were then 
tapped with an 8Ba tap and the plate firmly fixed to the skull 
with three stainless steel screws. Thus the tube was stabilised 
in position (Fig. 1:5) and since the correct siting could be 
verified by eye there was no need to carry out a test puncture. 
Finally the muscles were brought together in a continuous 
blanket suture with 3.0 chromic gut and a similar suture was 
employed to close the subcutaneous fascia over the guide tube 
funnel. The skin incision was closed with silk thread using 
interrupted everting mattress sutures. 
Sterile dressings were placed over the wounds and lightly 
bandaged into position, taking care not to obstruct the airway. 
The syringe containing the anaesthetic was removed from the vein 
and the endotracheal tube withdrawn. A special protective collar 
was placed over the dog's head to prevent its disturbing the 
bandages, and it was returned to a recovery kennel where the 
temperature was maintained at 2400, until it had recovered from 
the anaesthetic. To minimise infection the dogs were given 
prophylactic antibiotics (1 ampoule crystamycin (Glaxo) - 1,000,000 
units benzyl penicillin and 0.5 g streptomycin - intramuscularly 
once daily). 
Perhaps the best explanation of the operation is provided 
by Figs. 1:6, 1:7 and 1:8 which show various views of a dog's 
skull with the guide tubes and cannulation needles in position. 
Po erative 
Seven days after the operation the skin sutures were removed. 
If this proved in any way painful to the dog the procedure was 
carried out under light sodium thiopentone anaesthesia. The 
protective collar was left in place for a few days as a further 
precaution against the dog scratching the freshly healed wound. 
Four weeks after the operation, when all the tissue reaction 
had subsided, tests were carried out to verify correct placement 
of the guide tubes, and determine the lengths of needles required 
for cannulation of the ventricular and cisternal spaces. The 
dog was anaesthetised with intravenous sodium thiopentone and a 
21 gaue,e stainless steel needle was pushed through the skin of 
the dog's head and into one of the ventricular guide tubes. The 
needle was then slowly advanced down the guide tube and into the 
ventricle. Placement of the needle in the ventricle could be 
established by carefully withdrawing c. s. f. into a syringe under' 
slight negative pressure. The length of needle required to 
penetrate to the ventricle was noted and the needle was then with- 
drawn. A similar procedure was carried out for the other two 
guide tubes and subsequently a set of three appropriately cut 
needles was prepared for the sampling or perfusion of that 
particular dog. 
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FIG. 1:6 Guide tubes inserted into a dog skull (lateral view) 
An x -ray showing the ventricular system after an intraventricular 
injection of Myodil has been inserted into the appropriate 
position in the skull. The photograph demonstrates the position 
of the guide tubes and needles during perfusion. 
FIG. 1:7 Guide tubes inserted into a dog skull (posterior view) 
The posterior view demonstrates how the cisternal needle is held 
in position. In this case it has been necessary to drill 
through a lip of the occipital bone to allow the needle direct 
access to the atlanto- occipital membrane. 
FIG. 1:8 Guide tubes inserted into a dog skull (Superior view) 
The superior view demonstrates the positioning of the ventricular 
guide tubes and the method of fixation of the cisternal guide 
tube. 
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After a further two weeks the dog was considered to be 
ready for experimental use and it could be perfused up to once 
every two weeks or sampled two or three times a week. 
Drugs and Chemical Reagents Used in Animal Experiments 
Sodium thiopentone (Pentothal) Abbot Laboratories 
Heparin (1,000 i.u. /ml) Boots 
Diphenylhydantoin (Epanutin) Parke Davis 
Carbamazepine (Tegretol) Geigy 
Sulthiame (Ospolot) FBA Pharmaceuticals 
Phenobarbitone May and Baker 
Ascorbic acid B.D.H. 
ANIMAL and EXPERIMENTAL PROCEDURES 
4 adult male Beagle dogs with permanently implanted 
ventricular and cisternal guide tubes were used in these studies. 
Throughout the period of the experiment the dogs were kept on a 
standard batch prepared diet (Pedigree Chum, Petfoods Ltd.) and 
any sampling of body fluids was carried out between 09.30 and 
12.00 hours. 
Diphenylhydantoin (7.5 mg /kg /day), phenobarbitone (15 mg/kg/ 
day), sulthiame (15 mg/kg /day) and carbamazepine (15 mg/kg/day) 
were administered orally in tablet or capsule form at 09.00 and 
17.00 hours. The doses chosen were calculated to be equivalent 
on a weight basis to the doses used to control epilepsy in 
humans. 
After a period to establish control values for the para- 
meters being measured (folate activity in c.s.f. and plasma; 
HVA and 5 -HIAA concentrations in ventricular and cisternal 
c.s.f.), each of the dogs was put on one of the above drugs 
for a period of five weeks. 
Standard sampling procedure was as follows. First the dog 
was anaesthetised with a minimal amount of intravenous sodium 
thiopentone and laid on its side. A 21 gauge needle was then 
inserted percutaneously into one of the ventricular guide tubes, 
advanced to the predetermined depth (see page 28) and c.s.f. was 
then slowly withdrawn, under slight negative pressure, into a 
disposable polyethylene syringe. The amount which could be 
withdrawn from one ventricle on any one occasion varied from 
dog to dog but since 0.5 ml was required for a folate assay, 
and at least 0.2 ml for estimation of the acid metabolites of 
the amines (HVA and 5- HIAA), it was normal practise to withdraw 
between 0.7 and 1.0 ml. If the volume from one ventricle was 
insufficient the other ventricle could also be sampled. After 
the required volume had been withdrawn the needle was removed 
from the syringe, and the c.s.f. gently expelled into a 15 ml 
glass centrifuge tube. 
During sampling from the cisterna magna, light anaesthesia 
was maintained and the dog's head was flexed forward acutely. 
A 21 gauge needle was then inserted percutaneously through the 
atlanto -occipital membrane (note - without using the guide tube 
to the cisterna magna) and 2.5 ml of cisternal c.s.f. was with- 
drawn slowly into a disposable polyethylene syringe. After 
the required volume had been removed the needle was gently with- 
drawn and the c.s.f. expelled into a 15 ml glass centrifuge tube. 
If the c.s.f. samples showed any trace of contamination by blood 
they were centrifuged at 1,300 g for five minutes at room temper- 
ature to remove the erythrocytes. This was necessary since 
haemolysis products interfere with HVA assays giving erroneously 
low values. Also, since erythrocytes contain large amounts of 
folate derivatives significant contamination of c.s.f. by blood 
can give erroneously high values for c.s.f. folate activity. 
For a folate assay 0.5 ml of the c.s.f. sample was treated 
with 5 mg of ascorbic acid to give a 10 mg/ml solution with 
respect to ascorbate. This sample was then labelled and stored 
at -20 °C until the assay could be performed. 
For HVA and 5 -HIAA assay an aliquot of between 0.2 and 0.5 ml 
for ventricular c.s.f., or 1.5 - 2.5 ml for cisternl c.s.f., was 
pipetted straight into a clearly marked 35 1n1 glass centrifuge 
tube. This tube was then stoppered and stored at -20 °C until 
assay. 
When a blood sample was required it was withdrawn from any 
suitable vein, other than that by which the anaesthetic was being 
administered. The vein was penetrated percutaneously with a 
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21 gauge needle and 5 ml of blood slowly taken up into a 10 ml 
disposable polyethylene syringe which contained 0.1 ml of 
heparin solution (1,000 I.U. /ml). The needle was then withdrawn 
from the vein and the syringe inverted gently a few times to 
heparinise the blood thoroughly. The heparinised blood was 
then centrifuged at 1,300 g for 10 minutes. 2.5 ml of the 
plasma fraction were carefully removed and placed in a small 
glass vial. 25 mg Ascorbic acid was then added to the plasma 
and the sample was labelled and stored at -20 °C until assay. 
BIOCHEMICAL ANALYSES 
Estimation of Homovanillic Acid HVA and 5 -H drox indol -3- 
ylacetic Acid (5 -HIAA) in Cerebrospinal Fluid. 
The method used to measure the concentrations of homovanillic 
acid (HVA) and 5- hydroxyindol- 3- ylacetic acid in the cerebrospinal 
fluid (c.s.f.) was essentially that of Ashcroft, Crawford, Dow 
and Guldberg (1968). 
Materials 
Authentic homovanillic acid and 5- Hydroxyindol- 3- ylacetic 
acid were obtained from Koch -Light Co. Ltd. 
All other reagents were obtained from British Drug Houses 
(B.D.H.) and were Analar grade, except for the ammonia solution 
and the hydrochloric acid which were both Aristar grade. 
A fresh bottle of ethyl acetate (500 ml) was opened for each 
assay. 
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Distilled deionised water was used throughout, and all 
extractions and reactions were carried out in glass tubes fitted 
with glass stoppers. 
Standard solutions and buffers were prepared as follows : - 
Stock solutions of HVA and HIAA 
Solutions containing 1 mg/ml of HVA and 5 -HIAA in 
water were stored at 40G for periods of up to 3 weeks after 
which time they were renewed. During a three week period 
there was no detectable deterioration of the pure substances 
under these conditions. 
Borate Buffer 
0.1 M boric acid adjusted to pH 8.6 with 0.1 M sodium 
hydroxide solution. 
Phosphate Buffer 
0.1 M potassium dihydrogen orthophosphate adjusted to 
pH 7.4 with 0.1 M disodium hydrogen orthophosphate. 
Spectrofluorimetry 
The fluorescence measurements were made on an Aminco- Bowman 
Spectrophotofluor meter with slit arrangement No. 5 (Aminco- 
Bowman Manual). Solutions whose fluorescence was to be measured 
were placed in 3 ml capacity Spectrosil cells (Scientific Supplies) 
with a 10 mm square internal cross section. For a true fluor- 
escence reading the minimum volume of solution which could be 
used was 1.2 ml. 
Extraction of Phenolic Acids 
A measured volume of c.s.f. of between 0.2 ml and 1.0 ml 
for ventricular samples, and 1.5 and 2.0 ml for cisternal 
samples, was pipetted into a 35 ml glass centrifuge tube and the 
volume made up to 5.0 ml with water. The sample was then salt 
saturated with approximately 2 g of sodium chloride and taken 
to pH 1 -2 with 25 }xl of concentrated hydrochloric acid. 10 ml 
of ethyl acetate was added and the tube stoppered and shaken 
vigorously for 5 minutes. The mixture was then centrifuged 
at 1,900 g for 5 minutes to separate the two phases and 9.0 ml 
of the upper organic phase containing the extracted acids were 
withdrawn and pipetted into a fresh tube. Another 10 ml of 
ethyl acetate were added to the aqueous residue and the extraction 
repeated. This time however 10 ml of the organic phase were 
withdrawn and they were pooled with the first 9 ml giving 19 ml 
of ethyl acetate extract. The way in which this pooled extract 
was split for HVA and 5-HIAA assays depended on the estimated 
content of these acids in the original sample. In normal dog 
ventricular c.s.f. the concentration of HVA is much higher than 
that of 5 -HIAA and a pooled ethyl acetate extract of such a 
sample was therefore divided to give 4 ml of extract for HVA 
assay and 15 ml for the 5 -HIAA assay. The pooled ethyl acetate 
extract from cisternal samples was divided into two equal 9.5 ml 
fractions for the assay of HVA and 5 -HIAA. 
Estimation of 5 -HIAA 
The method used was a modification of that described by 
Ashcroft and Sharman (1962) . 
The ethyl acetate extract (15 ml for a ventricular sample 
and 9.5 ml for a cisternal sample) was shaken for 5 minutes 
with 1.4 ml 0.1 M phosphate buffer, pH 7.4, and the mixture 
centrifuged at 1,900 g. for 5 minutes. 1.0 ml of the lower 
aqueous phase was then carefully withdrawn and pipetted into a 
15 ml glass test tube. This solution was then acidified with 
0.4 ml concentrated HC1 containing 50 mg% w/v ascorbic acid, and 
transferred to a cell for fluorimetry. The fluorescence of the 
hydroxyindol group was measured with an activation wavelength 
of 310 i,vand a fluorescence wavelength of 550 m}x. A yellow 
filter with a lower cut -off of 420 mil was placed between the 
fluorescence monochromator and the photomultiplier in order to 
cut out a secondary scatter peak. 
The fluorescence from the c.s.f. samples was compared with 
the fluorescence of standards of 5 -HIAA, made up by diluting 
known aliquots of the stock solution in phosphate buffer, and 
acidifying with concentrated HCl containing ascorbate in exactly 
the same way as was done for the c.s.f. samples. 
Estimation of HVA 
The method used was essentially that of Andén, Roos and 
Werdinius (1963) as applied by Ashcroft, Crawford, Dow and 
Guldberg (1968) except that as in the 5-HIAA assay the tris 
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buffer was replaced by a buffer giving a lower blank. The 
phosphate buffer which was used in the 5 -HIAA assay was not 
suitable since it caused quenching of the HVA fluorophor, and a 
borate buffer was found to be more satisfactory (Pullar, 1971). 
The ethyl acetate extract (4 ml for a ventricular sample or 
9.5 ml for a cisternal sample) was shaken for 5 minutes with 
1.4 ml 0.1 M borate buffer pH 8.6 and the mixture centrifuged 
at 1,900 g. for 5 minutes. 1.0 ml of the lower aqueous phase 
was then carefully withdrawn and pipetted into a 15 ml glass test 
tube. To this were added 1.0 ml 5N ammonia solution and O. 2 ml 
of freshly prepared potassium ferricyanide solution (10 nmg% w /v). 
After exactly 4 minutes the reaction was terminated by the addition 
of 0.2 ml of freshly prepared I,- cysteine solution (100 mg¡ w /v). 
The fluorophor derived from HVA was then measured at an activation 
wavelength of 325 mu and a fluorescence wavelength of 430 mJi. 
These settings were found to give maximum readings for the 
fluorophors derived from standards of authentic HVA. As in 
the 5 -HIAA assay the fluorescence of the c.s.f. samples was 
compared with the fluorescence of standard solutions of HVA in 
borate buffer after they had been treated in exactly the same 
way as the borate buffer extracts of the c.s.f. samples. 
Recoveries and blanks 
In order to determine the efficiency of the extraction of 
the acids1known amounts of the pure substances were made up in 
5 ml of water in 30 ml glass centrifuge tubes and then taken 
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through the whole procedure exactly as if they were c.s.f. 
samples. By comparing the final fluorescence with standards 
of HVA and 5 -HIAA it was possible to calculate a recovery figure 
which could then be applied to the c.s.f. samples to calculate 
the absolute concentrations of these acids in the c.s.f. 
"Extraction Blanks" were obtained by taking 5 ml of water 
through the whole procedure and treating the appropriate buffer 
extracts with the fluorophor -producing reagents. 
Normal assay procedure 
The most economical way of assaying a large number of c.s.f. 
samples was to run them through the whole procedure in batches, 
along with tubes for blanks and recoveries. The assay plan is 
shown in Table 1:2. 
At the stage of splitting the ethyl acetate extract (see page 37) 
tubes 1 -7 were treated as if they contained ventricular c.s.f. 
samples, while tubes 8 -14 were split as if they contained cisternal 
c.s.f. samples. The mean recovery figures for tubes 2 and 7 
were then directly applicable to the ventricular c.s.f. samples 
in tubes 3 -6 while the mean recoveries for tubes 9 and 14 were 
directly applicable to the cisternal c.s.f. samples in tubes 10 -13. 
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TABLE 1:2 : Protocol for assay of HVA and 5HIAA in c.s.f. samples 
1. Blank 
2. Recovery : 2 pg HVA and 100 ng 5 -HIAA 




7. Recovery : 1 j'g HVA and 200 ng 5 -HIAA 
8. Blank 
9. Recovery : 2 yig HVA and 100 ng 5 -HIAA 




14. Recovery : 1 p.g HVA and 200 ng 5 -HIAA. 
ESTIMATION OF FOLATE IN PLASMA AND CEREBROSPINAL FLUID 
Introduction 
Although folic acid and its derivatives can be estimated 
colourimetrically after a diazotisation procedure (Hutchings, 
Stokstad, Boothe, Mowat, Waller, Angier, Semb and Subbarow, 
19ó0), these methods are not sensitive enough to assay the levels 
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found in plasma and c.s.f. For this reason we used a micro- 
biological assay technique based on the principle that the 
amount of folate in a sample can be determined from the growth 
response of a folate-dependent micro -organism when an aliquot 
of the sample is added to a folate free, but otherwise nutrition- 
ally adequate, culture of the micro -organism. 
The method used was essentially that of Waters and Mollin 
(1961) and make: use of a folate-dependent strain of lactobacillus 
cases. This is the least discriminating of the normal test 
organisms in that it can utilise all the biological forms of 
folate except those which are conjugated with three or more 
glutamic acid residues. 
Materials 
The test micro -organism, aactobacillus caseii, strain 
NCIB 8010, was obtained from a stock held in the Department of 
Therapeutics, Royal Infirmary of Edinburgh. 
Folic acid and L- tryptophan were obtained from Koch -Light 
L 
Co., Ltd. and the basic folic acid -i. caseik culture medium 
(Baker, Herbert, Frank, Pasher, Hutner, Wasserman and Sobotka, 
1959) was obtained from Difco Laboratories. 
All other reagents were Analar grade (B.D.H.) or equivalent 
quality and distilled water was used throughout. 
Stock solutions and buffers were prepared as follows:- 
Folic acid standard solution 
This was prepared freshly for each assay by two 
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consecutive 1:200 dilutions of a 40 pg/ml stock solution 
to give a solution of 1 ng /ml folic acid. The stock 
solution was kept in a dark bottle at 4°C. 
L. caseit medium 
This was prepared by adding 1- tryptophan to the basic 
Difco folic acid -Z. caser medium (10 mg tryptophan/100 ml 
basic medium) (Ball and Giles, 1964). 
Phosphate buffer 
0.1 M sodium dihydrogen orthophosphate adjusted to 
pH 6.1 with 0.1 M disodium hydrogen orthophosphate. Note 
that before use as a serum diluent this buffer was supple- 
mented with ascorbic acid, 200 mg/100 ml. 
PLASMA ASSAY 
The sample of ascorbate treated plasma (see p. 35) was 
thawed out and 0.7 ml pipetted into a glass universal tube and 
diluted with 6.3 ml 0.1 M phosphate buffer containing ascorbic 
acid (200 mg /100 nil). The sample was then autoclaved at 
15 lbs. /sq. in. for 2.5 minutes to precipitate protein. After 
cooling, the tube was centrifuged at 1,000 g. for 5 minutes and 
the supernatant filtered through Whatmans No. 40 paper. 2.5 ml 
of the filtrate were then made up to 10 ml with water and 2 ml 
aliquots of this diluted plasma extract were added to 4 test- 
L 
tubes,each containing 2 ml of L. caseii medium. 
Standards to cover the range of 0 -1.4 ng folate per tube 
were prepared in duplicate by adding appropriate volumes of 
the I ng /ml folic acid standard solution to tubes containing 
2 ml of medium and then making the volume up to 4 ml with water. 
The normal practise was to prepare duplicate sets of standard 
tubes containing respectively 0, 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 
1.2 and 1.4 ng folic acid. In addition an extra "blank" tube 
containing 2 ml of medium and 2 ml of water was prepared. At 
a later stage in the assay when the standard and plasma tubes 
were inoculated with the - .casei micro -organism this tube 
remained uninoculated and it was subsequently used as the "blank" 
in the turbidity measurements. 
Standard and plasma tubes along with the "blank" were auto- 
claved at 10 -12 p.s.i. for 10 minutes. After this sterilisation 
procedure the tubes were allowed to cool down; then all, except 
the blank, were inoculated with the folate- dependent strain of 
.casein. The tubes were then incubated at 37 °C for 18 -30 hours. 
The end point of the assay was set at the time when the 
standard tubes containing 0.6 ng of folic acid developed an 
optical density of 0.156. The optical density measurements 
were carried out on a Spekker absorptiometer by reading the 
samples against the uninoculated "blan.k" at filter setting No. 3 
(460 - 530 mu). Under these conditions the optical densities 
of the solutions were directly related to their turbidities. 
When the end point of the assay was reached all the samples were 
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removed from the incubator and their optical densities were 
measured. A standard curve of optical density against nano - 
grams of folate per tube was then drawn up (Fig. 1:9), and this 
was used in the calculation of the folate concentration in each 
plasma tube. This value was then multiplied by the dilution 
factor of 80 to give the plasma folate concentration in nanograms 
of folate per ml of plasma. 
In this assay each sample of plasma gave rise to 4 different 
estimates of the plasma folate concentration. Unless there 
was an obvious error in any of the estimations the mean of the 
4 values was accepted as the best estimate. 
C.S.F. ASSAY 
The c.s.f. assay was basically similar to the plasma assay 
except that there was no necessity for an initial protein precipi- 
tation step. In order to bring the folate activities of the 
c.s.f. samples within the sensitive range of the standard curve 
it was necessary to assay c.s.f. at higher dilutions than those 
which were employed in the assay of plasma samples. 
The ascorbate treated c.s.f. sample (see page 34 ) was 
thawed out, and an 0.2 ml aliquot diluted to 10 ml with 1% (w /v) 
ascorbic acid solution. A further 0.2 aliquot of c.s.f. was 
then diluted with 19.8 ml 1% (w /v) ascorbic acid solution and 
10 ml of the resultant solution removed to another tube and 
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FIG. 1:9 Standard growth curve for folate -dependent 1.casei 
The optical &bnsity (460 -530 41) of a solution after 
incubation (see text pp 43 -45) is a measure of the rate of 
growth of 1.casei in that solution. 
-47- 
Four 2 ml aliquots of each of these three c.s.f. dilutions 
(1:50, 1:100, 1:150) were then added to tubes containing 2 ml 
of medium, giving in all, 12 tubes per c.s.f. sample. These 
tubes, along with a "blank" and duplicate standards covering 
the range 0 -1.4 ng /tube, as in the plasma assay, were th.en 
taken through the steps of sterilisation, inoculation (all 
except the "blank"), incubation and finally turbidity measurement. 
As a rule only one, or perhaps two, of the dilutions gave 
readings on the sensitive part of the standard curve. The 
estimates from satisfactory dilutions were multiplied by the 
c.s.f. 
appropriate dilution factors to give values for pa folc.ate 
s.f. 
concentration in terms of nanograms of folate per ml of a.. 
The mean of all satisfactory estimates was accepted as the best 
result. 
RESULTS 
Pre -Treatment Control Studies 
Assays on samples taken from the dogs before anticonvulsant 
treatment was started revealed that the folate activities of 
c.s.f. and plasma in the dog were similar to those reported for 
man (Table 1:3). The mean c.s.f. folate concentration. found 
in this study on the dog was rather higher than the values 
previously reported for human lumbar c.s.f. (Table 1:3; Wells 
and Casey, 1967; Jensen and Olesen, 1971). However it is 
difficult to say whether tAs is a true difference since in fact 
controls from a later study with the same dogs (Section 1 B; see 
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TABLL 1:3 : Folate Activity in Body Fluids of Dog and Man 
Plasma or Serum C. s. f. 
DOG 12.2 (6.2 - 25.0)0 41.5 (10 - 70)1 
MAN 9.9 (5.9 - 20 )2 20.9 ( 9 - 38)3 
DOG 
MAN 
C.S.F. /Plasma Folate Ratio 
1.9 - 7.1 
3.04 
O - mean (range) (ng /ml) 
1 - values for combined ventricular and cisternal 
c.s.f. estimations. 
2 - serum Waters and Mollin (1961) 
3 - lumbar c.s.f. Reynolds, Preece and Chanarin (1969) 
4 - mean reported by Herbert and Zalusky (1961). 
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page 73) displayed much looser c.s.f. folate activities. In 
the dog, the ratio of folate activity between c.s.f. and plasma 
ranged from 1.9 - 7.1 as compared with a mean ratio of 3.0 which 
Herbert and Zalusky (1961) reported for man. 
Because of the similarities between plasma and c.s.f. folate 
activities in the dog and in man, both in relative and absolute 
terms, it seems reasonable to assume that the dog is a good test 
animal for studies of folate distribution which may be capable 
of extrapolation to man. 
Dogs Al (Fig. 1:10), A2 (Fig. 1:11) and A3 (Fig. 1:12) all 
displayed a positive correlation between the folate activity of 
plasma samples and the corresponding samples of c.s.f. obtained 
at the same time (p <0.05). A similar result has been reported 
for studies in man by Wells and Casey, 1967, Reynolds, Preece 
and Chanarin, 1969 and Jensen and Oleson, 1971). The ventricular 
and cisternal values have been plotted separately since a very 
slight but significant difference was found (ventricular cisternal : 
mean difference 5.2 ng /ml : p 0.001) when carrying out a paired 
t -test on samples which had been taken at the same time. Plotting 
the values separately in this fashion demonstrated an interesting 
trend in that the three dogs which displayed a positive correla- 
tion between c.s.f. and plasma folate all showed a greater 
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SIG. 1:10 Correlation between c.s.f. and plasma folate 
activity in dog Al. The points are derived from paired samples 
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FIG. 1:11 Correlation between c.s.f. and plasma folate 
activity in dog A2. The points are derived from paired samples 
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Plasma Folate ng / ml 
FIG. 1:12 Correlation between c.s.f. and plasma folate 
activity in dog A3. The points are derived from paired samples 
of c.s.f. and blood collected during the control period. 
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Anticonvulsant Treatment 
As can be readily seen from Tables 1:4 -7 none of the anti - 
convulsants carbamazepine (15 mg /kg/d), diphenylhydantoin 
(7.5 mg /kg/d), phenobarbitone (15 mg /kg /d) or sulthiame 
(15 mg/kg /d) in the time for which the drugs were administered 
(36 days), had any detectable effect on the folate activities 
of either c.s.f. or plasma. This is perhaps not unexpected 
with sulthiame and carbamazepine, since neither of these drugs 
have been reported to reduce folate concentrations in man. The 
lack of effect of diphenylhydantoin and phenobarbitone suggests 
either that their folate depleting actions may only be obvious 
after a long period (years) of treatment, or that there is a 
species difference between man and dog with respect to anti - 
convulsants and folate metabolism. 
HVA and 5 -HIAA studies 
Pre- treatment control studies confirmed the presence of a 
sharp gradient in the concentrations of both these acids between 
the ventricle and the cistern (Guldberg, Ashcroft and Crawford, 
1966), which is due to a localised transport system for the 
removal of these metabolites in the region of the fourth 
ventricle (Ashcroft, Dow and Moir, 1968). Treatment with the 
anticonvulsants had no detectable effect on the HVA and 5 -HIAA 
concentrations in the lateral ventricles or the cisterna magna 
(Tables 1:8 -11). This was not unexpected in view of the lack 
of change in folate concentrations in the c.s.f. (Tables 1: 4 - 7 ). 
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TABLE 1:4 : Dog Al - TREATMENT - CARBAMAZEPINE 
Folate Concentration 
C.S.F. 
Vent. Cist. Day 
(ng /mi) 
Plasma 
4 - 30 - 
8 58 48 13.0 
14 68 32 
16 - 49 
20 70 47 15.6 
CONTROL 
22 - 49 12.4 
27 40 28 8.3 
29 41 30 9.3 
34 - - 19.5 
36 54 37 13.2 
42 44 8 - 
Mean - S.D. 53.6 ± 12.5 38.8 ± 8.7 13.0 - 3.8 
44 51 39 
50 IMO 8.2 
TREATMENT 56 43 45 16.9 
58 51 40 7.6 
63 33 36 8.7 
79 59 40 10.3 
Mean ± S.D. 47.4 ± 9.8 40.0 ± 3.2 
10.3 3.8 
CONTROL 92 39 34 8.9 
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TABLE 1:5 : Dog A2 - TREATMENT - DIPHENYLHYDANTOIN 
Day 
Folate Concentration (ng /ml) 
C.S.F. 









14 - 47 - 
16 43 35 - 
20 71 50 12.4 
CONTROL 
22 50 44 7.5 
27 29 19.6 5.9 
29 33 30 6.2 
34 - - 10.4 
36 41 39 9.4 
42 36 22 




TREATMENT 58 42 
63 43 
79 39 







32.3(6) 5.9- 1.1( 5) 
ONO 
CONTROL 92 38 38 6.4 
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TABLE 1:6 : Dog A3 - TREATMENT - PHENOBARBITONE 
Day 
Folate Concentration (ng /ml) 
C.S.F. 





























Mean ± S.D. 39.6 -10.3(7) 38_.6 -10.5(7) 15.4 -7.4(5) 
44 45 42 10.3 
50 32 28 7.0 
56 39 38 9.4 
TREATMENT 58 46 45 9.5 
63 27 38 15.4 
79 37 5.2 
Mean ± S.D. 37.8 ±8.2(5) 38.0 ±5.8(6) 
CONTROL 92 38 42 
9.513.5(6) 
9.0 
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TABLE 1:7 : Dog A4 - TREATMENT - SULTHIAME 
Folate Concentration (ng /ml) 
Day 
C.S.F. 
Vent. Cist. Plasma 
4 40 34 
8 48 47 25 
14 55 
16 48 45 
20 51 62 19.4 
CONTROL 
22 57 52 11.6 
27 43 36 - 
29 39 36 12.4 
34 46 40 14.5 
36 42 44 15.0 
42 43 44 





















46.2 ±9.8(6) 11.2 -1.6 
CONTROL 92 47 38 7.4 
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5 -HIAA Conc. in 
C.S.F. 
Vent. Cist. 
CONTROL 1 740 104 290 37 
15 790 103 250 56 
21 800 112 230 23 
TREATMENT 28 1330 84 280 29 
31 920 158 200 27 
Mean 
± 
S.D. 1017 ±278(3) 118 ±38(3) 237 ±40(3) 26 ±3(3) 




















21 2100 133 308 29 
TREATMENT 28 2680 108 318 37 
31 2320 107 199 16 
Mean ± S.D. 2366 ±293(3) 116 ±15(3) 275 ±66(3) 27.3 ±11(3) 
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21 2140 103 333 28 
TREATMENT 28 2370 131 343 26 
31 2210 139 241 24 
Mean 
± S.D. 22401118(3) 124.3 ±19(3) 306 ±56(3) 26 ±2(3) 
TABLE 1:11 : Dog A4 - TREATMENT - SULTHIAME 
Day 
HVA Conc. in 
C.S.F. 
Vent. Cist. 
5 -HIAA Conc. in 
C.S.F. 
Vent. Cist. 
CONTROL 1 2250 167 284 41 
15 2 560 135 300 21 
21 2490 128 283 25 
TREATMENT 28 2780 - 335 - 
31 2660 175 278 23 
Mean 
1 
S.D. 26431333(3) 152133(2) 299 ±32(3) 24 ±1.4(2) 
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Discussion 
Many different theories have been proposed to account for 
the disturbances in folate metabolism brought about by chronic 
treatment with the anticonvulsants d iphenylhydaantoin pheno- 
barbitone, and primidone. Before it was known that there was 
an actual decrease in folate concentration in plasma and c.s.f. 
Girdwood and Lenman (1956) suggested that the anticonvulsants, 
by virtue of their structural similarities to folates, might be 
inhibiting the activities of folate-dependent enzymes. Alter- 
natively they might be blocking the interconversion of the 
various folate derivatives. However Klipstein (1964) showed 
that the anticonvulsants do not interfere with l.caseii assays 
and Hamfelt and Wilmans (1965) could not demonstrate any 
inhibi-Lory effect on dihydrofolate reductase, methylene tetra - 
hydrofolate dehydrogenase or formyl tetrahydrofolate synthetase. 
When it became known that serum folates were reduced in 
anticonvulsant -induced anaemias Klipstein (1964) suggested that 
the anticonvulsants might be displacing folate from plasma 
proteins and thereby lowering total plasma concentrations. 
There has been no experimental proof to support this however, 
and no such effect was seen in the present study. 
There is evidence that anticonvulsants interfere with the 
absorption of the folates derived from food. Hoffbrand and 
Necheles (1968) and Rosenberg, Godwin, Streiff and Castle (1968) 
both reported that anticonvulsants inhibited the intestinal 
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'conjugase' enzymes. As most of the folates present in food 
are in the polyglutamate form (Butterworth, Santini and 
Frommeyer, 1963) such an action could result in poorer utilisa- 
tion of dietary folate since only non -conjugated derivatives 
appear to be actually absorbed (e.g. Butterworth, Baugh and 
Krumdieck, 1969). Both Hoffbrand and Nechelles (1968) and 
Rosenberg et al. (1968) reported that the absorption of folic 
acid itself was unaffected by anticonvulsants. However 
Meynell had reported in 1966 that the absorption of pure folic 
acid was reduced by an acute dose of diphenylhydantoin. 
Several subsequent studies have not only confirmed this latter 
finding but have been unable to find any effect of anticonvul- 
sants on preparations of intestinal 'conjugase' enzymes (Baugh 
and Krumdieck, 1969; Bernstein, Gutstein, Weiner and Efron, 
1970; Gerson, Hepner, Brown, Cohen, Herbert and Janowitz, 
1970). These findings are exactly the reverse of those 
reported by Hoffbrand and Necheles, and Rosenberg et al.. How- 
ever, whichever mechanism of action proves to be right, or 
indeed if both do, one might not expect anticonvulsant therapy 
to affect body stores of folate unless the dietary intake of 
folate was barely sufficient and anticonvulsants were administered 
in high dosage over a long time. If this were the only way in 
which anticonvulsants interfere with folate transport and meta- 
bolism there might be no measurable change in the folate activity 
of plasma and c.s.f. until the large tissue stores of folates 
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were considerably depleted (Herbert, 1962). This may be one 
reason why we saw no effect in this study after only 4 weeks of 
anticonvulsant treatment. Another possibility is that because 
of species differences in metabolism the dosage of anticonvulsants 
administered (equivalent to therapeutic doses in man) were not 
sufficiently high. 
The effect of diphenylhydantoin on the transport of folates 
between the plasma and the c.s.f. is also the subject of some 
debate. Levitt, Pincus, Nixon and Bertino (1969) reported 
that methyl tetrahydrof olate is actively taken up into the c.s.f., 
and that diphenylhydantoin had no effect on this transport. 
However preliminary findings from Woodbury and Kemp (1971) 
indicate that the uptake of folic acid into all tissues, including 
the c.s.f., is inhibited by diphenylhydantoin. The contrasting 
conclusions of these two studies may be explained by the fact 
that the transport of different derivatives was being studied, 
but until more is known of the exact experimental procedures 
this can only be speculation. 
When Reynolds (1967) observed an increase in frequency and 
severity of fits in patients on anticonvulsant therapy who were 
given folic acid this was taken as support for the hypotaesis 
that the anti-- folate effects of anticonvulsants were related 
to their 1herapeutic effects. However, there is evidence that 
the restoration of tissue folates results in more rapid metabolism 
of the anticonvulsant drug, to the extent of producing sub- 
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therapeutic plasma concentrations of the anticonvulsant (Baylis, 
Crowley and Preece, 1971; Oleson and Jensen, 1970). These 
findings have not been supported by Andreasen, Hansen, Skovsted 
and Nielsen (1971) who were unable to demonstrate any effect of 
folic acid treatment on the metabolic half life of diphenyl- 
hydantoin in man. 
In conclusion therefore it can be said that there is very 
little evidence to support a causal relationship between the 
anti -folate effects of anticonvulsant drugs and their thera- 
peutic actions, though there are certainly some interactions 
in man between prolonged anticonvulsant therapy and folate 
metabolism. 
In view of the fact that the folate activities of c.s.f. and 
plasma were unaltered in this study, the absence of any change 
in the c.s.f. concentrations of the amine metabolites, HVA and 
5 -HIAA, was not unexpected. Even if the anticonvulsants had 
reduced the c.s.f. and plasma folate activities there is some 
evidence to suggest that the availability of co- factor for 
aromatic amino acid hydroxylation in the brain might not have 
been significantly affected. 
Allen and Klipstein (1970) have reported that the brains 
stores of folate are very much more resistant to depletion during 
the development of a folate deficiency state, than are those of 
the liver. More significantly Goodfriend and Kaufman (1961) 
found that there was very little reduction in the availability 
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of pteridine co- factor in the liver in even a severe folate 
deficiency state. These two findings suggest that the amine 
synthesising systems in the brain may be relatively "protected" 
during the development of a folate deficiency state. In this 
context it may be significant that in contrast to peripheral 
hydroxylation systems the enzyme and co- factor for brain 
tryptophan hydroxylation are very firmly bound to particulate 
matter (Grahame -Smith, 1967). 
SECTION 18: The Effect of Folic Acid Administration on 
(a) the Folate Activity of c.s.f. Plasma and Plasma 
Ultrafiltrate and (b) the Concentrations of HVA and 
5HIAA in Ventricular and Cisternal c.s.f. 
Introduction 
While carrying out investigations on the inter -relations 
between folic acid and vitamin B12 metabolism Hunter, Barnes, 
Oakeley and Matthews (1970) administered large doses of folic 
acid (15 mg daily) to a group of healthy volunteers. As 
they report however, the trial "was abandoned after one month 
of a projected three month project because of the unexpected 
development of increasingly disturbing toxic effects in the 
majority. Most of the subjects experienced mental changes, 
sleep disturbances and gastrointestinal symptoms." The 
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mental changes which included altered sleep patterns, irrit- 
ability, overactivity and excitement, suggested a rather non 
specific heightening of mood and an increase in the general level 
of arousal. Since there was no concomitant change in vitamin 
B12 levels the authors deduced that the effects described were 
due specifically to the folic acid treatment. It was these 
findings of Hunter et al. which led to the work reported in 
this section of the thesis. 
Since our own studies were started, Hunter et al.'s work 
has been much criticised for its uncontrolled nature (Snaith, 
1970; Ralston, 1970; Standage, 1970; Davis and Woodliff, 
1971; Gibberd, Nicholls, Dunne and Chaput de Saintonge, 1971), 
but both before and after this report there have been other 
independent studies which have implied a link between folic 
acid and mental function. Reynolds, Milner, Matthews and 
Chanarin in their 1966 paper put forward the hypothesis that 
drug-induced disturbances in folate and B12 metabolism may be 
concerned in the production of mental symptoms in epileptic 
patients. Reynolds et al. (1967) reported a marked improve- 
ment in drive in 22 out of 26 patients who were given folic 
acid to correct an anaemia induced by anticonvulsant therapy. 
Neubauer (1970) was of the opinion that folic acid was helpful 
in alleviating the mental retardation which can develop in 
drug treated epileptics. On a broader theme Strachan and 
Henderson (1967) have described two patients with dementia who 
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improved when their low serum folates were restored to normal 
with folic acid treatment. Low serum folates have been 
reported in up to a quarter of psychiatric in- patients 
(Carney, 1967; Hunter, Jones, Jones and Matthews, 1967; 
Kallstrom and Nylöf, 1969; Reynolds, Preece, Bailey and 
Coppen, 1970) though, as Carney and Sheffield (1970) pointed 
out, a combination of many different factors may contribute to 
this finding. Mental retardation has been a feature of 
certain congenital metabolic disorders involving folate absorp- 
tion (Lanzkowsky, 1970) and folate metabolism (Arakawa, 1970). 
Thus, despite the fact that several trials (Snaith, 1970; 
Ralston, Snaith and Hinley, 1970; Jensen and Oleson, 1970; 
Gibberd et al., 1971; Hellstróm, 1971) have not confirmed the 
effects of folic acid reported by Hunter et al. (1970) there 
is other evidence linking folic acid with mental function. 
Hunter et al. (1970) hypothesised that the mental symptoms 
of "folic acid intoxication" observed by themselves, and the 
"alterting" effect of folic acid observed by Reynolds (1968), 
might be due to changes in brain amine synthesis. As indicated 
earlier (Section lA, page 19) the rate limiting steps on. the 
pathways leading to the formation of dopamine and 5- hydroxy- 
tryptam.ine, namely the hydroxylation of tyrosine and tryptophan 
respectively, are dependent on pteridine co- factors, (Nagatsu 
et al. 1964; Gal et al. 1968). Folates themselves form a 
class of substituted pteridines and it has been demonstrated 
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that certain folate derivatives can replace the natural 
pteridine co- factor in the aromatic amino acid hydroxylation 
systems of the liver (Kaufman, 1963). On the basis of the 
normal finding of very much higher folate activity in c.s.f. 
than in plasma, Hunter et al. had inferred that theirvolunteers 
on folic acid would have very high concentrations of folate 
in their c.s.f. If this were the case it might also mean that 
there was an increase in the availability of co- factor for the 
rate -limiting steps in brain amine synthesis. This seemed a 
reasonable hypothesis since the c.s.f. is known to be very 
similar in composition to brain extracellular fluid (see 
review - Dayson, 1968). Such a hypothesis could also provide 
an explanation for the mental changes observed after folic acid 
treatment since aminergic systems in the brain are thought to 
play a part in the control of mood and the activity of the non 
specific arousal systems. 
In order to test these possibilities we carried out a 
short study in the dog in which we measured c.s.f. and plasma 
folate activity both before, and during the administration of 
large oral doses of folic acid. To provide more information 
on the nature of the gradient in folate activity between c.s.f. 
and plasma we also measured the folate activity of protein - 
free plasma ultrafiltrate. 
Many investigations within this department have shown that 
changes in the synthesis and release of 5- hydroxytryptamine and 
dopamine are reflected by changes in the levels of their acid 
metabolites, 5 -HIAA and HVA, in the c.s.f. (see Section lA 
page 19). Therefore to test for an effect of folic acid 
therapy on brain amine synthesis we have examined the concentra- 
tions of 5 -HIAA and HVA in the dogs' ventricular and cisternal 
c.s.f., before and during the treatment period. 
METHODOLOGY 
Animal and Experimental Procedures 
As in the anticonvulsant studies the animals used were 
adult male Beagle dogs with permanently implanted ventricular 
and cisternal guide tubes. Throughout the period of the experi- 
ment the dogs were kept on a standard diet (Pedigree Chum, 
Petfoods Ltd.) and sampling of body fluids was carried out be- 
tween 09.30 and 12.00 hours. 
After a period to establish control values for the para- 
meters being measured (folate activity in c.s.f., plasma and 
plasma ultrafiltrate; HVA and 5 -HIAA concentrations in ventricular 
and cisternal c.s.f.) the three dogs (originally four, but one 
developed a severe infection and had to be put down) were put 
on a course of folic acid for a period of five weeks. 
Folic acid (5 mg /day) was administered orally in tablet 
form, 2.5 mg at 09.00 hours and 2.5 mg at 17.00 hours. On a 
weight for weight basis this is equivalent to a dose of 25 mg/ 
day in humans and as such it is nearly twice the normal 
therapeutic dose (15 mg /day) administered to humans in the 
trial reported by Hunter et al. (1970). 
The blood and c.s.f. samples were withdrawn using the 
techniques described in Section lA (pages 33-35). For the 
preparation of the plasma ultrafiltrate a 10 ml portion of 
venous blood was centrifuged at 1,900 g for 10 minutes, at 
room temperature, and the plasma fraction was carefully removed 
and treated as detailed below. 
Pre aration of Plasma Ultrafiltrate 
Plasma ultrafiltrates were prepared by a modification 
(Moir, 1971) of the method of 'IcMenamy, Lund, Van Marcke and 
Oncley (1961). After careful washing and drying, 1 foot 
lengths of Visking dialysis tubing (size 8/32, Scientific 
Instrument Centre Ltd.) were inflated, folded in the middle, 
and placed inside a 12 ml centrifuge tube. The folded tubing 
rested on a small teflon plug (13 mm diameter, 4 mm thick, 
serrated at the edge) which blocked off the conical section of 
the centrifuge tube (Fig. 1: 13 ) . 
4 ml of plasma were then run into the two side arms of the 
u -tube formed by the tubing, and the centrifuge tube was 
tightly stoppered, jamming the top of the dialysis tubing be- 
tween the side wall of the tube and the stopper. The tube was 
then centrifuged at 1,900 g for one hour at 37 °C. The ultra - 
filtrate collected in the conical section of the tube, below 














FIG. 1:13 Apparatus for preparation of plasma ultrafiltrate. 
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provided about 0.75 - 0.80 ml of ultrafiltrate. 
For folate assay an 0.5 ml aliquot of ultrafiltrate was 
pipetted into a labelled glass vial containing 5 mg ascorbic 
acid. The vial was then stored at -2000 until assay. 
B I O CH EïvMI CAL ANALYSES 
Estimation of HVA and 5 -HIAA in cerebrospinal fluid 
The basic methodology for ITTA and 5 -IIIAA analyses has been 
described in Section lA (pages 35 -41) but this basic procedure 
was modified in three different ways. 
Firstly, the double extraction of the acids with two 10 ml 
volumes of ethyl acetate was replaced by a single extraction 
with one 10 ml volume of butyl acetate. This modification con- 
siderably shortened the time of an assay without any decrease 
in the efficiency of extraction of HVA and 5 -HIAA. 
Secondly, for the extraction of 5 -HIAA from the butyl 
acetate back into aqueous solution, the phosphate buffer used 
in earlier studies (0.1M, pH 7.4) was replaced by the borate 
buffer already used in the back extraction of HVA (0.1M, pH 8.6). 
This buffer gave a slightly lower blank in fluorimetry readings. 
Finally, the Aminco- Bowman spectrophotofliiorimeter used in 
the earlier study was replaced by a Perkin Elmer IMP -2A spectro- 
photofluorimeter. By the use of special micro cells available 
with this instrument it was possible to measure the fluorescence 
of 0.5 ml of solution. This facility, together with the higher 
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sensitivity of the instrument allowed the borate buffer extract 
for HVA assay to be split into two 0.5 ml fractions, one of 
which was used to prepare a "sample blank". One of the 0.5 ml 
fractions was treated, as before, with 0.5 ml 5N ammonia 
solution and 0.1 ml of freshly prepared ferricyanide solution. 
After exactly 4 minutes the reaction was terminated by the 
addition of 0.1 ml of freshly prepared 1- cysteine solution 
(100 mg % w /v). The other 0.5 ml fraction was treated with 
the same reagents but in the reverse order, with the cysteine 
solution being added before the ammonia and ferricyanide solution. 
Both solutions were then read on the spectrophotofluorimeter and 
the latter fraction acted as a "sample blank" for the first 
fraction. This adaptation increased the sensitivity and 
accuracy of each HVA estiîrp tion. 
Estimation of folate activit in sam les of lasma lasma 
ultrafiltrate and c. s. f. 
The basic methodology for the folate assays was unchanged 
from that described in Section 1A (pages 41-47). The plasma 
ultrafiltrate samples, being protein free, were not subjected 
to a protein precipitation procedure. During the period of 
folic acid administration very much higher levels of folate 
activity were encountered in the plasma and plasma ultrafiltrate 
samples, and it was necessary to do a preliminary assay with 
different dilutions of samples, to establish what dilutions were 
necessary to bring the activity of the samples on to the standard 
curve. 
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RESULTS 
In this study no distinction has been made between 
ventricular and cisternal c.s.f. when assaying for folate activity. 
Therefore the c.s.f. folate activities reported in this section 
refer, in most cases, to means of the estimates obtained from 
paired samples of ventricular and cisternal c.s.f. The justi- 
fication for this policy was that the previous study (Section 1A, 
page 49) had shown very little difference between the folate 
activities of ventricular and cisternal c.s.f. 
Pre -Treatment Control Period 
C.S.F. and Plasma Folate Concentrations 
At 18.3 
± 
6.1 ng/ml (mean ± s.d., 28 estimates from 3 dogs) 
the mean c.s.f. folate concentration during the control period 
of this study (Table 1:12) was significantly lower (t = 10.3, 
p < 0.001) than the value of 41.7 
± 
11.4 ng/ml (mean ± s.d., 
83 estimates from 4 dogs) which was found in the control period 
of the previous anticonvulsant study (Section lA). The mean 
control plasma folate concentration of 8.2 ± 3.8 ng/ml (mean 
± 
s.d., 21 estimates from 3 dogs) in the present study was not 





s.d., 31 estimates from 4 dogs). 
The difference in c.s.f. folate activities between the two 
control periods cannot be ascribed to the use of a different 
"population" of dogs since they were all derived from similar 
TABLE 1:12 : Folate Concentrations in Plasma, Protein -Free Plasma Ultrafiltrates and C.S.F. 




1 5 8 16 20 22 26 29 34 36 47 
DOG 
A 2 13.5 8.5 6.4 9.4 13.6 4.4 14.2 4.2 
A 5 17.2 5.3 5.5 6.2 9.8 4.8 
A 6 4.5 9.6 5.3 5.3 6.5 7.1 11.1 
54 60 64 67 71 74 81 88 
108 94 46 
117 114 45 80 104 85 





A 2 5.3 3.5 2.8 3.3 2.8 3.8 4.3 3.8 
A 5 4.0 2.3 3.3 4.3 3.8 2.8 
A 6 3.3 3.5 3.0 3.3 2.8 3.3 3.8 
22 19 6.8 
23 23 11.5 14 17 18 
15 6.5 23 8 15 
C. s. f. 
ng/ml 
A 2 24 27 17.5 17.3 15.1 14.9 16.6 26 22 18.3 23 
A 5 13.8 7.5 9.0 10.3 14.3 18.5 19.5 15.3 22 
A 6 16.0 17.0 16.0 13.8 15.8 23 23 37 
22 20 17.4 24 19.0 23 24 23 
15.5 16.5 28 14.3 18.5 14.0 15.5 15.3 
28 27 24 36 30 29 32 
FOLIC ACID 
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breeding stock. In fact dog A2 was common to both studies. The 
rest period of three months between the experiments makes it 
unlikely that dog A2 was still being affected by the earlier 
anticonvulsant treatment. Nor is it likely that a change in 
the dietary intake of folate could be held responsible since 
both groups were maintained on the same standard diet. The 
techniques of withdrawal and preparation of c.s.f. were identical 
in both studies. 
One possible explanation for the different c.s.f. folate 
activities may lie in the fact that two different preparations 
of medium were used in assaying the two different groups of 
samples. One might speculate that this produced a situation 
where certain factors present in the c.s.f. samples, but not in 
the folic acid standards, interacted differently with the two 
media giving two different estimates of c.s.f. folate activity 
despite similar standard curves for pure folic acid. Certainly 
we have had experience of at least one occasion where a 
supposedly sound batch of medium produced sensible figures for 
plasma folates, but nonsensical figures for c.s.f. folate. 
Unfortunately such difficulties in the standardisation of 
microbiological assay procedures are only too common as Table 
1:13 illustrates. This Table lists various "normal" values for 
L 
humanserum folate as measured by /.caseig assay. As can be 
seen, the means alone range from 5.1 ng /ml (Temperley and Horner, 
1966) to 16.0 ng /ml (Santini et al., 1966). The variation 
within any particular assay may be very much less. For 
instance Waters (1963) found a coefficient of variation of only 
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TABLE 1:1 : Serum folate concentrations in normal subjects 
Author ng/m1 
Range Mean 
Toennies et al. (1956b ) 




Cooperman et al, (1960) 4.0 - 45.6 15.9 
Waters & Mollin (1961b) 5.9 - 21.0 9.9 
Hansen & Weinfeld (1962) 3.7 - 9.3 5.4 
Grossowicz et alv(1962) 3.2 - 15.0 8.3 
Davis & Kelly (1962) 2.7 - 18.5 5.9 
Spray (1964) 21. - 28.0 7.8 
Kershaw & Girdwood (1964) 4.9 - 18.5 9.5 
Reizenstein (1965) 2.4 - 7.4 4.6 
Santini et al(1966) 8. - 29 16.0 
Grzesiukowicz et al,(1965) 6.7 - 14.6 9.2 
Giles (1966) 3.4 - 11.6 6.6 
Temperley & Horner (1966) 2.1 - 9.5 5.1 
Vanier & Tyas (1966) 7 - 20 13.1 
Spector & Hunter (1966) 3 - 11.5 7.4 
Banerjee & Chatterjea (1965) 3.0 - 22.3 7.2 
Magnus (1967) 3.0 - 11.0 5.7 
Leevy et al.(1965) 4.0 - 10.0 - 
Cooper & Lowenstein (1964) 4.0 - 18 8.1 
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15% when carrying out repeat assays on the same serum sample. 
Therefore while comparisons of folate activity may be valid 
within a particular series, it may be dangerous to compare values 
between series. 
However, despite these doubts about the methodology, we 
cannot exclude the possibility that the observed difference in 
control c.s.f. folate between the two studies may not be a 
methodological artifact but an accurate reflection of a real 
change. In two recent studies involving humans (Spaans, 1971; 
Shaw, MacSweeney, Johnson, O'Keefe, Naidoo, Macleod, Jog, Preece 
and Crowley, 1971) comparable changes in c.s.f. folate activity 
have been reported to occur spontaneously over periods of 
1 -3 months. 
Of the two different values which we found for control c.s.f. 
folate activity in the dog, the figure from the present study of 
18.3 ± 6.1 ng/ml (mean 
± 
s.d.) was very much nearer to the 
values of 20.9 ng /ml (Reynolds, Preece and Chanarin, 1969), 
23.6 ng /ml (Wells and Casey, 1967) and 14.2 ng/ml (Weckman and 
Lehtovaara, 1969) which have been reported for human lumbar c.s.f. 
Relationshi between c.s.f. and lasma folate activities 
In the previous study (Section 1A,) there was evidence for a 
positive correlation between c.s.f. and plasma folate activities 
(see page 49) but in the present study there was no correlation 
between these two parameters in any of the three dogs (Table 1:12). 
These conflicting findings were particularly puzzling with respect 
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to dog A2 which was common to both series of experiments. 
From human studies also there have been conflicting 
reports on the relationship between c.s.f. and plasma folate 
activity. Wells and Casey (1967), Reynolds et al. (1969), 
Jensen and Olesen (1971) and Shaw et al. (1971) all report 
finding a significant positive correlation between c.s.f. and 
plasma folate activity in paired samples withdrawn at the same 
time from the same individual. However, the largest survey 
(paired data from 416 patients) , carried out by Weckman and 
Lehtovaara (1969) gave no evidence for such a correlation. The 
results of the study by Spaans (1971) are inconclusive on this 
point but on balance tend to agree with the findings of 'Weckman 
and Lehtovaara (1969) that there is no correlation between c.s.f. 
and plasma folates. 
The assessment of these various studies is hindered by two 
problems. The first is that minor differences in sample 
preparation and assay technique between various laboratories 
may influence their results. The second problem arises from 
the ethical difficulties of obtaining c.s.f. from healthy 
control subjects. Because of these difficulties all the 
human studies have had to be restricted to groups of patients 
who were being investigated for some neurological or psychiatric 
complaint. The question therefore arises as to whether the 
same "population" was being observed in the various studies. 
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This topic has been fully discussed by Wells (1969). 
To illustrate the complexity of the situation consider the 
following data from Wells and Casey (1967) (Group I) and 
and Lehtovaara (1969) (Group 2). 
Plasma folate C.S.F. folate C.S.F. /Plasma 
(ng /m1) (ng/ml) Correlation 
Group 1 (n = 30 ) 5.4 23.6 ± 11 (s.d.) Positive 
Group 2 (n = 416) 5.5 14.3 ± 10 (s.d.) x 
It can be seen that these two studies differ not only on 
the question of a c.s.f. /plasma correlation with respect to 
folate activity, but also on the more basic issue of the c.s.f. 
folate concentration. One is tempted to think that thesetwo 
observed differences may be related to one common difference 
between the two studies. As to what this difference might be 
one can only speculate. It is possible that two different 
classesof patients were being studied but this does not seem 
likely. More probable is some systematic difference in the 
time of day at which samples were withdrawn. Another possibil- 
ity is that some constant error in sample preparation or assay 
technique was affecting the folate assays, particularly of 
c.s.f., either producing a c.s.f. /plasma correlation when none 
was present, or masking the existence of a real correlation. 
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It seems certain therefore that many problems in$ampling 
procedures and folate methodology will have to be resolved 
before the relationship between c.s.f. and plasma folate 
activities can be properly evaluated. 
Plasma Ultrafiltrate 
The plasma ultrafiltrate studies revealed that much of the 
folate activity in dog plasma is not freely diffusible. 
During the control period the plasma ultrafiltrate was found 
to have only 43 ± 3% (mean 
± 
s.d.) of the folate activity of 
whole plasma (Table 1:12). These figures are in agreement with 
earlier studies on the plasma binding of folate in man (Johns, 
Sperti and Burgen, 1961), in the dog (Goresky, Watanabe and 
Johns, 1963) and in the rat (Neal and Williams, 1965). Sur- 
prisingly, during the control period, there was no correlation, 
between the folate activities of paired samples of plasma and 
plasma ultrafiltrate (Table 1:12). This lack of correlation 
may be due to the combination of a small range of values and 
a relatively large error variation in the assay procedure. 
HVA and 5 -HIAA in C.S.F. 
The HVA and 5 -HIAA assays on samples of c.s.f. taken 
during the control period confirmed the gradient in concentration 
of these acids which is known to exist between the lateral 
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ventricle and the cisterna magna (Table 1:14). A feature of 
the control data was the ventricular EVA concentration in 
Dog A6, which was well below the "normal" for these dogs. In 
fact this particular dog had been newly operated on and as 
sometimes happens in such cases the early c.s.f. samples were 
markedly blood -stained. The low HVA value for this dog 
(Table 1:14) can be considered a direct result of this contamin- 
ation since blood is known to interfere with the HVA assay. 
This was confirmed by repeat control estimates in the same dog, 
some three months later, when a ventricular HVA concentration 
of 1501 
± 
1009 ng /ml (mean - s.d., 16 estimates) was found. 
Treatment with Folic Acid, 5 m /day 
Plasma and Plasma Ultrafiltrate 
After the start of oral folic acid treatment there were 
striking increases in the folate activity of both plasma and 
plasma ultrafiltrate (Table 1:12, Fig. 1:14). 
The plasma folate activity rose ten fold from 8.2 
± 
3.8 
ng /ml (mean ± s.d.) to 79 
± 
27 ng /ml (mean ± s.d.). This 
change was significant in each of the three dogs at a- 
p-r-o-b 1 in a thousand, t,e ?toba6"l~t of 
l1PfP hetnc no dcT-erence be"n9 i055 Ri4n cmQ tn-, 0. 14,-1c,,nahd. 
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TABLE 1:14 : Homovanillic acid (HVA) and 5- Hydroxyindol- 3- ylacetic 
(5 -HIAA) in c.s.f. before and after chronic folie 
acid administration. 
Sample Dog 





A2 297±53(9)1 250± 45(7) 1768 ±215(10) 1977 ±542(7) 
from 
lateral AS 297±43(6) 159 ±111(6) 1137 ±446(7 ) 1019 ±477(6) 
ventricle 
A6 131±47(5) 137± 47(5) 274'223(6)2 1211 +670(5) 




A5 19± 6(5) 20± 5(4) 
36± 
8(6) 39± 18(3) 
magna 
A6 37± 8(4) 16 & 52 99± 35(5) 80 ±148 
1 
Mean standard deviation (number of samples in parentheses) 
2 Abnormally low initial values due to contamination with 
blood; control values taken three months after stopping 




The plasma ultrafiltrate however displayed only a five 
fold rise in folate activity from 3.5 ± 0.7 ng/ml (mean ± s.d.) 
to 15.8 
± 
6.0 ng/ml (mean ± s.d.). This change was also 
statistically significant in each of the three dogs (p c 0.01 
for dogs A2 and A6, p ! 0.001 for dog A5) . 
It should be noted that these changes represent a decrease 
in the proportion of folate activity which is ultrafilterable. 
During the control period plasma ultrafiltrate had a folate 
activity 43 ± 3% (mean ± s.d.), that of whole plasma. After 
folic acid treatment this percentage dropped to 21 
± 
2% 
(mean s.d.). This finding may indicate that the increased 
folate activity in plasma is in a form which is more tightly 
bound to plasma proteins than are normal plasma folates. 
During the period of folic acid treatment there was a 
significant correlation (r = +0.88, p< 0.001) between the 
folate activities of plasma and plasma ultrafiltrate. 
C.S.F. 
In view of the fact that c.s.f. folate activity is normally 
some three times greater than the plasma folate activity, in 
both man (Herbert and Zalusky, 1961) and dog (Table 1:3) we, in 
company with Hunter et al. (1970), expected that oral folic acid 
supplements might have an even greater effect on the c.s.f. 
folate activity than on the plasma folate activity. 
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This was not the case. A ten fold rise in plasma folate 
activity during the treatment period was associated with only 
a 22.00 increase in the folate activity of c.s.f. (Table 1:12, 
Fig. 1:14). From a control period mean of 18.3 ± 6.1 ng /ml 
(mean s.d.) the folate activity of c.s.f. rose to a mean of 
22.4 ± 6.2 ng /ml (mean ± s.d.). Even this small increase could 
not be immediately attributed to the folic acid treatment since 
dogs A5 and A6 both showed a significant positive regression in 
c.s.f. folate activity throughout the control period (Fig. 1:15). 
Thus oral folic acid administration produced no significant 
increase in c.s.f. folate activity despite producing very large 
increases in plasma folate activity. 
This inability of oral folic acid therapy to raise the 
folate activity of the c.s.f. has recently been confirmed by a 
number of similar studies in man (Spawns, 1971; Shaw et al., 
1971; Hunter, Barnes, Kantamaneni and Duncan, 1971). 
In the light of these results it appears unlikely that the 
mental changes observed by Hunter et al. (1970) were due to an 
increased folate activity in the central nervous system. 
HVA and 5 -HIAA in C.S.F. 
We have found no evidence that oral folic acid treatment 
alters the concentration of either HVA or 5 -HIAA in the 


































FIG. 1:14 Effect of folic acid treatment on the folate 
activities of plasma, - plasma ultrafiltrate and c.s.f. The 
columns represent mean activities while the vertical bars 
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FIG. 1 :15 Regression of c.s.f. folate activity in dogs A5 
and A6 during the control period prior to treatment with folic 
acid. The points displayed during the treatment period 
represent the means (± standard deviations) of the c.s.f. folate 
activities in the two dogs during this period. 
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before /after treatment difference in the ventricular HVA 
concentration of dog A6 was caused by a methodological problem 
which has been discussed earlier. 
From these results one can infer that oral folic acid 
administration has no effect on the synthesis in the brain of 
either dopamine or 5- hydroxytryptamine (see earlier discussion, 
page LA - 
This is not surprising since it appears that the folate 
activity in the central nervous system is unaffected by large 
oral doses of folic acid. 
These findings in the dog have recently been confirmed in 
an by Hunter et al (1971). When they administered folic acid 
orally, at a dosage of 15 mg /day (splitting the daily dose) over 
a period of a few weeks, they found no evidence of any change in 
the concentrations of folate, HVA and 5 -HIAA in the lumbar c.s.f. 
However, 4 hours after a single large oral dose of 30 mg folic 
acid they found a significantly lowered HVA concentration in the 
lumbar c.s.f. They attributed the differing results of these 
two folic acid treatments to the fact that the latter treatment 
achieved very high plasma folate concentrations (525 ± 92 ng/ml, 
mean s. e.) . 
The distribution of 140 -meth ltetrah drofolate between c.s.f. 
and plasma. 
We have carried out two short preliminary experiments in 
rabbits to examine a hypothesis which might explain some of the 
rather unexpected results of the folic acid studies. 
Active transport of the methyltetrahydrofolate derivative 
into the c.s.f. has been proposed as a mechanism (Levitt et al. 
1969) to account for the concentration gradient in folate activity 
which exists between c.s.f. and plasma (Herbert and Zalusky, 1961). 
The nature of the active folate derivatives in c.s.f. is not 
known but it is known that methyltetrahydrofolate is the pre - 
dominant plasma form (Herbert et al., 1965). The lack of effect 
of oral folic acid treatment on c.s.f. folate activity need not 
rule out the active uptake of methyltetrahydrofolate into the 
c.s.f.: the large increases in plasma folate activity which are 
seen during such treatment are almost certainly due to unreduced 
folic acid (Butterworth et al., 1969; Melikian, Paton, Leeming 
and Portman -Graham, 1971), a compound which enters c.s.f. at a 
much slower rate than methyltetrahydrofolate (Levitt et al., 1969). 
14C- methyltetrahydrofolate (Radiochemical Centre, Amersham), 
in aqueous ascorbate solution, was injected intravenously into 
two rabbits. Venous blood samples were withdrawn at intervals, 
up to the time when the animal was bled out under pentobarbitone 
anaesthesia. For each blood sample taken a plasma ultra - 
filtrate was prepared as described on page 69 . A cisternal 
c.s.f. sample was withdrawn at the time of death. After death 
the brain was removed, weighed and homogenised in 3 volumes of 
water. 
Aliquots of plasma, plasma ultrafiltrate, c.s.f. and brain 
homogenate were taken up in a minimal volume of solubiliser 
(N.C.S., Searle and Co., Ltd.) and counted in a liquid scintilla- 
tion counter (Mark II, Nuclear Chicago) using toluene scintillant 
solution (see page _4) 
As Figs. 1:16 and 1:17 indicate there was little evidence 
to suggest that methyltetrahydrofolate is actively concentrated 
by the c.s.f. Both at 3.2 and 5.0 hours after the injection 
of 14C- methyltetra.hydrofolate the plasma was more highly 
labelled than the c.s.f. If 14C- methyltetrahydrofolate was 
being actively transported into the c.s.f. it must have been 
very rapidly removed by uptake into the brain. In both animals 
the brain was about 6 times more highly labelled than the c.s.f. 
at the time of death. Preliminary results from comparable 
studies in the rat suggest similar findings. 
There have been two very short reports in the literature 
on the transport of folates between plasma and c.s.f. Levitt 
et al. (1969) found that methyltetrahydrofolate and formyl- 
tetrahydrofolate, both natural folate derivatives enter dog c.s.f. 
much more readily than do folic acid and methotrexate. Woodbury 
and Kemp (1971) state that 3H- folic acid is concentrated in the 
c.s.f. one hour after administration. Unfortunately they give 
no details as to the species of animal being used, nor the dosage 
or route of administration of the folic acid. Until the experi- 
mental details of both these studies are known it will be difficult 
to compare their findings with our own. Certainly our own data 
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FIG. 1:16 Distribution of 14C activity in plasma, plasma 
ultrafiltrate and brain of rabbit A after the intravenous 
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FIG. 1:17 Distribution of 14C activity in plasma, plasma 
ultrafiltrate and brain of rabbit B after the intravenous 
injection of 14C- methyltetrahydrofolate (140 - MeTHF). 
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active transport of methyltetrahydrofolate into the c.s.f. 
accounts for the concentration gradient in folate activity 
between c.s.f. and plasma. 
DISCUSSION 
The finding that oral folic acid treatment can raise the 
plasma folate activity to very high levels without any appreciable 
effect on the folate activity of c.s.f., has considerable bearing 
on a number of issues in the field of folate metabolism. 
Firstly, if, as has been suggested (Wells and Casey, 1967; 
Hunter et al., 1970), the folate activity of c.s.f. reflects 
the folate content of the brain one might infer from our findings 
that oralfolic acid therapy has little effect on the folate 
content of the brain. It is thus unlikely that the mental 
changes observed by Hunter et al., (1970) following administration 
of folic acid to healthy volunteers could be, as they suggest, 
due to toxic effects of folate on the central nervous system. 
Certainly we have found no evidence that oral folic acid, as 
administered by Hunter et al. (1970), has any effect on the turn- 
over of dopamine and 5- hydroxytryptamine in the central nervous 
system. 
The second issue on which our present results have some 
bearing is the relationship between folic acid, anticonvulsants 
and epilepsy. Reynolds (1967) has reported that folic acid 
treatment in epileptics on anticonvulsants causes an improvement 
in their mood and an increase in drive. Fit frequency and 
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severity was also increased (see review - Reynolds, 1971). 
Folic acid therapy has also been said to bring about a signifi- 
cant improvement in patients with organic psychoses, endogenous 
depression and schizophrenia (Carney and Sheffield, 1970). In 
the light of our present findings it is doubtful whether a 
specifically central action of folic acid can be responsible 
for these effects of folic acid therapy. Indirectly therefore, 
our findings lend support to the hypothesis that the effect of 
folic acid on fit frequency and severity is principally a result 
of increased peripheral metabolism of the anticonvulsant drug, 
leading to sub -therapeutic anticonvulsant drug levels. (Jensen 
and Olesen 1970; Baylis, Crawley, Preece, Sylvester and Marks, 
1971) . 
The most basic issue upon which our findings have a bearing 
is the whole question of the transport and distribution of 
folates between the plasma and the c.s.f. The current state of 
ignorance in the field stems largely from the fact that there are 
no sensitive and specific assay procedures which candifferentiate 
quantitively between the various folate derivatives (see intro- 
duction to Section 1). Thus, folate activity, as measured in 
the 1. caseii assay, cansefer to many different folate derivatives 
(Table 1:1) all of which may have different transport 
characteristics. 
In normal untreated animals inethyltetrahydrofolate appears 
to be responsible for most of the folate activity of plasma 
(Herbert et al., 1965). However the question of which derivatives 
are responsible for the increased plasma folate activity observed 
after oral folic acid, is still a matter of some debate. Baker, 
Frank, Feingold, Ziffer, Gellene, Leevy and Sobotka (1965) 
reported that an oral dose of 5 mg of folic acid in man raised 
the l.caseii activity of plasma but had little effect on the 
s.faecalis activity. The authors deduced from this that methyl - 
tetrahydrofolate was responsible for the large increases in the 
plasma folate activity seen after this dose of oral folic acid. 
This interpretation fits well with the report that dihydrofolic 
acid and tetrahydrofolic acid are methylated during absorption 
from the gut (Chanarin and Perry, 1969). However recent studies 
combining microbiological assay with radioactive (Butterworth 
et al. 1969) and chromatographic techniques (Melikian, Paton, 
Leeming and Portman Graham, 1971) indicate that the increased 
plasma folate activity after large oral doses of folic acid is 
due to folic acid itself. 
From our own studies with plasma ultrafiltrates it appears 
that oral folic acid treatment increases the proportion of 
total plasma folate activity which is bound to plasma proteins. 
This is the opposite of what one might elpect on the basis of 
simple saturation of protein binding. One explanation may be 
that the change in binding is reflecting the presence of a 
different form of folate: one which has a higher affinity for 
protein binding sites than the normal plasma forms. One might 
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specuhte that this difference in protein binding of the folate 
activity results from the presence of large amounts of folic 
acid in plasma. 
On the balance of the evidence therefore, it seems likely 
that oral folic acid treatment leads to a high plasma concentra- 
tion of folic acid itself. In normal circumstances this com- 
pound would not be present in the body: in some respects there- 
fore oral folic acid treatment creates a "non -physiological" 
increase in the folate activity of plasma. 
Blair (1970) has suggested that these very high tissue levels 
of folic acid may actually decrease the levels of the metaboli- 
cally active folate derivatives. This proposal was made on the 
ground that unreduced folic acid may act as a competitive inhibitor 
of the enzyme dihydrofolic acid reductase (Bertino, Perkins and 
Johns, 1965). This enzyme has an important role in recycling 
dihydrofolate (an important side product of thymidilate 
synthetase) back into the general pool of metabolically active 
folate derivatives such as methyltetrahydrofolate and tetra- 
hydrofolate. However the evidence from "in vivo" studies 
(Auletta, Mead and Waravdekar, 1970) suggests that this effect 
of folic acid may not be significant at normal dosage levels. 
Even if it were true that folic acid was inhibiting dihydrofolic 
acid reductase, it is doubtful whether such an action (Kaufman, 
1963) would influence the availability of reduced pteridine co- 
factor (see earlier discussion, page ó;) in the way Hunter et al. 
(1971) have suggested. 
-96- 
The interpretation that the increased plasma folate activity 
observed in our dogs was due to folic acid itself, suggests a 
simple hypothesis which might explain why c.s.f. folate activity 
is not raised. Levitt et al. (1969) have reported that folic 
acid enters c.s.f. at a very much slower rate than does methyl- 
tetrahydrofolate. Since this latter compound is the normal 
plasma form, selective uptake of methyltetrahydrofolate by the 
c.s.f. and exclusion of folic acid itself could explain both the 
no mal c.s.f. /plasma folate distribution and the altered distribution 
seen after oral folic acid treatment. Unfortunately, however, 
Woodbury and Kemp (1971) report that folic acid is selectively 
concentrated by the c.s.f. while we ourselves could find no evi- 
dence that methyltetrahydrofolate is selectively concentrated by 
the c.s.f. 
Another possible explanation for the observed folate activity 
distributions, before and after folic acid treatment, is that folates 
are unable to diffuse across the choroid plexus epithelial barrier, 
but that they are taken into the c.s.f. by a specific transport 
mechanism, which is normally working at saturation level. This 
would explain the lack of correlation between c.s.f. and plasma 
folates (ßr eckman and Lehtovaara, 1969) . By the same token, of 
course such a mechanism would be highly unlikely if the reported 
correlations between c.s.f. and plasma folate activity (Wells 
and Casey, 1967; Reynolds et al., 1969; Shaw et al., 1971) 
proved to be correct. Perhaps the strongest evidence for such a 
mechanism comes from Lanskowsky's report (1970) on a case of 
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folate malabsorption. In order to achieve detectable plasma 
folate activities (in this patient) by way of oral administration, 
it was necessary to give very high doses of folic acid (40 mg /day). 
However even after the plasma folate activity was raised, either 
by this means or by intramuscular injection, no folate activity 
could be detected in the c.s.f. These findings imply that the 
transport of folate both from gut to plasma and from plasma to 
c.s.f. involve essentially similar active processes in which 
diffusion plays little part. 
Investigation of folate absorption from the gut has established 
that poly - glutamate forms of folate, which make up the bulk of 
dietary folate, must be degraded to simpler folates before they 
can be absorbed ( Streiff and Rosenberg, 1967; Rosenberg, Streiff, 
Godwin and Castle, 1969; Hoffbrand, Necheles, Moldonado, Horta 
and Santini, 1969 ; Butterworth, Baugh and Krumdieck, 1969; 
Bernstein, Gutstein, Weiner and Efron, 1970). It has also been 
established that an active transport mechanism located in the 
duodenum and jejunum (Burgen and Goldberg, 1962; Cohen, 1965; 
Booth, 1968; Hepner,Booth, Cowan, Hoffbrand and Mollin, 1968; 
Hepner, 1969) could account for the rapid, and nearly complete, 
absorption of physiological doses of pure folic acid (Girdwood, 
1953; Anderson, Belcher, Chanarin and Mollin, 1960). 
Despite the proven existence of these folate transport 
mechanisms in the intestine it may be that the folate activity in 
c.s.f. is functionally isolated from the folate activity in plasma 
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and reflects only the folate activity of brain (Spaans, 197). 
Certainly, the brain seems to be a reservoir of considerable 
folate activity (150 ng /Jng wet weight), much of which is in a non - 
conjugated form (McClain and Bridgers, 1970). 
In the final analysis however this hypothesis is only specula- 
tion, as indeed are all the others which we have advanced to 
explain the known facts on the distribution of folate activity 
between c.s.f. and plasma. Complete understanding of this problem 
will depend to a large extent on the development of reliable 
techniques for the separation and analysis of each individual 
folate derivative. 
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SUIZVlARY 
SECTICT.d lA 
Four anticonvulsant drugs, diphenylhydantoin, phenobarbitone, 
sulthiame and carbamazepine were administered to dogs over a 
period of five weeks. None of these drugs had any effect on 
the level of folate activity in the c.s.f. or plasma. Nor did 
they alter the levels of the amine metabolites, homovanillic 
acid (HVA) and 5- hydroxyindol -3- ylacetic acid (5 -HIAA) in the 
ventricular and cisternal c.s.f. These results are discussed 
in relation to the lowered plasma and c.s.f. folate activities 
produced in man by chronic anticonvulsant treatment. 
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SECTION 1B 
Folic acid was administered to dogs over a period of five 
weeks. This treatment was found to cause a 10 -fold rise in 
plasma folate activity and a 5 -fold rise in plasma ultrafiltrate 
activity but to have no effect on c.s.f. folate activity. The 
c.s.f. levels of the amine metabolites, riVx and 5 -HIAÁ, were 
also unaffected by the folic acid treatment. It was concluded 
that folic acid treatment would be unlikely to have any signifi- 
cant effect on normal cerebral function. A short ancillary 
study in the rabbit found no evidence for the active transport 
of methyltetrahydrofolate (the predominant plasma form of 
folate) into the c.s.f. The implications of these findings 
are discussed, firstly in relation to the various clinical 
actions which have been attributed to folic acid therapy, and 
secondly in relation to the normal distribution of folate 
activity between c.s.f. and plasma. 
SECTION II 
THE EFFECTS OF ANAESTHETIC AND ANTICONWLSANT DRUGS 
ON C.S..F. POTASSIUM FLUXES. 
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INTRODUCTION 
Potassium and Convulsant Activity in the Brain 
In 1899 Meltzer reported that intracerebral injections of 
potassium chlorate produced hyperactive behaviour followed by 
convulsions, and finally coma. Sodium chlorate injected in 
equimolar quantities produced no significant effects. Similar 
excitatory effects of potassium on the central nervous system 
have since been reported by many others, including Koenigstein 
(1951); Feldberg and Sherwood (1957); John, Tschirgi and 
Wenzel (1958) and Nakajima (1964). 
The effects of excess potassium on the neurones in the 
hippocampus of the cat have been examined in detail by Zuckerman 
and Glaser (1968). In their experiments the inferior horn of a 
lateral ventricle of a conscious cat was perfused with artificial 
c.s.f. solutions in which varying amounts of sodium had been 
repl -;ced by potassium. When the concentration of potassium in 
the perfusion fluid was increased to twice normal (i.e. 2.7 meq/1- 
5.4 meq/l) single shock stimuli to the dorsal hippocampus were 
observed to give rise to localised epileptiform discharges: a 
phenomenon which was never seen when the perfusion fluid contained 
normal amounts of potassium. Perfusion of solutions of between 
three and five times the normal potassium concentration produced, 
after a latent period, s_}ontaneous paroxysmal discharges in the 
region of the dorsal hippocampus. The incidence and severity 
of the epileptiform activity was proportional to the increase in 
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the potassium concentration of the perfusion fluid. Zuckerman 
and Glaser therefore concluded that the activity resulted from 
an increased potassium concentration in the extracellular fluid 
of the hippocampus. 
Their hypothesis assumes that potassium can pass freely 
from the c.s.f., across the ependyma, into the extracellular 
fluid of the brain. This assumption would appear to be well 
justified. In the first instance Wallace and Brodie (1939 and 
1940) have demonstrated that iodide, bromide and thiocyaate, 
after introduction into the plasma, distribute in the brain extra - 
cellular fluid and the c.s.f. to an equal extent. More recently 
it has been shown that even large water soluble molecules such as 
inulin (Rell, Oppelt and Patlak, 1962; review - Rail, 1968) and 
ferritin (Brightman, 1965) can slowly diffuse out of the 
ventricular c.s.f. into the intercellular spaces of the brain. 
When it has been possible to compare brain extracellular fluid 
with c.s.f. these fluids have been found to be similar with 
respect to hydrogen ion and bicarbonate concentrations 
(Pappenheimer, 1967), and also with respect to potassium concen- 
tration (Cohen, Gerschenfeld and Kuffler, 1968). However per- 
haps the most direct evidence has come from studies in which the 
cerebroventricular system has been perfused with 42K solutions 
containing various concentrations of potassium (Cserr, 1965; 
Bradbury and Dayson, 1965; Katzman, Graziani, Kaplan and 
Escriva, 1965). It would appear from these studies that there 
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is a large and probably diffusion -limited exchange of potassium 
across the ependymal barrier. 
In view of these and other experimental findings it seems 
likely that the effects observed by Zuckerman and Glaser (1968) 
were indeed due to an increased potassium concentration in the 
extracellular fluid of the hippocampal region. Certainly the 
depolarising action of potassium and its potentiating effects 
on transmitter release in peripheral cholinergic neuronal systems 
(Gage and Quastel, 1965; Parsons, Hoffman and Feigen, 1965) 
suggest an appropriate scientific basis for the results observed 
by Zuckerman and Glaser (1968). With regard to the depolarising 
action of potassium it is interesting that a profound depolarisa- 
tion shift has been a common finding in intracellular recordings 
from neurones involved in experimentally induced seizure phenomena 
(Kandel and Spencer, 1961; Sawa Maruyama and Kaji, 1963; 
Matsumoto and Ajmone- Marsan, 1964; Sawa, Kaji and Usuki, 1965; 
Creutzfeldt, Watanabe and Lux, 1966; Sawa, Nakamura and Naito, 1968; 
Prince, 1968). 
Considerations such as these outlined above lead one to 
examine the factors involved in maintaining the "status quo" of 
brain and c.s.f. potassium. Under normal circumstances the c.s.f. 
potassium concentration is very much lower than that of a plasma 
dialysate (Flexner, 1934), and even chronic elevation of plasma 
potassium has been shown by Bekaert and Demeester (1951a); 
Dunker (1957); Kemeny)Boldizar and Pethes (1964); Bradbury and 
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Dayson (1965); and Bradbury and Kleeraan (1967) to have very 
little effect on c.s.f. potassium. Again there is only a very 
small drop in c.s.f. potassium when the plasma potassium is 
chronically lowered by glucose and insulin injections (Bekaert 
and Demeester, 1951b) . Si_nilarily, Cserr and Rall (1967) and 
Cohen et al. (1967) have reported the homeostatic control of 
c.s.f. potassium in the dogfish and necturus maculosus respect- 
ively. Total brain potassiixra is also amazingly constant in the 
face of chronic elevation of the plasma potassium (Davenport, 
1949; Leiderman and Katzman, 1953; Timiras, Woodbury and 
Goodman, 1954). 
This finding of stable c.s.f. and brain potassium concentra- 
tions and the effects seen when this stability is experimentally 
disturbed suggest that a breakdown of mechanisms controlling 
potassium concentration in the brain and c.s.f. might play a part 
in The epileptic process either in its genesis, propogation or 
continuation. This was first put forward as a hypothesis by 
Green in his review on hippocampal function (1964) and it has 
been discussed further by Zuckerman and Glaser (1968). Fertziger 
and Ranck (1970) have even proposed a model in which potassium 
accumulation in the intestitial spaces of the brain is an 
important step in seizure generation. 
4e were attracted by this hypothesis and decided to test it 
further by examining whether those drugs which prevent or 
terminate epileptic activity, namely the anticonvulsants, have 
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any uniform effects on potassium dynamics in the brain and c.s.f. 
Woodbury and Kemp (review -1971) have talked of anticonvulsants 
as membrane stabilisers and have reported that diphenylhydantoin 
affects sodium levels'in the brain and potassium levels in the 
c.s.f. The permeability of the "blood -brain barrier" has been 
reported to be increased by a variety of convulsive agents 
( Ovcharov, 1967), and anticonvulsants are said to block the 
increased permeability. As Ovcharov states /however., it is 
impossible to say whether the effects on permeability are 
primary or secondary to the convulsions. 
This problem of "cause and effect" is very common in 
studies of model systems of epilepsy and to avoid itwe decided 
to examine whether anticonvulsant drugs had any effect on the 
c.s.f. potassium transport mechanisms of the normal dog. 
Although one might argue such a study has little to do with 
anticonvulsant actions in epilepsy it may not be far removed 
since it is very likely that anticonvulsants act principally on 
normal brain tissue, by modifying t1 e r3sponse to the abnormal 
activity of an epileptogenic focus. 
The drugs included in the study were sodium thiopentone, 
sodium pentobarbitone, paraldehyde, diazepam and diphenylhydantoin. 
The first two of these are rather non -specific depressants of 
neuronal activity and the latter three are more specifically 
anticonvulsants. These particular drugs were chosen because 
their clinical effectiveness in status epilepticus indicated a 
-105- 
rapid onset of action after acute administration, thus making 
them suitable for use in acute experiments. 
Ideally we would have liked to be able to measure the 
potassium concentrations of the intra- and extracellular compart- 
ments of brain during these studies but this is not yet possible 
in mammalian brain. Woodbury (1955) has calculated intracellular 
potassium in brain with the assumptions that the extracellular 
fluid volume is equivalent to the chloride space and that all 
the potassium in brain is intracellular but neither of these 
assumptions is valid enough to make the method reliable. 
In the absence of direct methods of studying the effects of 
anticonvulsants on brain potassium it was decided to approach 
the problem by examining the transport of potassium into and out 
of the cerebrospinal fluid. All previous studies of this nature 
have been carried out by the technique of ventriculo- cisternal 
perfusion (Pappenheimer, Heisey, Jordan and Downer, 1962; 
Cserr and Pappenheimer, 1964; Cserr 1965; Bradbury and Dayson 
1965; Katzman et al., 1965) and it was therefore decided to 
adapt the "recirculatory" perfusion systemdeveloped in this 
department (Ashcroft, Dow and Moir, 1968) to a system which 
would permit "open" perfusion studies in the conscious dog. 
Stress should be laid on the desirability of studying the con- 
scious animal since studies of cerebral mechanisms carried out 
under anaesthesia are certainly not studies of "normal" 
mechanisms. In this respect our studies supplement the earlier 
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studies of Cserr (1965), Bradbury and Dayson (1965) and Katzman 
et al. (1965) where only anaesthetised animals were used. 
Ventricular-Cisternal Perfusion 
The first description of a ventricular -cisternal perfusion 
was by Adam, McKail, Obrador and Wilson (1938) from the 
Department of Pharmacology and Surgery of this University. The 
technique has since been widely applied to the study of the 
central nervous system and its environment. 
In early experiments the method was used to study the 
release of transmitters from the brain (Adam et al., 1938), to 
study the response to alteration of the ionic environment of the 
brain (Leusen 1950, 1954 a, b), and to administer drugs directly 
to the ventricular surface of the brain (Royer, 1950). This 
qualitative type of application has continued to be most productive 
and has been developed (e.g. Bhsttycharya and Feldberg, 1958 a, b ; 
Carmichael, Feldberg and Fleischauer, 1964) to the extent that 
it is now possible to localise the site of action of particular 
treatment (e.g. Zuckerman and Glaser, 1968), or the site of 
release of a specific compound (e.g. Beleslin, Carmichael, and 
Feldberg, 1964; Portig, Sharman and Vogt, 1968) to a definite 
area of brain. 
The other major development in perfusion technique has been 
the introduction of analytical techniques which enable one to 
carry out quantitative studies on the rates of entry and /or 
removal of substances from the c.s.f. The pioneer work in this 
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field was carried out by two research groups led by Pappenheimer 
and Dayson. In their initial study Pappenheimer and his 
colleagues (Pappenheimer, Heisey and Jordan, 1961) reported the 
ventriculo- cisternal perfusion of the conscious goat and demon- 
strated that diodrast and phenelsulphonpthalein were actively 
transported from the c.s.f. In a further paper (Pappenheimer, 
Heisey, Jordan and Downer, 1962) they described the perfusion 
technique in detail, and reported calculated rates of removal 
of inulin, creatinine, fructose, urea, sodium and potassium from 
the system. It was noted that potassium and urea appeared to 
be distributed in a larger volume than the other substances, and 
it was suggested that this might indicate that the ependymal cells 
lining the ventricles were more permeable to these substances. 
In a companion paper (Heisey, Held and Pappenheimer, 1962) they 
reported the detailed kinetic analysis of the perfusion system, 
describing how inulin dilution could be used to measure the rate 
of formation of c.s.f. within the ventricles. They also described 
the use of inulin clearance as a measure of the rate of loss of 
fluid from the system by bulk flow to the subarachnoid spaces. 
This use of inulin dilution to measure c.s.f. formation 
rates and bulk absorption rates for c.s.f. has been a common 
feature in many studies and is worth considering in detail. 
The method relies on the assumption that the diffusional losses 
of inulin in passage through the system are negligible. The 
justification for this assumption which was put forward by 
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heisey et al. (1962) was that the rate of removal of inulin 
from the system varied linearly with changes in c.s.f. pressure, 
almost no inulin being lost when the pressure was reduced to 
zero. This finding was confirmed by Bering and Sato (1963). 
Dayson, Kleeman and Levin (1962) and Pollay and Dayson (1963) 
both reported that the values of c.s.f. formation rate obtained 
from inulin dilution calculations were in good agreement with 
these obtained from straightforward measurements of c.s.f. flow 
from a cisternal cannula. In view of these findings inulin has 
been added to the perfusion fluid in all our studies as a marker, 
allowing calculation of the rates of formation and bulk absorption 
of c.s.f. 
With the use of inulin as a "non- diffusible" marker to 
monitor the bulk flow of perfusion fluid, it became possible, for 
the first time, to carry out quantitative studies of the efflux 
of a substance from the c.s.f. Among the compounds where trans- 
port from the c.s.f. has been studied in this way are iodide, 
paraaminohippuric acid and thiocyanate (Pollay and Dayson, 1963), 
homovanillic acid and 5- hydroxyindol- 3- ylacetic acid (Ashcroft, 
Dow and Moir, 1968) and tryptophan (Geddes and Moir, 1969). 
Of particular relevance to our own project are the studies 
reported in 1965 from three independent groups of workers 
following up Pappenheimer's original observations on potassium 
transport from the c.s.f. (Pappenheimer, Heisey and Jordan, 1962). 
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These reports came from Cserr (1965), who had given a preliminary 
communication ( Cserr and Pappenheimer, 1964), Bradbury and 
Dayson (1965) and Katzman et al. (1965). The studies were 
carried out on dogs, rabbits and cats respectively, all in the 
anaesthetised state. 
Despite the species differences the findings were essentially 
the same in all the studies,namely: that the "clearance" of 
42K from the perfusion system was very much greater than the 
r 
"clearance" of inulin; that most of the 2K cleared from the 
ventricular spaces could be recovered from the brain (assuming 
that the normal c.s.f. concentration of potassium, i.e. approx- 
imately 2.9 meq/l, was adhered to in perfusion) at the end of 
a perfusion; that ouabain reduced the ependymal efflux of 42K 
to roughly one quarter of its pre-ouabain level; that for influx 
concentrations between 0 and 10 meq/1 a constant fraction of the 
potassium in the c.s.f. appeared to cross the ependymal or 
choroidal epithelial barriers; and that the influx of potassium 
into the c.s.f. seemed to be principally derived from brain. 
These findings suggested that an examination of the effects 
of anaesthetics and anticonvulsants on the c.s.f. potassium fluxes 
might contribute to a better understanding of the relationship 
between potassium and convulsant activity in the brain. In view 
of the fact that Pappenheimer, Fenci, Heisey and Held (1965) in 
repeating earlier work of Leusen (1954 a, b) found that the 
changes in respiration seen after altering the ionic content of 
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c.s.f. were very much greater in the conscious animal than in 
the anaesthetised animal, we decided there would be major 
advantages in carrying out our study on conscious animals. 
METHODOLOGY 
Perfusion Technique 
The perfusion technique used in this study was a hybrid of 
the open perfusion system developed by Pappenheimer's group 
(Pappenheimer, Heisey and Jordan, 1961) and the recirculatory 
perfusion system developed in this department (Ashcroft, Dow and 
Moir, 1968) . An "open" system, that is one in which fluid is 
pumped from a reservoir to the lateral ventricle and collected 
from the cisterna magna, was chosen in preference to a recircu- 
latory system because an open system is much simpler to analyse 
kinetically and reaches a "steady state" more rapidly. However, 
in order to carry out open perfusions in conscious free -moving 
animals it was necessary to find an alternative to a simple 
pressure- controlled outflow at the cisternal site. 
This problem was solved by putting another pump on the out- 
flow side, functioning at the same rate as the inflow pump. The 
pressure control within the c.s.f. perfusion system (actually 
the volume of fluid held between the two pumps) was thus left to 
the dogs' normal mechanisms for regulating c.s.f. pressure. In 
this respect the system is similar to a closed recirculatory 
perfusion. 
The basic animal methodology, that is, the use of permanently 
implanted guide tubes to the ventricles and the cisterna magna, 
was identical to that described in Section I of this thesis and 
was unchanged from the form originally developed for recirculatory 
- 112 - 
perfusion studies (Ashcroft, Dow and Moir, 1968). 
Needles 
The needles used to make the percutaneous puncture and 
connect the external perfusion circuit to the doges ventricular 
system were 21 gauge, luer- fitting stainless steel needles with 
a short b evel and a small side hole near the tip. A set of 
three such needles, one for each of the two ventricular guide 
tubes and one for the cisternal guide tube, was prepared to the 
exact length specifications (see page 28) for each dog used in 
perfusion experiments. By this system it was possible to ensure 
rapid and reproducible entry to the ventricular and cisternal 
spaces simply by carefully advancing the needle down the guide 
tube to its full depth. 
Perfusion Circuit 
The open perfusion system which we have employed in these 
experiments is shown in the photograph, Fig. 2:1. Fig. 2:2 is a 
diagrammatic representation of the same system. As can be seen 
in Fig. 2:2 the basic features of the system are a reservoir of 
artificial c.s.f., two pumps, both with identical flow rates, the 
dog itself and a fraction collector to collect successive aliquots 
of the perfusate. 
These component parts of the system were linked up with 
silicone rubber tubing of 0.8 mm internal diameter and 4.0 mm 
external diameter (Watson -Marlow). Luer -lock adapters (Fig. 1 :7) 
fraction 
collector 
reservoir of A 
artificial ç.s.f.= 
FIG. 2:1 Photograph of perfusion system showing a dog being 
p erfus ed . 























FIG. 2:2 Diagram of "open'' cerebroventricular perfusion system. 
The inflow and outflow pumps are separate modules of the 
same multichannel pump. Both modules are set to pump at an 
identical flow rate. 
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were used to connect the tubing of the external circuit to the 
perfusion needles in the ventricular and cisternal guide tubes. 
Inflow Side of Circuit 
The inflow perfusion fluid (pagel-LG)was contained within a 
reservoir bottle kept at 37 °C by a heated water bath. The 
rubber cap of the bottle was pierced by three hollow needles, one 
to bubble 5iß CO2 in oxygen into the fluid, one to withdraw fluid 
and one to allow the injected gases to escape. From this 
heated reservoir the artificial c.s.f. was pumped to the inflow 
needle, leading into one of the dog's lateral ventricles. In- 
serted into the inflow tubing, between the pump and the inflow 
cannula, was a small glass drip-chamber which allowed rapid con- 
tinuous assessment of the rate of inflow into the lateral 
ventricle. 
Outflow Side of Circuit 
From the needle in the cisternal guide tube outflow fluid was 
pumped directly to a fraction collector. The fraction collector 
was set to change sample tubes after a fixed number of drops, 
this number depending on the volume of fluid required for assay 
procedures and on the number of sampling points required in a 
fixed time interval. 
Pumps 
In early perfusion experiments an M. H.:R. E. Flow Inducer pump 
(Watson Marlow Ltd.) was used, with two of the available channels 
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acting as inflow and outflow pumps. Before each perfusion the 
two channels were checked and,if necessary, adjusted to ensure 
that both were pumping at 0.300 
± 
0.003 ml /min. 
In later experiments this pump was unavailable and a Technicon 
fractionating pump was used. This pump, while perhaps delivering 
a more constant flow over a period of several hours, suffered 
from the disadvantage that it was capable of exerting considerable 
pressure should any block develop in the perfusion circuit. 
As is shown in the results section,both pumps were relatively 
non -pulsatile and did not cause any serious disturbance in the. 
pressure of c.s.f. within the dog's ventricular system. 
Pre aration of Artificial C.S.F. 
Batches of sterile artificial c.s.f. were prepared in 100 ml 
or 200 ml volumes by the Pharmacy Department at the Edinburgh 
Royal Infirmary. 
The composition of the fluid perfused is shown in Table 2:1. 
In fact the substances marked with an asterisk, potassium 
chloride (sterile aqueous solution of 20% KC1) and sodium bicarb- 
onate (solid) were not added until the morning of the perfusion. 
The omission of potassium chloride until this late stage 
meant that experiments did not have to be restricted to a fixed 
time in relation to the delivery of the short-lived isotope: a 
relatively constant amount of 42K could be added to the perfusion 
fluid (10 }ac /100 ml) regardless of the specific activity of the 
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Chlorid e 132.83 
Constituents 
Sodium Chloride 7.320 
Potassium Chloride 0.222 
Magnesium Chloride 0.095 
Calcium Chloride 0.158 
Sodium Dihydrogen Phosphate 0.070 
Sodium Bicarbonate 2.150 
Glucose 0.800 
see text (pagel .ú) . 
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radioactive 2otassium chloride solution. Sodium bicarbonate was 
not added until after sterilisation in view of the difficulties 
encountered during heat sterilisation. 
Solid inulin was added to the artificial c.s.f. to give an 
inflow concentration of the order of 150 -250 )2g/ml. Within this 
range the actual amount added was not critical since absolute 
measurements of inulin concentration were not required. Only 
the relative concentrations of the inflow and outflow fluids were 
necessary for analysis of the inulin data. 
Preparation for ventricular- cisternal erfusion 
Food was withheld from the animal for 18 hours prior to the 
experiment but water remained freely available up till the time 
of the experiment. 
Approximately one hour before the start of an experiment the 
perfusion circuit was sterilised by pumping boiling water through 
it for 40 minutes and then allowing it to empty. The needles 
and stilettes appropriate to the dog being studied (see page n2), 
were sterilised in boiling water, along with the three hollow 
steel needles which were to enter the bottle of sterile perfusion 
fluid. 
Before commencing a perfusion the bottle of artificial c. s. f. , 
containing 2K and inulin in addition to the standard ingredients 
(Table 2:1), was equilibrated with 5% 002 in oxygen and this was 
continued throughout the perfusion. After 15 minutes to allow for 
complete equilibration the inflow circuit of the perfusion system 
- 119 - 
was primed with artificial c.s.f. Narrow range indicator paper was 
used to confirm that the pH of the inflow fluid was approximately 
7.4. 
The next step in the experimental procedure was to cannulate 
the ventricle and cisterna magna of the dog. 
Ventricular Puncture 
The skin overlying the ventricular guide tube on the side to 
be punctured was infiltrated with a small volume of lignocaine.(2%) 
The dog's head was steadied by an assistant and a needle of 
appropriate length, with its stilette in position, was pushed 
firmly through the skin into the guide tube and advanced to its 
full depth, after which the stilette was removed. A satisfactory 
placement within the ventricle was verified either by spontaneous 
welling up of c.s.f. into the cup of the needle, or by the appear- 
ance of c.s.f. when slight negative pressure was applied with a 
1 ml syringe. When a free flow of c.s.f. had been established 
the luer-lock on the inflow tubing was firmly screwed onto the 
needle. The dog showed no more distress during this procedure 
than it would during a venepuncture. 
Cisternal Puncture 
As at the ventricular site the area of skin overlying the 
entrance to the guide tube was infiltrated with a small volume of 
lignocaine. Then, while an assistant supported the dog's head in 
a flexed position, a ci- ternal needle of appropriate length, with 
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its stilette in position, was pushed firmly through the skin into 
the guide tube and advanced for approximately half its length, 
after which the needle was given a slight bend. This bend in the 
needle acted as a spring to keep the needle firmly in position in 
the guide tube. After putting this bend in the needle a 
rotatory movement was used to advance the needle down the tube 
and through the atlantor occi vital membrane into the cisterna 
magna. Satisfactory placement was verified when, on removal of 
the stilette, c.s.f. welled up into the cup of the cisternal 
needle. Occasionally it was necessary to apply slight negative 
pressure with a 1 nil syringe before c.s.f. could be drawn up into 
the cup of the needle. Once a free flow of c.s.f. had been 
established the luer fitting on the outflow tubing was screwed 
firmly onto the hub of the needle. 
The position of the needles relative to the ventricle and 
cisterna magna is shown in Fig. 1: 6 . 
Perfusion 
Once both the ventricular and cisternal needles were in 
position and connected to the perfusion circuit (Fig. 2:3 ), 
perfusion tubing was secured to the back of the dog's neck with 
adhesive tape, in order to prevent tension in the tubing putting 
any direct pull on the needles. After a final check, a clock 
was started and the inflow and outflow pumps switched on. Having 
ensured that c.s.f. was flowing freely from the cisternal needle and 
that all was well on the inflow side the experimenter could then 
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FIG. 2:3 Photograph of dog Ao(Dougal) during perfusion. 
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settle down to a routine of tuning sample changes, keeping alert 
to any signs of blockage or leak in the system and amusing the 
dog, which in the case of an active dog was usually the most 
difficult task. 
In control experiments the perfusion was continued for a 
period of 3 -4 hours. In a drug experiment the perfusion 
proceeded as in a control experiment until a reasonable number 
of "steady- state" samples had been collected. The drug was 
then administered. Because of the considerable dead space in 
the outflow tubing (about 1.5 ml) the first one or two samples 
collected within ten minutes of giving the drug were not regarded 
as characteristic of the post -drug state. 
If the drug being administered was an anaesthetic the dog 
had to be supported carefully during the induction period to 
make sure it did not collapse and disturb the perfusion needles. 
The unconscious dog was laid flat on its side and covered with 
a blanket. Since the perfusions were carried out in a waria 
room (2500) no other measures were found to be necessary to 
maintain the dog's temperature at its normal level (37.8°C). As 
a check a rectal thermometer was routinely inserted after 
anaesthetising the dog. 
From early experiments it was found that, at the flow rate 
of 300 ± 3 pi /min which was used in all these studies, a steady 
state was reached after 70 -100 minutes of perfusion. During 
2 
this steady state the concentrations of inulin and K in the 
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outflow fluid were relatively constant. 
At the end of the perfusion (between 3 and 4 hours usually) 
the pumps were switched off and the ventricular and cisternal 
needles gently removed. The dog was then returned to temperature - 
controlled kennels which were suitable for animals producing 
radioactive excreta. (In fact the excreta of these dogs did 
not reach detectable levels of radioactivity.) 
Crystamycin (Glaxo) was given routinely by intramuscular 
injection, 1 ampoule (1,000,000 units benzyl penecillin and 0.5 g 
streptomycin) daily for three days. 
The numbered samples of outflow fluid were removed from 
the fraction collector and placed along with three similar samples 
of inflow fluid ready for 42K, inulin and total potassium assays. 
Because of the short half life of 42 K (12.5 hours) it was advisable 
to carry out the assay for this substance on the day of the 
perfusion. Once aliquots had been removed for the 42K assay the 
samples were deep frozen until next dayyat which time inulin and 
total potassium concentrations were estimated. 
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ANALYTICAL METHODOLOGY 
Chemical Reagents and Drus 
Inulin 
42K potassium chloride solution 
Indol -3 -y1 acetic acid 
Ligno -caine ( "Xylocaine ") 
Sodium thiopentone ( "Pentothal ") 
- British Drug Houses 
- Radiochemical Centre,Amersham 
- Koch Light Co., Ltd. 
- Astra Chemicals 
- Abbott Laboratories Ltd. 
Sodium pentobarbitone ( "Nembutal") - Abbott Laboratories Ltd. 
Diazepam ( "Valium") - Roche Products Ltd. 
Diphenylhydantoin ( "Epanutin ") - Parke -Davis 
Paraldehyde - Evans Medical. 
All reagents not mentioned above were analytical grade 
except hydrochloric acid which was micro- analytical grade 
(British Drug Houses). Distilled de-ionised water was used 
throughout. 
The 2K potassium chloride solution had a specific activity 
of 675 Jlc /meq at 13.00 hours on the day of delivery and could be 
used for up to three days after delivery. 
Estimation of Inulin in Perfusion Fluid 
Inulin in the inflow and outflow fluid samples was measured 
by an adaptation of the method of Heyrovsky (1956) in which no 
protein precipitation step was necessary because of the low levels of 
protein in the samples. 
The assay procedure depends on the hydrolysis of the inulin 
to fructose units and their subsequent formation of a purple 
condensation product with indol- 3- ylacetic acid. 
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With inflow concentrations of between 150 and 400 N.g /ml 
and "steady state" outflow levels between 80 and 95% of that 
figure, an aliquot of 0.1 ml of perfusion fluid contained an 
appropriate amount of inulin for an assay within the linear range 
of the standard curve. 
Procedure 
An 0.1 ml aliquot of perfusion fluid was made up to 0.5 ml 
with water in a 15 ml glass tube and to this was added 0.1 ml 
indol- 3- ylacetic acid solution (0.5% w/v in ethanol), and 4.0 ml 
concentrated hydrochloric acid. The contents of the tube were 
thoroughly mixed and then incubated at 40 °C for 80 minutes. After 
cooling the tubes, the optical density of the purple solution was 
measured in a spectrophotometer (Unicam SP 500) at 530 m)i, against 
a water blank which contained all the reagents and had been taken 
through the incubation. 
Over the range of inulin concentrations of the samples the 
optical density of the solution was directly related to the inulin 
concentration. It was not strictly necessary to include 
standards in the assay but duplicate standards containing 0,40 jig 
inulin per tube were always included with perfusion samples,('ig.2:4). 
In the time taken to read the optical density of all the 
samples from a perfusion (up to 1.5 hours) it was found that the 
intensity of colour in the samples increased without a corresponding 
increase in the blank. Presumably this was because the hydrolysis 
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FIG. 2:4 Inulin Standard Curves 
The curves demonstrate good linearity within the 
specified range of inulin concentrations. 
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incubation. A correction based on the average change in the 
standards over the time of optical bnsity measurements was 
applied to all samples. 
Estimation of zK in Perfusion Fluid 
In aqueous solutions the high energy emissions of 42K 
generate Cerenkov radiation and this can be detected in a liquid 
scintillation counter. The efficiency of counting was determined 
by a channels ratio method (Moir, 1971) based on the original 
channels ratio method of Baillie (1960). 
In the early experiments counting was done in the department 
of Medical Physics, Edinburgh Royal Infirmary on a Packard Series 
3003 Tri -Cab Liquid Scintillation counter. Most of the counting 
was however done in Nuclear Chicago Mark II Liquid Scintillation 
Counter and the methodology to be described applies only to 42K 
estimation using this instrument since the earlier methodology has 
been fully described by Moir (1971). 
Because of the rapid decay of 42K (half life 12.5 hours) 
the general level of activity in the samples tended to vary from 
experiment to experiment and the proportion of sample which was 
actually counted could be varied according to the estimated 
activity. Within each assay however the volume of sample 
counted remained constant. An aliquot of perfusion fluid 
(always between 0.2 and 1.0 ml) was made up to 10 ml, with water, 
in a 20 ml glass scintillation vial and counted at the settings 
szown in Table 2:2. The counts were first corrected for background 
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FIG. 2:5 Channels ratio quench curve for Cerenkov counting 
of 42K activity in aqueous solutions. 
'4uenching agent - blood 
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and then for quenching, using the efficiency /channels ratio 
curve shown in Fig. 2:5. 
1 
TABLE 2:2 : Instrument Settings for Cerenk ov Counting of 42K 
in Perfusion Fluid. 
Gain Setting Discriminator Settings 
Lower Upper 
2 
Channel 1 A - 1000 05 - 30 
Channel 2 A - 1000 05 - 99 
1 
- Nuclear Chicago Mark II Liquid Scintillation Counter 
2 - Channels Ratio - Channel 1 / Channel 2. 
On some occasions the radioactivity in the samples was low 
and the time taken to reach a satisfactory number of counts was 
long so that a correction factor had to be applied to the 
calculated counts in order to bring them to a common time of 
counting. For instance, if the samples were counted for 2 
minutes each, the 30th sample would contain only 94.6% of the 
activity when the first sample was counted. The correction 
factors were obtained from isotope decay tables (Documenta 
Geigy, 1971). 
Estimation of Total Potassium in Perfusion Fluid 
Potassium was estimated by flame emission, with an SP 90 
Atomic Absorptionmeter (Pye- Unicam) set in the emission mode. 
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An absorption filter was placed between the flame and the mono - 
chromator to reduce sodium interference to a minimum. 
With the air /acetylene emission burner head in position the 
optimum conditions of assay were usually as follows: 
Slit Width : 0.08 mm 
Wavelength : 7665 rap. 
Air Flow : 4 1 /min 
Acetylene Flow : 650 ml /min 
Filter : ;Vratten No. 35 (Kodak) 
Gain : High gain, position 3. 
Burner Height : 1.4 cm. 
An 0.1 ml aliquot of sample was pipetted into a small poly- 
ethylene container. (capacity 4 ml) and diluted to 2.1 ml with 
distilled deionised water. The emission of the solution was 
measured at the potassium resonance wavelength of 7665 41. Samples 
were read along with identical dilutions of potassiva standards 
covering the range 2 -4 meq/1. To account for any residual inter- 
ference from the sodium in the samples the potassium standards were 
made up in a solution of sodium chloride (160 meq/l) with approx- 
imately the same sodium content as perfusion fluid and c.s.f. 
All standard solutions were stored in polyethylene bottles. 
Over the range of potassium studied the emission was linearly 
related to the potassium concentration in the solution being 
atomised. 
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Estimation of p002 of alveolar air 
End alveolar air was obtained by a method based on that 
described by Travis, Wiley, Nechay and LIaren (1964). One of the 
fingertips was cut out of a standard surgical glove and a hollow 
cardboard tube (diameter 1.5 cm, length 8 on) was inserted into 
th finger, and the other four fingers were tied off. A small 
flexible butyl rubber tube (non- porous to 002), of internal 
diameter 0.25 cm, was then stuck to the inside of the tube, with 
one end facing into the glove and theother end free. This 
specially prepared glove was then fitted over the dog's nose and 
mouth and adjusted so that the cardboard tube was in direct 
apposition to the dog's nostrils, thus minimising the dead space. 
As the dog breathed out the expired gases in the rubber tube were 
sampled by a 002 gas analyser (Beckman IB I, Medical Gas Analyser). 
The content of CO2 in the expired gases could be read off directly 
from this instrument. At the end of each breath the 002 content 
of the expired gases was stable and this value was taken as the 
best estimate for the CO 
2 
content of end alveolar air. 
Estimation of p002 and pH of C.S.F. 
For the sampling of c.s.f. a small three way T- junction was 
inserted into the perfusion circuit immediately next to the outflow 
from the needle in the dog's cisterna magna. A small piece of 
butyl rubber tubing (non -porous to 002) was then connected up to 
the free arm of the junction which was normally kept closed by 
a small bulldog clip. Small glass capillaries (200 p1) could 
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then be inserted into the sampling arm and when the bulldog clip 
was released and placed on the perfusion outflow tubing beyond 
the junction, perfusate from the cisterna magna passed into the 
capillary. 
From the capillary the sample was rapidly transferred to the 
sampling chamber of pH /p CO2 analyser (Radiometer - Blood Micro 
System). After allowing the sample time to equilibrate to the 
operating temperature of the system (37 
± 
0.03 °C), the pH and 
CO2 measurements were performed and the results were read off 
directly from the instrument. 
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THEORY 
The basic equations necessary for kinetic analysis of open 
cerebroventricular systems were derived by Pappenheimer and his 
co- workers during their perfusion studies in the conscious goat 
(Pappenheimer, Heisey and Jordan, 1961; Heisey, Held and 
Pappenheimer 1962). Using fundamentally similar methods of 
analysis Cserr (1965), Bradbury and Dayson (1965) and Katzman, 
Graziani, Kaplan and Escriva (1965) have investigated the trans- 
port of potassium between blood, brain and c.s.f. 
In our own studies the perfusion data have been analysed in 
terms of a simple two compartmental model (Fig. 2:6), with the 
c.s.f. as one compartment and the brain and the blood as a 
composite second compartment. 
Fig. 2:7 illustrates the time course of a typical perfusion 
experiment. In the first 70 -100 minutes of a perfusion the 
endogenous c.s.f. in the dog's ventricular system is gradually 
displaced by perfusion fluid containing inulin and 42K. This 
phase is represented by the increasing inulin and 42K concentrations 
in the outflow fluid. When the process is complete a "steady 
state" is achieved in which the concentrations of 42K and inulin 
in the outflow fluid remain constant, signifying that the rates 
of loss of 42K and inulin from the system are also constant. 
The two compartmental analysis to be presented below applies 
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FIG. 2:6 Two- compartmental :Model of ventricular perfusion 
system. Compartment V is that part of the 
ventricular system which is being perfused. B is 
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FIG. 2:7 Time course of a control rerfu ions concentrations 
of inulin, 
42g and total potassium in the outflow 
perfusion fluid. The inulin and 42K concentrations 
have been expressed as a percentage of their concentra- 
tion in inflow fluid. 
In this experiment the system reached a "steady - 
state" after a period of 60 to 80 minutes of perfusion 
(flow rate 0.300 ml /min). 
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Definitions 
The flux of substance from one compartment to another is 
defined as the amount of substance which crosses the boundary 
in unit time. In the present experiments the area of the 
boundaries to the c.s.f. compartment perfused is not known but 
is assumed to remain constant throughout an experiment. 
The loss of fluid from the system by bulk absorption refers 
to fluid which passes out of the cisterna magna into the sub - 
arachnoid spaces from where it drains back into the blood stream 
via the arachnoid villi. The clearance of substance x from 
compartment A by the pathway leading to compartment B is defined 
as the volume of A from which x is effectively removed per unit 
time via that pathway. It therefore has the dimensions of flow 
(volume of fluid /unit time), and when used in the term inulin 
clearance from the c.s.f. it actually refers to the flow of fluid 
out of the perfusion system into the subarachnoid spaces. 
Symbols 
V = flow rate - ml /min 
C = concentration - meq/ml 
C* = radioactivity - d.p.m. /m1 
C = mean concentration - meq/ml 
Clin = inulin clearance from 
ventricular system 
- ml /min 
J = flux - meq/min 
J = flux (as applied to 
radioactive substance) 
- d.p.m. /min 
N = net flux - meq/min or d.p.m. /min 
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Subscripts have been applied as follows: - 
i - perfusion inflow fluid 
o - perfusion outflow fluid 
f - freshly secreted c.s.f. 
a - fluid lost from system by bulk flow into 
the subarachnoid spaces 
v - ventricular compartment 
b - composite brain and blood compartment 
These last two subscripts v and b when used in 
combination imply direction from the first to the second. 
Rate of Formation of C.S.F. in the Ventricles - Vf 
Assumption I - Diffusional losses of inulin from the 
c.s.f. compartment are negligible. 
Then where C refers to inulin 
Vi Ci = (Vi + Vf) Co 
, 
Vf = Vi (Ci - Co) Eqn. (1) 
Co 
Va Rate of Bulk Ab sors tion of Fluid - 
Assumption. II - The volume and pressure within the 
c.s.f. compartment are constant. 
0 fl ® 
Then Vi + Vf = Vo + Va Eqn. (2) 
In our experiments Vi = Vo 
i D 
. ' . Vf = Va 
However the bulk absorption of c.s.f. may also be 
derived directly as below - 
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Assumption III - The fluid absorbed in bulk from the 
c.s.f. compartment has a similar inulin 
concentration to perfusion outflow fluid. 
Assumption IV - The concentration of inulin in freshly 
secreted c.s.f. is negligible. 
Then where C refers to inulin: 
d . c 
Vi Ci = Vo Co + Va Co 
. a o 
. ' . Va = Vi Ci - Vo Co Eqn. ( 3 ) 
Go 
. o 
As Vi = Vo in our system eqn. (3) is identical with 
eqn. (1). Va (bulk absorption) has been termed Cl in 
(Inulin Clearance) by Pappenheimer and colleagues, where 
clearance is expressed in ml of outflowing perfusate. 
Potassium Data 
Once the rate of formation/bulk absorption of c.s.f. have 
been calculated from the inulin data it is possible to split up 
the steady -state loss of 42K from the system into that fraction 
which is lost by bulk absorption of fluid, and that fraction which 
passes either into the brain across the ependymal barrier or into 
the blood across the choroid plexus epithelium. 
The net flux of substance across the cellular barriers 
making up the boundaries of the c.s.f. compartment is equal to 
the flux of substance out of c.s.f. (i.e. efflux) minus the flux 
of substance into the c.s.f. (i.e. influx). 
i. e. N 
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= Jvb - Jbv Eqn. (4) 
s e o e 
and Vi Ci + Vf Cf + Jbv = Vo Co + Va Co + Jvb Eqn. (5) 
N =Vi Ci - Vo Co+ 
Vf Cf - Va Co Eqn. (6) 
In the case where 42K is present in tracer amounts in the 
perfusion fluid - 
Assumption V - During the time course of the experiment 
there is no appreciable labelling of 
brain or plasma therefore: 
Jbv = 0 
and Cf = 0 
. ' . Combining Eqn. (4) with Eqn. (6) 
4 -;{ 
Jvb = Vi Ci - Vo Co - Va Co 
= Vi Ci - (Vo + Va) Co Eqn. (7) 
Assumption VI - The tracer atoms of 42K behave in manner 
representative of the parent species. 
To convert this efflux in terms of tracer 42K to an efflux 
in terms of potassium the terms on the right of Eqn. (7) were 
divided by the mean specific activity of the ventricular 
compartment. 
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Assumption VII - The mean specific activity of the c.s.f. 
compartment can be represented by the 
arithmetic mean of the specific activities 
of the inflow and outflow fluid. 
For potassium 
0 ,* 
Jvb = Vi Ci - (Vo + Va) Co 
(Ci + Co ) x 0.5 
(Ci Co ) 
Returning now to Eqn. (5) 
4 G o o 
Eqn. (8) 
Vi Ci + Vf Cf + Jbv = Vo Co + Va Co + Jvb Eqn. (5) 
we can see that all the terms are known for potassium except 
Cf and Jbv. 
Assumption VIII - The concentration of potassium in newly 
secreted c.s.f. in the dog has a constant 
value of 3.0 meq/1 (Ames, Sakanoue, and 
Endo, 1964; - Cserr, 1905). 
6 0 
Then Jbv = Vo Co - Vi Ci + Va Co - Vf.3.0 + Jvb Egn. (9) 
Both the efflux (Jvb) and influx (Jbv) of potassium from 
and into the c.s.f. compartment have the units of r -I. 
rneq /min . 
"Clearance" Co- efficients 
In the studies of Cserr (1965), Bradbury and Dayson (1965) 
and Katzman, Graziani, Kaplan and Escriva (1965) the efflux 
of potassium from the system was divided by the mean concentration 
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of potassium in the c.s.f. compartment to give an efflux co- 
efficient having the dimensions of clearance, namely ml /min. 
In order to compare our results with the results of these earlier 
studies we have also calculated these efflux co- efficient terms. 
Potassium Efflux Co- efficient = Jvb 
Cv 
= Vi Ci - (Vo + Va) Co Egn.(10) 
3k 
* * * 
where C = Co + 0.37 ( Ci -- Co) (logarithmic mean) 
In these earlier studies this estimate of C for the c.s.f. 
compartment was justified on the basis of the ventricular system 
being similar to a hollow tube of uniform diameter. However, 
the concentrations of 42K and inulin in the outflowing perfusate 
during the early phase of a perfusion are not well fitted by 
single exponentials so that the assumption made in calculating 
C as the logarithmic mean does not seem justified. 
In analysing our own data we have used both this method of 
calculating the mean activity of c.s.f. with respect to 42K, and 
the more straightforward method of taking a simple arithmetic 
mean of inflow and outflow fluids. 
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RESULTS 
Behaviour during Perfusion 
The dogs were contained within a box of opaque perspex, 
the side of which could be completely removed. This box which 
is shown in Fig. 2:1, was sufficiently large to allow the dogs 
to move about and lie down and the open side gave ready access 
to the dog for procedures such as intravenous injections. 
During a perfusion the dog's behaviour was always normal 
(Fig. 2:3), provided there were no technical difficulties with 
the perfusion. One or two of the dogs would sit quietly through- 
out the whole procedure but more usually the dog would expect to 
be petted by the experimenter and would maintain great interest 
in all the activity in the laboratory. Towards the end of a 
long (3 -4 hour) perfusion it was not uncommon to find the more 
active dogs showing signs of a slightly stiff neck, but this 
appeared to resolve itself spontaneously within a few hours of 
stopping the perfusion. 
Pressure Changes in the Ventricular System during Perfusion 
As was mentioned in the methods section (page iii) this open 
perfusion technique differed from previous open systems (e.g. 
Pappenheimer, Heisey, Jordan and Downer, 1962) in that fluid was 
pumped out of, as well as into the ventricular system. Theoret- 
ically, provided the rate of perfusion is not too rapid, the dog 
should be able to control the pressure within the ventricular 
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system by its normal physiological mechanisms. To check this 
point low pressure transducers (Sanborn) were connected to the 
inflow and outflow sides of the perfusion circuit, as near as 
possible to the ventricular and cisternal needles, and pressure 
changes within the system recorded. Fig. 2:8 illustrates the 
typical pressure changes which were observed. As can be seen, 
the pump, when working at a flow rate of 0.3 ml /min, decreased 
cisternal pressure by approximately 3 cm of water. This is the 
order of pressure change in the c.s.f. system which was produced by 
a spontaneous deep breath. The ventricular c.s.f. pressure was 
increased by a similar amount during operation of the perfusion pump. 
During later experiments the Watson -Marlow pump was replaced 
with a Tec:inicon Auto -Analyser proportioning pump and the pressures 
developed within the system with this pump were again checked 
and found to be of the same order. On this occasion the pressure 
changes were recorded on a differential pressure gauge (Sifam). 
Presentation of Data 
The initial computer analyses for each individual perfusion 
experiment are shown in Appendix I of this thesis. 
During the early stages of this project, while the experi- 
mental procedure was being developed, a simple graphical presenta- 
tion of the primary data was found most useful. The concentra- 
tions of 42K, inulin and total potassium in each sample of out- 
flow fluid were plotted against the time after starting perfusion. 
From such a graph (Fig. 2:7) it was possible to see at a glance 






















FIG. 2:8 : Effect of perfusion on pressure within a 
dog's c.s.f. system. 
At the point on the trace marked "calibration 3 ans 
water" an offset voltage was applied to the transducer 
output which produced an apparent decrease in cisternal 
pressure to the extent of 30 mm water. 
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"steady state" levels over a period of 60 -90 minutes. 
For a precise analysis of "steady state" fluxes of potassium 
into and out of the c.s.f. compartment, the primary data were 
subjected to the mathematical treatment outlined in the previous 
theoretical section. The largely repetitive mathematical calcul- 
ations were carried out by way of a specially designed computer 
programme (see Appendix I). The computed results from a typical 
control experiment are shown in Table 2:3. 
Columns I and II specify the outflow sample number and the 
time after the start of the perfusion at which it was collected. 
The first few samples shown, with a collection time of zero, are 
in fact samples of inflow fluid and in their case the "K out" 
column refers to the potassium concentration of the inflow fluid. 
Column III, marked inulin clearance, ml /min, shows the 
inulin clearance at the time of collection of the particular 
sample. As has been demonstrated in the theoretical section 
(Eqn. (3) in the theoretical section) this is equivalent to the 
rate of bulk absorption of fluid. In the conditions of our 
particular perfusion system, where the inflow perfusion rate is 
equal to the outflow perfusion rate (i.e. Vi = Vo), inulin clear- 
ance is also equivalent to the rate of formation of c.s.f. within 
the ventricular system (Eqn. 1 - theoretical section). 
Column IV shows the concentration of total potassium in the 
outflow perfusion fluid (with the exception of the first few 
samples where it refers to inflow fluid as explained above) 
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while column V, "1(42 channels ratio", has been included simply as 
a check on the radioactivity measurements. 
Column VI, "K42 out /in ratio ", is the ratio of 42K activity 
in outflow fluid to the activity in inflow fluid. 
Column VII and VIII refer to the efflux (Jvb) and influx 
(Jbv) of potassium into and out of the c.s.f. compartment. 
These parameters (Eqns. 8 and 9 in the theoretical section) have 
been corrected for loss of 421( by bulk flow into the sub- 
arachnoid spaces, and refer to fluxes across the ependymal 
barrier of the brain and the choroid epithelial barrier of the 
blood. In the present study we have not differentiated between 
these two possibilities. 
The last column, "K(2) efflux ml /min ", is the potassium 
efflux coefficient of Cserr (1965), Bradbury and Dayson (1965) 
and Katzman et al. (1965) (Eqn. 10 in the theoretical section). 
The preceeding column, "K(1) efflux ml /min" , is the same para- 
meter except that in this case the mean activity of the c.s.f. 
compartment has been calculated as the arithmetic mean of the 
inflow and outflow fluids rather than as the logarithmic mean 
which was employed in the calculation of the K(2) coefficient. 
As one might expect from examination of the primary data 
(Fig. 2:7) the computed parameters, inulin clearance and 
potassium efflux and influx, reach steady state levels about 
70 minutes after the start of the perfusion (Table 2:3). 
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Analysis of Drug Effects 
It was originally intended that values for efflux and influx 
of potassium collected in the "steady state" period before the 
administration of the drug should act as controls for the post - 
drug "steady-state" values. However from examination of the 
control data it became apparent that flux values during the 
"steady- state" did not in fact remain constant but tended to 
decrease throughout the time of a perfusion. This may be because 
the assumption of negligible labelling of the brain compartment 
becomes increasingly less valid as perfusion time increases. 
Whatever the reason for this trend towards lower efflux and 
influx values with increasing time of perfusion, it was assumed 
to occur in drug experiments independently of any specific drug 
effect. 
To assess the extent of the deviations from "steady- state" 
the potassium flux values from five control conscious perfusion 
experiments were plotted against perfusion time, over the approx- 
imate "steady- state" period. To standardise the data from the 
five experiments the flux values for each individual sample within 
an experiment were expressed as a percentage of the mean control 
value in that experiment, during the period 90 -120 minutes. 
The data from the five different experiments could then be plotted 
on the one scale and the composite graphs for control efflux and 
influx data are shown in Fig. 2:9 and Fig. 2:10 respectively. 
Inspection of Fig. 2:9 suggested that the Efflux data could 
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FIG. 2:9 Composite graph showing c.s.f. potassium efflux 
data from five control experiments. 
The efflux data for each experiment has been expressed as 
a percentage of the mean efflux in that experiment during the 
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FIG. 2:10 Composite graph showing c.s.f. potassium influx 
data from five control experiments. 
The influx data for each experiment has been expressed 
as 
a percentage of the mean influx in that experiment during 
the 
time period 90 -120 minutes (see text p.148). 
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The fitted curve is shown superimposed on the individual efflux 
values. When an attempt was made to express the influx data 
(Pig. 2:10), as a simple quadratic the square term of the 
resultant expression was so small as to be negligible. The 
influx data was therefore represented as a simple straight line. 
These expressions, calculated from the pooled results of five 
control perfusions, could then be fitted to data from the control 
periods of drug experiments. Then by extrapolation it was 
possible to calculate hypothetical flux values which might have 
been obtained if no drug had been given. If these hypothetical 
values were calculated at the times for which there were actual 
flux estimations it was possible to compare post -drug values 
with hypothetical non -drug values. Since such a comparison was 
made whenever post -drug flux values were known it was possible to 
obtain an estimate of the size of the drug effect and of the 
error variation involved. The real and the hypothetical flux 
values were subjected to a paired t -test analysis. The procedure 
has been illustrated below by considering an experiment in which 
pentobarbitone was administered 136 minutes after the start of 
a conscious perfusion. 
The computed print -out is shown in Table 2:4. To simplify 
the explanation only efflux data will be analysed. The "steady - 
state" period has been considered to start with sample 18 
(94.7 min), by which time the inulin clearance and potassium 
efflux have stabilised. As in most experiments the transitional 
-152 - 
20/4 /71 A7(JAH-A) 
EXP T. 6 











A i I 
,A.000 













2./2 0.638 .10-40 0,0000 0,0000 
3.:A8 390 ,,,t,,,,1 1.9097 0,5958 0,8046 
3.2:3 0.650 139 1(A913 0,3582 0,4458 
b 35.G: :.;;.195,1 307 0.649 f1.193 1.o089 0.3429 0,4161 
















54.1 ,?1,0822 2.98 0.642 0,267 I. .9427 0.3127 0,3680 
11 59.2 0,,4/17 3,00 0,641 0.258 Vsb998 'fi 9836 0.3245 0,3833 
12 64.3 ;Y,632 3.42 V.647 v,268 V.888i (4 ,9796 0,3197 0,4/62 
13 69,3 0,0681 3.02 0,642 v,8937 0,9850 V,3218 0,3794 
14 /4,4 0,0538 3.04 0647 V.278 0,8787 A.9768 0,31b6 0,3700 
lb /9.6 o.555 JAi 0,642 :,',267 0,9(11. 0,3241 0,3816 
16 84.6 0,0563 3.43 0,645 fA.260 V,914/, 1,0086 0,3289 0,3881 
1/ 89.7 0.0505 3,06 0,650 r:',279 V.8811 0,9862 0,3161 0,3704 
0,0448 2.96 0,652 0.305 0,627 r'),8990 0,2989 0,3470 
1, 99.7 0,0448 3,06 0,647 0.289 Vebo7.2' 0,9717 0,3108 0,3628 
20 0,0429 3.03 0,653 0,263 0,9227 1101/0 0,3320 0,3913 
21 109.7 0,0440 3.47 0,645 v,262 0,9275 1.0356 0,3329 0,3927 
22 114./ 0,0440 3. 0.646 0.296 0,8556 0,97A6 0.3563 Control 
23 119.9 0,0440 J. 0541 0.9164 L.3286 0,3868 
24 0.0382 3., 0,648 0,323 t,,Fik7,79 0,9190 L.2886 0,3329 
25 0311 3 "2 .547 v,339 V 7335 ,1.8811 .2802 0,3214 
26 135.3 0,0275 3..71 .651 ,,b329 .2980 0,3445 
2/ 14,z,/ !,)0243 305 .647 .31- -,8498 ,4,95-110 yí $i'44 0,352/ 
2 145./ 2.9/ ,.8b72 1.9312 V.3-91 o,3598 
151.1 2.99 5.50 0.309 83(iic, A,91-'15 0,2987 0,3462 
.3e) 16/.0 .i5/1 2,94 0,544 0,322 0,8027 0,8665 0,2897 0,3343 
31 162.2 ;44 2,96 0,637 (,1,352 0,7498 -.82A4 0,2698 0,3083 
32 167.3 i52 3.?1 0,642 (,,371 0.7150 .8023 0,2560 0,2906 
33 172,4 3.00 0,647 0.370 1L.7209 .);049 0.2584 0,2935 
34 177. $19 J.40 0,640 0,378 0,7472 .7912 (2533 0,2870 
35 3.J4 0,546 2-1,382 V ./0y3 ,.79/7 ç; .2500 0,2829 Treatment 
36 2,92 0,637 0,381 7,7A22 2533 02867 
37 2,97 0,636 V .378 0.7113 )11 0,2894 
3e 2.99 0,643 y.2510 0,2841 
39 3,00 0,648 0.387 0.692A 0,2800 
4 ,226 3.00 0,647 0,398 0,5858 ./tC,+; V .2454 0,2763 
41 22'71 0.e)44 0.39/ 0,5859 .7/ .2458 
42 220. 3.00 0,637 °,.388 0,S872 .7/IR .24161 Y.2/79 
- 153 - 
sample collected just after administering the drug, in this case 
sample 27, has been omitted from the analysis. The mean potassium 
efflux in the post -drug period was only 84.9 
± 
6.4% of the mean 
efflux in the pre -drug control level. The following analysis 
was carried out to investigaLe whether this was a specific drug 
effect. 
Mean time of collection of pre -drug control samples 
= 114.9 min 
From standard control curve 
Potassium efflux at 114.9 min = 96.3 + 114.9 (0.126) 
- (114.9)2x 0.00079 units = 100.35 units. 
In fact mean control potassium efflux = 0.8602 meq/min. 
100 units on standard control curve = 0.8572 meq/min 
Let us now consider sample 35 collected at 182.7 min. 
From the standard curve potassium efflux at this time 
should be 
= 9b.3 + 0.126 (182.7) - 0.00079 (182.7)2 units 
= 92.95 units 
which in this particular experiment would be 
= 92.95 x 0.8572 melAalmtn 
= 0.7968 meqraamm 
Actual observed value = 0.7003 meq 1 min 
Difference = -0.0965 meq/x. min 
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If the recorded values for all the samples are compared in 
this way with hypothetical control values we can prepare a table 
of differences (Table 2:5). 
The differences were then subjected to a paired t -test 
analysis. 
Mean difference = -0.0636 
Variance = 0.00114 
Degrees of freedom = 14 
t = -7.02 
This t value is significant at level of probability 
0.001 and it indicates that in this experiment pentobarbitone 
has significantly lowered the efflux of potassium from the c. s. f. 
The analysis of influx data follows exactly the same 
pattern. 
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TABLE 2:5 : Analysis *of Drug Effect on Potassium Efflux 









145.7 0.8391 0.8572 +0.0181 
151.1 0.8341 0.8300 -0.0041 
157.0 0.8282 0.8027 -0.0255 
162.2 0.8226 0.7498 -0.0728 
167.3 0.8167 0.7150 -0.1017 
172.4 0.8105 0.7209 -0.0896 
177.5 0.8039 0.7072 -0.0967 
182.7 0.7968 0.7003 -0.0965 
187.8 0.7895 0.7022 -0.0873 
193.0 0.7817 0.7113 -0.0704 
198.2 0.7736 0.7001 -0.0735 
203.4 0.7650 0.6 92 0 -0.0730 
208.7 0.7600 0.6858 -0.0702 
214.8 0.7451 0.6869 -0.0582 
220 0.7354 0.6872 -0.0482 
* 
See text pages 148 to 154 
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Sodium Thiopentone : Effect on C.S.F. Potassium Fluxes 
Sodium thiopentone (50 mg /ml solution) was administered 
intravenously in a dose which rapidly induced in the dog a state 
of light anaesthesia. In this state the corneal reflex was 
still present but the dog barely reacted to a moderately painful 
pressure stimulus applied between the toes. The required dose 
was found to be approximately 23 mg /kg. As the perfusion pro- 
gressed it was necessary in some dogs to give supplementary 
intravenous doses of drug to maintain anaesthesia at a constant 
level. 
Table 2:6 summarises the potassium efflux data from five 
experiments in which sodium thiopentone anaesthesia was induced. 
In experiment I the anaesthetic reduced the potassium efflux by 
31.6 %. As the individual sample data plotted in Fig. 2:IL 
illustrate , this effect was seen almost immediately. The only 
other experiment in which a significant change was seen was 
reduction 
experiment 4 where there was an 8.7jä clearance -in potassium efflux. 
In experiments 2, 3, and 5 there was no significant change in 
potassium efflux. 
Table 2:7 summarises the potassium influx data from the 
same five experiments. As in the case of the efflux data, the 
most significant change was observed in experiment 1, where there 
was a 34% decrease in the influx of potassium into the c.s.f. 
In experiment 4 also,a significant decrease (15%) in influx was 
observed. In experiment 2 there was a barely significant 








Observed Post -Drug 
Potassium Efflux 
as % of 




due to drug 
(meq/min) 
fA Change in 3 
Potassium 'efflux 









1 1/4/69 A 2 0.6219 
± 
0.0159(6) 62.9 ± 6.0%(10) -0.1964 ± 0.0265(10) 31.6% y 21.98 <0.001 




0.0195(10) 0.4% 4 0.34 - 
3 28/10/70 A10 0.7414 ± 0.0246(5) 92.6 ± 8.i %(8) -0.0015 ± 0.0227(8) 0.2% 4, 0.17 - 
4 5/11/70 A 1 0.6124 ± 0.0364(9) 83.9 
± 
3.0/(6) -0.0535 ± 0.0248(6) 8.7% 4, 4.81 4 0.01 
5 25/11/70 A 1 0.5976 ± 0.0263(7) 94.8 ± 6.5 %(8) +0.0066 ± 0.0218(8) 1.1% j 0.80 - 
1 - mean standard deviation; no. of estimates in parentheses. 
2 - this column represents the mean difference between hypothetical control values extrapolated from the pre -drug period and the 
actual post -drug values observed (see full explanation in text, page' ). 
3 - in this column the mean difference in potassium efflux is presented as a percentage of the pre -drug efflux value. 
4 - Paired t -test between hypothetical control values and actual observed values (paired with respect to time of estimates). 
TABLE 2: 7 : Influx of Potassium from the C.S.F. : Effect of Sodium Thiopentone Anaesthesia 





Observed Post -Drug 
Potassium Influx 
as % of 
Pre -Drug Value 
Change in2 
Potassium Influx 
due to drug 
(meq /min) 
Change in 3 
Potassium Influx 









1 1/4/69 A 2 0.5905 ± 0.0110(6) 61.7 ± 5.9%(10) -0.2034 ± 0.0292(10) 34% 4 20.93 ( 0.001 
2 8/4/69 A 2 0.5891 ± 0.0173(6) 92.4 ± 5.2%(10) -0.0223 ± 0.0259(10) 3.8% 4/ 2.59 <0.05 
3 25/10/70 A10 0.5887 ± 0.0311(5) 95.8 ± 5.1iß(8) -0.0079 ± 0.0249(8) 
i 
1.3% 4, 0.84 - 
4 5/11/70 A 1 0.6577 ± 0.0414(9) 81.5 ± 4.3%(6) -0.0985 ± 0.0276(6) 15% 4, 7.98 <0.001 
5 25/11/70 A 1 0.6945 ± 0.0394(7) 92.8 ± 6.4 %(8) -0.0258 ± 0.0355(8) 3.7% 4, 1.92 - 
j 
1 mean - standard deviation; no. of estimates in parentheses. 
2 this column represents the mean difference between hypothetical control values extrapolated from the pre -drug period and the 
actual post -drug values observed (see full explanation in text, page -). 
3 in this column the mean difference in potassium influx is presented as a percentage of the pre -drug influx value. 
4 Paired t -test between hypothetical control values and actual observed values (paired with respect to time of estimates). 
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FIG. 2:11 Time course of action of sodium thiopentone on 
c.s.f. potassium efflux and influx. 
At each sampling point the difference between the observed 
flux value and the extrapolated pre -drug control flux value 
(see text pages 148 to 155) has been expressed as a percentage 
of the mean flux value in the pre -drug control period. 
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(p< 0.05) decrease of 3.8% in the potassium influx. Examination 
of the time course of the drug action in this experiment 
(Fig. 2:11, Expt. 2) suggests a more delayed effect. 
In none of these experiments was there a significant decrease 
in rectal temperature during the period of anaesthesia. 
Sodium Pentobarbitone : Effect on C.S.F. Potassium Fluxes 
Sodium pentobarbitone (60 mg/ml solution) was administered 
intravenously in a dose which was judged to give a level of 
anaesthesia comparable with that achieved in the thiopentone 
experiments. The induction period with sodium pentobarbitone 
was appreciably slower (3 -8 minutes) than with thiopentone but 
in fact the dosage used was very similar ( 23 mg /kg). In one 
experiment (experiment 8, Fig. 2:IL) the initial dose administered 
was insufficient and a supplementary dose of 3 mg /kg was admin- 
istered to restore the desired level of anaesthesia. 
The potassium efflux data from three sodium pentobarbitone 
experiments are shown in Table 2:8. The time courses of signi- 
ficant drug effects are shown in Fig. 2:12. In all three experi- 
ments the anaesthetic caused a significant decrease in the 
potassium efflux from the c.s.f. The 42% decrease seen in 
experiment 7 is comparable to the 31.6% decrease seen in an 
earlier sodium thiopentone experiment (experiment 1, Table 2:6). 
The decreases in the potassium efflux seen in experiments 6 and 8 
were both much smaller (7.3% and 3.1% respectively). 
TABLE 2:8 Efflux of Potassium from the C.S.F. : Effect of Pentobarbitone Anaesthesia 





Observed Post -Drug 
Potassium Efflux 
as % of 
Pre -Drug Value 
Change in2 
Potassium Efflux 














6 20/4/71 A 7 0.8608 ± 0.0525(9) 84.9 ± 6.4 %(15) -0.0633 ± 0.0338(15) 7.3% 4, 7.00 <-0.001 
7 28/4/71 A 1 0.7621 ± 0.0416(7) 54.0 ± 15.6/(9) -0.3211 - 0.0281(9) 42% ., 32.28 <0.001 
8 4/8/71 All 0.5430 ± 0.0285(13) 87.8 ± 4.4%(10) -0.0168 ± 0.0130(10) 3.1% 4 3.82 <0.01 
Footnotes - See Table 2: 
TABLE 2: 9 : Influx of Potassium from the C.S.F. : Effect of Sodium Pentobarbitone Anaesthesia 





Observed Post -Drug 
Potassium Influx 
as of 




















6 20/4/71 A 7 0.9624 ± 0.0564(9) 84.1 ± 5.4 %(15) -0.1176 - 0.0412(15) 12.2% 4. 10.67 <0.001 
7 28/4/71 A 1 0.7520 ± 0.0474(7) 50.7 ± 14.4 %(9) -0.3893 ± 0.0389(9) 49.7% 4( 28.34 <0.001 
8 4/8/71 All 0.7198 
± 
0.0627 85.3 ± 7.7%(10) -0.0745 - 0.0473(10) 10.4% 4, 4.72 <0.01 
Footnotes - See Table 2: 
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EXPT. 6 EXPT. 8 
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FIG. 2 :12 Time course of action of sodium pentobarbitone on 
c.s.f. potassium efflux and influx. 
At each sampling point the difference between the observed 
flux value and the extrapolated pre -drug control flux value 
(see text pages 148 to 155) has been expressed as a percentage 
of the mean flux value in the pre -drug control period. 
-164- 
The potassium influx data from these three experiments are 
shown in Table 2:9. As is the case with thiopentone anaesthesia 
it appears that pentobarbitone anaesthesia has a greater 
depressant effect on potassium influx than on efflux. The 
largest change was seen in experiment 7 where the drug decreased 
the potassium influx by 49.7 %. The decreases in experiments 6 
and 8 were 12.2% and 10.4/ respectively. 
In keeping with the gradual onset of anaesthesia, the maximum 
changes in c.s.f. potassium fluxes were not observed until some 
30 or 40 minutes after administering the drug (Fig. 2:12). 
As in the thiopentone anaesthesia experiments, no signifi- 
cant change in the dog's body temperature was noted during the 
period of pentobarbitone anaesthesia. 
Diazepam : Effect on C.S.F. Potassium Fluxes 
Diazepam (5 mg/ml solution) was administered by slow intra- 
venous injection. The dose which was given, namely 20 mg, is 
twice the initial dose which is used in man to induce brief 
anaesthesia or control status epilepticus. Before the injection 
was completed the dog usually displayed signs of muscle relaxation 
and became slightly ataxic, but anaesthesia was not induced. 
While the dogs appeared drowsy, their eyes remained open and they 
responded, in as normal a fashion as their ataxia allowed, to 
stimuli such as loud noises. 
The potassium efflux data from three diazepam experiments 
is shown in Table 2:10. In two of the experiments (experiments 
TABLE 2:10 Efflux of Potassium from the C.S.F. : Effect of Diazepam 





Observed Post -Drug 
Potassium Efflux 
as % of 
Pre -Drug Value 
Change in 2 
Potassium Efflux 
due to drug 
(meq/min) 
% Change in3 
potassium Efflux 





t -value of 
drug effect 
1 
9 21/4/69 A 2 0.5696 ± 0.0139(6) 82.9 ± 7.7qó(8) -0.0562 ± 0.0402 (8) 9.9% J- 3.70 <0.01 
11 28/9/71 A 9 0.6076 ± 0.0089(8) 93.3 ± 4.0(11) -0.0129 ± 0.0197 (11) 2.1% 4, 2.06 - 
12 4/11/71 A 9 0.5013 ± 0.0192(9) 85.6 ± 8.0 %(9) -0.0486 ± 0.0302(9) 9.7% 4 4.82 <0.01 
Footnotes - See Table 2: 
TABLE 2: 11 : Influx of Potassium from the C.S.F. : Effect of Diazepam 
Expt. Date Dog 
Potassium 
Influx 
Pre -Dru g 
(meq/min) 
Observed Post -Drug 
Potassium Influx 
as % of 
Pre -Drug Value 
Change in 
Potassium Influx 
due to drug 
(meq /min) 
d 3 Change in 
Potassium Influx 









9 ., 21/4/69 A 2 0.5395 ± 0.0230(6) 84.6 ± 5.0(8) -0.0603 ± 0.0356(8) 11.2% 4r 4.48 < 0.01 
11 ÿ 28/9/71 A 9 0.5930 ± 0.0242(8) 93.7 
± 
5.9 %(11) -0.0282 - 0.0307(11) 4.8% 4, 2.94 <0.02 
12 4/11/71 A 9 0.6291 ± 0.0217(9) 90.9 
± 
6.516(10) -0.0379 ± 0.0351(10) 6.0% y 3.24 <0.02 
Footnotes - See Table 2: 
EXPT. 9 
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FIG. 2:13 Time course of action of diazepam on c.s.f. 
potassium efflux and influx. 
At each sampling point the difference between the observed 
flux value and the extrapolated pre -drug control flux value 
(see text pages 148 to 155) has been expressed as a percentage 
of the mean flux value in the pre -drug control period. 
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9 and 12) diazepam caused a 9-10% decrease in the potassium 
efflux from the c.s.f. A decreased efflux was also seen in 
experiment 11 but this was not significant (p> 0.05). 
The potassium influx data is shown in Table 2:11. In 
experiment 9 there was a significant (p c 0.01) decrease in the 
potassium influx due to diazepam, but in experiments 11 and 12 
the decreases seen were smaller at 4 .8% and 6.0% respectively. 
In both experiments 11 and 12 there appeared to be a time lag 
before the drug had any appreciable effect on the potassium 
fluxes (Fig. 2:13). Even in experiment 9 the peak effect was 
not seen until 25 -30 minutes after administering the drug. 
This time lag before c.s.f. potassium fluxes were maximally 
affected contrasted with the behavioural changes observed. In 
behavioural terms the dog's recovery started within ten minutes 
of giving the injection and the dogs became progressively more 
alert and active. 
Dipaenylhydantoin : Effect on C.S.F. Potassium Fluxes 
Diphenylhydantoin was administered intravenously (48 mg/ml 
solution) in a dose of 80 mg (effectively 5 mg/kg). No behavioural 
changes or physical signs were seen after giving the drug. 
The potassium efflux data from two diphenylhydantoin experi- 
ments are shown in Table 2:12. No significant change was seen 
in either experiment after giving diphenylhydantoin. 
The influx data shown in Table 2:13 demonstrate that diphenyl- 
hydantoin slightly reduced potassium influx into the c.s.f. in both 
TABLE 2: 12 Efflux of Potassium from the C.S.F. : Effect of Diphenylhydantoin 





Observed Post -Drug 
Potassium Efflux 
as % of 
Pre -Drug Value 
Change in 2 
Potassium Efflux 
due to drug 
(meq,/min) 
% Change in 3 
Efflux Potassium 















0.9300 ± 0.0470(10) 
0.7021 ± 0.0330(15) 
92.5 ± 4.0(10) 
91.4 ± 5.0(12) 












Footnotes - See Table 2: 
ABLE 2:13 : Influx of Potassium from the J.S.F. : Effect of Diphenylhydantoin 





Observed Post -Drug 
Potassium Influx 
as of 
Pre -Drug Value 
Change in 
Potassium Influx 
due to drug 
(meq/min) 
% Change in Effect of 
Potassium Influx drug 
due to drug on influx 
4 















93.7 ± 4.0 %(10) 
89.7 ± 5.0(12) 
-0.0311 - 0.0399(10) 3% 







Footnotes - See Table 2: 
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EXPT.14 
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FIG. 2:14 Time course of action of diphenylhydantoin on 
c.s.f. potassium influx. 
At each sampling point the difference between the observed 
flux value and the extrapolated pre -drug control flux value 
(see text pages 148 to 155) has been expressed as a percentage 
of the mean flux value in the pre -drug control period. 
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experiments. When the time course of this action was plotted 
as in Fig. 2:14 it was seen that the data from experiment 14 
was highly irregular and therefore the significance of the drug 
effect in this case is rathr doubtful. 
Paraldehyde : Effect on C.S.F. Potassium Fluxes 
As distinct from all the other drugs used in this study 
paraldehyde was administered by intramuscular injection. The 
injection was extremely painful and the dose of 4 -6 ml was split 
into 4 aliquots to be administered at separate sites. Over a 
period of five to fifteen minutes the dogs gradually lapsed into 
a state of anaesthesia in which they no longer responded even 
to strong pressure between the toes. 
As can be seen from Table 2:14v paraldehyde caused an increase 
in the efflux of potassium fro:a the c.s.f. (13% in experiment ì6; 
8.2% in experiment 17) in two of the three experiments. In the 
third (experiment 18) it had no effect. 
Table 2:15 presents the influx data from the same experiments. 
Only in experiment 16 was there a significant change (p< 0.01). 
Again, the change seen was an increase (9.8 %) in the influx. 
This drug was the only one of the five studied which at any 
time caused a positive change in c.s.f. potassium fluxes. 
The relatively slow onset of paraldehyde anaesthesia after 
intramuscular injection was reflected in the slow appearance of 
effects on c.s.f. potassium fluxes (Fig. 2:15). 













0.6423 ± 0. 0303(6) 
0.5902 ± 0.0388(9) 
1.0774 ± 0. 0250(14) 
Footnotes - See Table 2: 
Observed Post -Drug 
Potassium Efflux 
as % of 
Pre -Drug Value 
Change in 2 
Potassium Efflux 
due to drug 
(meq /min) 
104.6 ± 5. 7%(12) 
96.5 ± 3 .3%(14) 
95.1 ± 1 .5S(15) 
3 
% Change in 
Potassium :Efflux 
due to drug 
+0.0828 ± 0.0554(12) 
+0.0485 ± 0.0307(14) 
















t 0. 001 
< 0.01 
TABLE 2: 15 : Influx of Potassium from the C.S.F. : Effect of Paraldehyde 





Observed Post -Drug 
Potassium Influx 
as % of 
Pre -Drug Value 
Change in2 
Potassium Influx 




due to drug 


















0.5812 ± 0.0317(6) 
0.5785 ± 0.0446(9) 




98.4 ± 4.5 %(14) 
96.3 ± 2.6 %(15) 













Footnotes - See Table 2: 
EXPT. 16 
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FIG. 2:15 Time course of action of paraldehyde on c.s.f. 
potassium efflux and influx. 
At each sampling point the difference between the observed 
flux value and the extrapolated pre -drug control flux value 
(see text pages 148 to 155) has been expressed as a percentage 
of the mean flux value in the pre -drug control period. 
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Other factors affecting c.s.f. potassium fluxes 
In two experiments (3 and 4) we examined the effects of 
sodium thiopentone anaesthesia on c.s.f. pH and pCO2. In 
experiment 3 we also monitored end -alveolar air pCO2. 
The results are shown in Fig. 2:16. After anaesthesia was 
induced by thiopentone (:'apt. 3) there was an immediate increase 
in end alveolar pCO2. In neither of the two experiments was 
there a significant post -drug alteration in the pCO2 of the c.s.f. 
In both experiments there was evidence of a small increase in the 
pH of the c.s.f. (less than 0.1 pH unit). 
In certain preliminary experiments in addition to measuring 
the c.s.f. fluxes of potassium we simultaneously measured the 
c.s.f. fluxes of sodium and calcium, using 
22Na 
and 45Ca. The 
fluxes of these two cations were not significantly affected by 
barbiturate anaesthetics despite the alterations caused in 
potassium fluxes. 
Experiments not included in the analysis of data 
As a result of a high level of fluctuation in. flux values 
between adjacent "steady- state" values many of the results from 
early perfusion experiments have not been fully analysed. The 
nigh error variation in these experiments was caused by several 
factors. 
During the development of the technique a reliable fraction 
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weighed and carefully checked as to the length of time of 
collection. Another problem encountered initially was in 
performing satisfactory inulin and potassium assays on samples 
which unavoidably had to be stored for a few days prior to assay. 
Perhaps the commonest problem was that of achieving satis- 
factory perfusion in a fully conscious and often highly active 
dog. On many occasions a perfusion had to be stopped to allow 
repositioning of the cisternal needle or enable a blockage to 
be cleared from the system. These difficulties were largely 
overcome by selecting only dogs of a docile temperament for 
perfusion experiments and by paying meticulous attention to the 
length and sharpness of the perfusion needles used for a 
particular dog. 
Although these early experiments have not been considered 
satisfactory in the light of our results with established technijues 
they indicated qualitatively that sodium pentobarbitone and 
sodium thiopentone reduced c.s.f. potassium fluxes. 
Two experiments (10 and 13) shown in Appendix I have not 
been included in the results section. In these experiments the 
perfusions appeared to go normally and the accuracy of the 
analytical results was confirmed by repeating the biochemical 
assays. As can be seen howeverythe inulin clearance in both 
experiments was extremely high and for this reason the data have 
not been considered reliable. Both these experiments concerned 
the same dog but this dog was used for other experiments, before, 
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between and after the two excluded experiments and on these 
occasions a normal inulin clearance was always observed. The 
values for potassium efflux and influx (which are of course 
corrected for loss of potassium in fluid absorbed in bulk into 
the subarachnoid spaces) in these two experiments did not appear 
abnormal and so the experiments have been included with the 
others in Appendix I. It is interesting that the diphenyl- 
hydantoin experiment (Expt. 13) agrees with the other two 
diphenylhydantoin experiments (14 and 15) in that the drug 
appeared to decrease the influx of potassium into the c.s.f. 
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DISCUSSION 
42K efflux from the c.s.f. as measured in these experiments 
is a composite parameter comprising efflux into brain and efflux 
into blood. Although the relative contribution of each efflux 
pathway has not been experimentally determined some information 
on this subject can be derived from previous ventriculax- 
cisternal perfusion studies of potassium fluxes in anaesthetised 
animals. 
In studies on the anaesthetised dog (Cserr, 1965) rabbit 
(Bradbury and Dayson, 1965) and cat (Katzman et al., 1965) it 
was found that most of the 42K leaving the c.s.f. could subse- 
quently be recovered from the brain. It appeared that this uptake 
was governed by simple diffusion and isotopic exchange with the 
large stores of intracellular potassium in the brain. Such a 
process seems unlikely to be involved in the long term regulation 
of c.s.f. potassium. 
The other major component of potassium efflux from the c.s.f. 
is potassium transport from the c.s.f. into blood. This efflux 
mechanism has been characterised by the studies of Bradbury and 
Stulcova (1970) on the anaesthetised rabbit. They found that 
with c.s.f. potassium concentrations below 3.2 meq/1 the potassium 
eff lux into blood was responsible for only a small fraction of 
the total efflux from c.s.f. Above this concentration, the 
transport of potassium from the c.s.f. into blood increased 
rapidly, until at a c.s.f. potassium concentration of 10 meq/1 
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it constituted almost 40% of the total efflux from c.s.f. This 
efflux from c.s.f. to blood was inhibited by ouabain. Bradbury 
and Stulcova hypothesised the existence of a sodium -potassium 
pump mechanism (potassium directed towards the blood) situated 
either at the choroid plexus or at the capillary blood -brain 
barrier. The existence of such a pump in the choroid plexus 
seems doubtful since Wright (1970) found no net flux of potassium 
across the choroid plexus of the frog nor were the individual one - 
way potassium fluxes across this tissue inhibited by ouabain. 
However the findings of a recent study by Bradbury, Segal and 
Wilson (1972) indicate that such a pump may be located at the 
blood -brain interface of cerebralcapillaries. The characteristics 
of the mechanism for transporting potassium from c.s.f. into 
blood suggest that it may be a vital factor in the homeostasis 
of c.s.f. and brain . extracellular fluid potassium (Bradbury and 
S tulc ová, 1970). 
How do these findings in the anaesthetised animal relate to 
our own findings in the conscious animal? Since the pump trans- 
porting potassium from the c.s.f. to the blood appears to be 
concentration dependent, and not very active at norm41 levels of 
c.s.f. potassium, it is unlikely to have been responsible for 
more than 20% of c.s.f. potassium efflux seen in our conscious 
animals. Thus, in our experiments, at least 80% of the observed 
efflux of 42K from the c.s.f. was probably due to isotopic 
excaange with unlabelled potassium in the brain. As a corollary 
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it seems likely that the major portion of the potassium influx 
into c.s.f. was derived from brain. This would agree with the 
evidence that 42K in the plasma penetrates very slowly into 
c.s.f., other than by way of newly secreted fluid (0serr, 1965; 
Bradbury and Dayson, 1965; Katzman et al. 1965). 
We have found that the barbiturate anaesthetics, sodium 
thiopentone and sodium pentobarbitone, in a comparatively low 
dosage (23 mg/kg) may depress the potassium fluxes of c.s.f. In 
view of this fact it seems possible that previous estimates of 
c.s.f. potassium fluxes in anaesthetised animals (30 mg/kg 
pentobarbitone was used in the studies of Bradbury and Stulcová,) 
maj not be representative of the fluxes in the conscious animal. 
The question arises as to which component of the fluxes has been 
affected by the anaesthetics. Two facts suggest that the 
anaesthetics may affect the potassium exchange with the brain. 
In the first place, in the deeply anaesthetised animals 
studied by Bradbury and Stulcová (1970) there did not appear to 
be any loss of homeostatic control of potassium in the c.s.f. 
This suggests that the pump transporting potassium from the c.s.f. 
into the blood is unaffected by anaesthetics. 
In the second place, in our experiments we have observed 
decreases of up to 40,L in the total efflux of potassium from the 
c.s.f. after administering an anaesthetic. Such alterations in 
efflux are unlikely to have been due to inhibition of the c.s.f. 
to blood transport since this mechanism probably accounts for 
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only a small fraction of the total potassium efflux from c.s.f. 
(Bradbury and ,Stulcová, 1970) . 
For these two reasons it seems probable that the barbiturate 
anaesthetics were depressing the efflux of potassium from the 
c.s.f. by inhibiting the exchange between potassium in the c.s.f. 
and potassium in the brain. This would fit with the depressant 
effects of anaesthetics on neuronal activity since a lesser 
number of excitation events across nerve membranes would be 
expected to lead to less rapid mixing of intra- and extracellular 
potassium. In this context it has been suggested by Thesleff 
(1956) that pentobarbitone may decrease the resting potassium 
conductance across excitable membranes. Pentobarbitone has 
also been shown to be antagonistic to the action of potassium on 
atrial muscle fibres (Smith and Gershwin, 1969). 
A depressant effect of the barbiturates on potassium exchange 
across neuronal membranes, such as we have po,tulated here, might 
be expected to decrease not only potassium efflux from, but also 
potassium influx into the c.s.f. In fact this is exactly what 
was seen in our experiments, the influx being depressed in a 
parallel fashion to the efflux. The actual potassium concentration 
in the c.s.f. remained unaltered. 
This lack of effect of pentobarbitone anaesthesia on the 
level of potassium in the c.s.f. contrasts markedly with its 
depressant effect on the plasma potassium (Bradbury and Dayson, 
1965), providing further proof that pentobarbitone anaesthesia 
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does not affect those transport mechanisms which are responsible 
for the homeostasis of c.s.f. potassium. 
The variability of the anaesthetic effects is not easy to 
explain. An explanation based on between -dog variation is not 
tenable since we observed very different depressions of c.s.f. 
potassium fluxes on different occasions in the same dog. We 
have considered the possibility that the changes in c.s.f. 
potassium fluxes were secondary to anaesthetic- induced changes 
in the electrical potential between c.s.f. and blood. Held, 
Fencl and Pappenheimer (1964) have shown that this potential in 
the conscious goat is approximately 6.8 mv (c.s.f. positive). 
In dogs under pentobarbitone anaesthetic they recorded potentials 
varying between -2 and 7 mv. They ascribed this large spread of 
values to variationsin arterial pH. In two of our own perfusion 
experiments in which sodium thiopentone was administered we 
recorded the pH and p002 of the cisternal effluent. In one of 
these experiments the p002 of end alveolar air was also recorded. 
The results suggested that the barbiturate anaesthetics were not 
seriously affecting c.s.f. pH or p002. It therefore seems 
unlikely that changes in the c.s.f. blood potential were responsible 
for the observed alterations in c.s.f. potassium fluxes. 
From preliminary experiments in which sodium and calcium 
fluxes from the c.s.f. were measured in parallel with potassium 
fluxes, it would appear that barbiturate anaesthesia does not 
significantly alter sodium and calcium fluxes, evenvhen it produces 
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depressions in c.s.f. potassium fluxes. 
Perhaps the explanation for the variability of the anaesthetic 
effect may lie in differences in the degree of anaesthesia from 
experiment to experiment. If this is true however, it must be 
that barely observable changes in depth of anaesthesia can 
produce large changes in c.s.f. potassium fluxes. 
The alterations in c.s.f. potassium fluxes produced by the 
three anticonvulsants studied were near the sensitivity limits 
of the method. For this reason any interpretation of their 
actions must be tentative. 
Diazepam produced a slight decrease in both efflux and influx 
of potassium. The fact that, as with the barbiturate anaesthetics, 
efflux and influx were equally affected suggested that the drug 
might be inhibiting a single exchange mechanism affecting both 
influx into and efflux out of the c.s.f. The likeliest mechanism 
would seem to be the exchange process between brain intracellular 
and extracellular potassium. However, unlike the barbiturates, 
diazepam did not produce anaesthesia so it is possible that a 
different mechanism of action may have been responsible for the 
decreased potassium exchange between c.s.f. and brain. 
As yet no explanation is available for diazepam's anti - 
convulsant action even though it is very widely used in the control 
of status epilepticus. It is worth noting that there nay be a 
marked species dif e2 etloe in the effect of this drug since the 
dose administered to the dogs in our experiments (20 mg) would 
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have been sufficient, in absolute terms, to anaesthetise a man 
five times the dog's weight. 
Diphenylhydantoin had no effect on potassium efflux from 
the c.s.f. but there was evidence that it had a slight depressant 
effect on potassium influx. These findings contrast with the 
report by Woodbury and Kemp (1971) that diphenylhydantoin 
increases potassium efflux from the c.s.f. However these results 
are not so divergent as might at first sight appear, since both 
bring about a lowered c.s.f. potassium concentration. In our 
experiments we only measured total efflux of potassium from the 
c.s.f. and it is possible that the efflux from c.s.f. to blood 
could have been increased and the efflux of potassium into brain 
decreased bj diphenylhydantoin. We would not have noticed such 
an effect since the total efflux from c.s.f. would have been 
unchanged. If the potassium influx from brain was also depressed 
these findings would be consistent with a dual action of 
diphenylhydantoin, firstly in reducing potassium exchange across 
the neuronal membrane and secondly in increasing potassium efflux 
from the c.s.f. to the blood. If, as seems probable, Woodbury 
and Kemp (1971) used anaesthetised animals in their study then the 
former action, namely decreasing potassium exchange across the 
neuronal membrane, may have been obscured by a similar action of 
the anaesthetic. In this case they would only have observed an 
increased efflux of potassium from the c.s.f. In such circum- 
stances our own findings and those of Woodbury and Kemp (1971) would 
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be compatible. However trie difference between the two studies 
may be due to a number of factors such as the species of animal 
being studied; the dosage of diphenylhydantoin used; whether 
the animal was being treated chronically or acutely; the method 
used to investigate potassium efflux from the c.s.f. 
Woodbury and Kemp (1971) have hypothesised that the anti - 
convulsant action of diphenylhydantoin is due to its stabilising 
effect on excitable membranes by increasing sodium transport out 
of the cell, thus producing a hyperpolarised membrane. This is 
supported by their own finding of a decreased intracellular 
sodium content and Festoff and Appel's (1968) finding that 
diphenylhydantoin stimulates sodium- potassium ATPase activity. 
However Izquierdo and Nasello (1970) have suggested that 
diphenylhydantoin may antagonise post- tetanic p$tentiation and 
seizure activity by an action on potassium transport. It may 
therefore be premature to exclude an effect on potassium in the 
brain from the action of diphenylhydantoin. 
Paraldehyde was unique among the drugs studied in that it 
appeared to increase potassium efflux from the c.s.f. in two out 
of three cases. In one of these two cases the influx was not 
affected but in the other it also was increased. The stimulation 
of c.s.f. potassium fluxes contrasted with the drug's obvious 
anaesthetic action. The drug was therefore similar to the 
barbiturates in terms of anaesthetic effects but dissimilar in 
its effects on c.s.f. potassium fluxes. This was surprising 
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considering that Thesleff (1956) has reported that these drugs 
have very similar effects on the ionic permeability of muscle 
excitable membrane. However very little is known about the 
mechanism of action of paraldehyde. It may be that we were 
observing a stimulant effect on potassium fluxes due to an 
independent action of the drug or it may be that some intermediary, 
such as the drug's metabolite acetaldehyde, was affecting potassium 
fluxes. 
In conclusion then how has our study contributed to work in 
this field? 
From a technical aspect it would appear that the animal 
techniques and analytical treatment of results which we have 
evolved provide, for the first time, a method of monitoring c.s.f. 
potassium fluxes in the fully conscious and free -moving animal 
over a period of 2 to 3 hours. The technique would appear to 
have a limited application in the study of transport of potassium 
from the c.s.f. to the blood since this can only be accurately 
measured by examining the amount of 42K left in the brain after 
perfusion. It would seem more economic to develop this type 
of study in the rabbit, using the conscious perfusion technique 
evolved by Moir and Dow (1970). 
With respect to drug studies we have sown that sodium 
pentobarbitone, sodium thiopentone and diazepam can all depress 
the c.s.f. potassium fluxes both into and out of c.s.f. We have 
speculated that these changes reflect a decrease in the exchange 
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of potassium between brain intra- and extracellular compartments. 
There is some evidence that paraldehyde stimulates potassium 
exchange between c.s.f. and the brain (at the same time as it 
produces anaesthesia), and that diphenylhydantoin may decrease 
the influx of potassium into the c.s.f. 
It would therefore appear from these studies that decreases 
in potassium fluxes of the c.s.f. may be associated with anaes- 
thetic or anticonvulsant action but it would seem, in the case 
of paraldehyde at least, that it is possible to achieve both 




A new technique was developed for "open" perfusion of the 
cerebroventricular system of the conscious dog. A kinetic analysis 
of the perfusion system is described. Dogs were perfused from 
lateral ventricle to cisterna magna with artificial c.s.f. to 
which had been added a non -diffusible marker substance, inulin, 
and tracer amounts of 42K. Inulin, total potassium and 42K 
estimations on samples of inflow and outflow fluid allowed cal- 
culation of both potassium efflux from, and potassium influx into, 
the c.s.f. 
The effect of barbiturate anaesthetics and anticonvulsants 
on these parameters has been studied. 
It was found that:- 
1) sodium thiopentone and sodium pentobarbitone, in a 
dose sufficient to induce light anaesthesia, may depress 
both potassium eff lux from, and potassium influx into, 
the c.s.f. 
2) diazepam has consistent depressant effect on the 
potassium fluxes of c.s.f. The effect is less marked than 
that seen with the barbiturates. 
3) diphenylhydantoin has no effect on potassium efflux 
from the c.s.f. but may slightly depress potassium influx 
into the c.s.f. 
4) paraldehyde, in a dose sufficient to induce light 
anaesthesia, slightly increases the potassium fluxes of c.s.f. 
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The depressant effect of the barbiturates and diazebam on 
c.s.f. potassium fluxes has been interpreted as being secondary 
to a depressant action on potassium exchange across neuronal 
membranes in the brain. 
These findings are discussed in relation to:- 
1) previous studies on c.s.f. potassium fluxes. 
2) possible mechanisms of actions of the drugs. 
It was concluded that the anaesthetic or anticonvulsant 
action of a drug is not related to the drug's effect on c.s.f. 
potassium fluxes. 
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SECTION III 
A NEW MICROTECHNIQUE FOR THE QUANTITATIVE DETERMINATION 
OF FREE AMINO ACIDS IN BRAIN TISSUE: ITS APPLICATION 
TO A STUDY OF GABA AND OTHER AMINO ACIDS IN A 
MODEL EPILEPTIC FOCUS. 
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INTRODUCTION 
Since the first reports of the presence of significant 
amounts of 6-amino butyric acid (GABA) in the brain (Awapara, 
Landua, Fuerst and Seale, 1950; Roberts and Frankel, 1950) 
there has been much evidence to suggest that this substance may 
have an L_hibitory transmitter function in the central nervous 
system, and that disorders in GABA metabolism may be causally 
related to convulsive phenomena. 
Krnjevic (1970) has recently carried out a comprehensive 
review of the evidence for GABA's transmitter function in the 
brain and in this short introduction I shall only summarise the 
main points in the argument. 
From Florey's early work on the depressant effects of beef 
brain extracts on the crayfish stretch receptor (Florey, 1954) 
it emerged that the active principle, which had been named 
Factor I by Florey, was in fact GABA (Bazemore, Elliot and 
Florey, 1957). On the same tissue Kuffler and Edwards (1958) 
and Takeuchi and Takeuchi (1965) established the identical effects 
of synaptic inhibition and iontophoretic application of GAGA. 
As a final confirmation of GABA's transmitter role it was 
demonstrated by Otsuka, Iversen, Hall and Kravitz (1965) that 
stimulation of the inhibitory nerve fibres of this preparation 
caused a specific release of GABA. 
The evidence is not so clear -cut in the mammalian central 
nervous system,but the early reports of Hayashi (1956); 
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Purpura, Girado, Smith, Callan and Grundfest (1959); Curtis 
and Watkins (1960); Krnjevic and Phillis (1963) and Crawford 
and Curtis (1964) established the depressant effects of GAGA 
on certain neurones in the mammalian central nervous system. 
It is now known that the post- synaptic hyperpolarisations 
produced by both synaptic inhibition and the application of 
GABA have an identical reversal potential (Krnjevic and Schwartz, 
1967; Dreifus, Kelly and Krnjevic, 1969) and that both are almost 
certainly due to an increase in chloride permeability of the post 
synaptic membrane (Kelly, Krnjevic, Morris and Yim, 1969). 
Complete electrophysiological investigation of a specific 
inhibitor pathway by Obata, Ito, Ochi and Sato (1967) gave strong 
evidence for believing that GAGA may be the inhibitory transmitter 
released onto the cells of Deiter's nucleus by cerebellar Prkinje 
fibres. 
From the many biochemical studies of the distribution of 
GABA within the brain (Baxter and Roberts, 1959, 1960; Singh and 
Malhotra, 1962; Krzalic Mandic and Milhailovic 1962; Lovell, 
Elliot and Elliot, 1963; Fahn and Caté, 1967) we know that like 
other postulated neurotransmitters such as acetylcholine and 
noradrenaline, GABA is non -uniformly distributed throughout the 
grey matter of the brain. We also know that the enzyme which 
is responsible for the formation of GABA from glutamate (Fig.3:1), 
namely glutamate decarboxylase (GAD), is distributed in a very 
similar pattern throughout the brain (Albers and Brady, 1959; 
( 
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Lowe, Robbins and Eyreman, 1958; Muller and Langemann, 1962; 
Roberts and Eidelberg, 1960; Chalmers, McGeer, Wilson and 
McGeer, 1970). The concentration of GABA in a particular brain 
area appears to be directly related to the GAD activity within 
that area. In contrast the enzyme responsible for the degrada- 
tion of GABA, namely GABA transaminase (Fig. 3:1), is distributed 
more generally throughout the central nervous system ( Waksman, 
Rubinstein, Kuriyama and Roberts, 1968). GABA transaminase 
catalyses the reversible transamination of GABA with 3- keto- 
glutarate forming succinic semialdehyde and glutamic acid. 
Succinic semi- aldehyde is in turn oxidised to succinic acid which 
then enters the tricarboxylic acid cycle.. In the mammalian brain 
therefore there exist the necessary enzymic mechanisms to syn- 
thesise and degrade GABA. 
Further support for a transmitter role for GABA can be gained 
from the presence of specific uptake mechanisms for the transport 
of GABA into brain cells (Elliot and Van Gelder, 1958; Tsukada, 
Nagata, Hirano and Matsutami, 1963) and, more specifically, nerve 
endings (Weinstein, Roberts and Kakefuda, 1963; Neal and Iversen, 
1969; Bloom and Iversen 1971; Logan and Snyder, 1971). "In 
vitro" preparations of cerebral nerve endings have also been 
shown to contain both GABA (Krnjevic and Whittaker, 1965; Mangan 
and Whittaker, 1966; Bradford and Thomas, 1969; Kuhar and 
Snyder, 1970) and its synthesising enzyme, GAD (Salganicoff and 
De Robertis, 1965; Fonnum, 1968). 
- 196 - 
The physiological release of GABA has not been easily 
demonstrated but Katz, Chase and 1opin (1969) and Srinavasan, 
Neal and Mitchell (1969) have reported that brain slices release 
GABA when stimulated either electrically, or by depolarising 
concentrations of potassium. In the "in vivo" situation, 
Obata and Takeda (1969) have observed an increased release of 
GABA into the 4th ventricle when the inhibitory pathway from the 
cerebellum to the nuclei around the ventricle was stimulated. 
Mitchell and Srinavasan (1969) also found an increased efflux 
of GAGA from the cortex during periods of induced cortical 
inhibition. 
As a final piece of evidence, it has been shown that at some 
neurones in the mammalian central nervous system both normal 
synaptic inhibition and the inhibition brought about by the 
iontophoretic application of GABA are blocked by bicuculline. 
(Curtis, Duggan, Felix and Johnstone, 1970a, b; Curtis, Duggan 
and Felix, 1970; l5be:is, Hösli and Haas 1971; Kelly and 
Reynaud, 1971). However Krnjevi6 has stressed the fact that 
bicuculline is not a specific antagonist at all inhibitory sites 
in the central nervous system. 
On the basis of all these findings it is reasonable to 
suggest that GABA may be an inhibitory transmitter in the 
mammalian central nervous system and as such it may play a part 
in maintaining the central neuronal population at a "normal" 
level of excitation. The latter hypothesis has been supported 
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in a more direct, though perhaps less exacting manner, by many 
experiments in which the tissue concentrations of GABA have 
been manipulated by the administration of various drugs. 
Kopeloff and Chusio (1965) reported that intravenous or 
intraperitoneal GABA protected against drug induced convulsions 
in dogs, while Kobrin and Seifter (1966) noted that intravenous 
zo Ce 
GABA blocked pentylenetetrae convulsions in day -old chicks. 
GABA has been shown to prevent the discharge of a chronic 
epileptic focus caused by either a freezing lesion (Berl, 
Purpura, Giradc and Waelsch, 1959; Berl, Takagaki, and Purpura 
1961; Strasberg, Krnjevie, Schwartz and Elliot, 1967) or an 
aluminium oxide implant (Guerrero -Figueroa, De Balbian Verster, 
Barras and Heath, 1964). GABA has also been shown to protect 
mice against audiogenic seizures either after topical application 
to the cortex (Ballantine, 1963), or after systemic administration 
(Pas quini, Salamone and Gomez, 1968) . 
Evidence linking GABA with convulsive phenomena has also 
come from studies in which seizure threshold has been altered by 
drugs which affect the metabolism of GABA. The enzymes respons- 
ible for the synthesis and degradation of GABA, namely glutamate 
decarboxylase (GAD) and GABA transaminase (GABA -T) respectively, 
are both dependent on pyridoxal phosphate. This coenzyme is 
formed from pyridoxal and adenosine tri- phosphate by the enzyme 
pyridoxal kinase. GAD is particularly sensitive to drugs which 
reduce the level of free pyridoxal phosphate. Many hydrazines 
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and hydrazides are capable of forming a covalent bond with the 
carbonyl group of pyridoxal phosphate, thus reducing its avail- 
ability for coenzyme functions. Certain hydrazones formed by 
the reaction between pyridoxal phosphate and a hydrazide may 
also reduce free levels of pyridoxal phosphate by inhibiting the 
enzyme pyridoxal kinase (Tapia, Pérez de la Mora and Massieu, 1969). 
From the early biochemical studies of Killam and his co- 
workers it seemed very likely that thiosemicarbazide- induced 
convulsions were a direct consequence of a decrease in cerebral 
GABA content subsequent to inhibition of GAD (Killam, 1957; 1958; 
Killam, Dasgupta and Killam, 1960; Killam and Bain, 1957). 
This simple explanation of the mechanism of hydrazide- induced 
convulsions was challenged in later experiments (Balzer, Holtz 
and Palm, 1960; Baxter and Roberts, 1960; Maynert and Kaji, 
1962) in which it was shown that there was a lack of correlation 
between the time of maximum decrease in GABA content of the brain 
and the time of maximum seizure susceptibility. The situation 
has been clarified somewhat by a recent comprehensive study in 
which various hydrazides were administered in doses such that 
convulsions occurred after an equal latent period with all the 
drugs. When this was done there were several common biochemical 
findings with all the drugs; firstly that the rate of decrease 
of GAGA concentration in the brain was similar for all the drugs; 
secondly, that GAD was always inhibited, though to varying 
degrees; and thirdly that there was very little inhibition of 
GI. BA -T (Wood and Abraham, 1970) . 
-- 199 - 
A similar spectrum of biochemical findins has been seen in 
rats which developed convulsions as a result of exposure to 
oxygen at high pressure ('food and Watson, 1963, 1964; Wood, 
Watson and Stacey, 1966; Wood, Watson and Ducker, 1967). In 
these experiments the severity of the convulsions correlated well 
with the extent of the decrease in brain GAGA content. 
However the situation is further complicated by the existence 
of two drugs, amino- oxyacetic acid (AOAA) and 1- glutamyl hydrazide, 
wliich raise tissue GABA levels at the same time as they cause 
convulsions (Tapia et al., 1969). At a convulsive dose level 
these drugs inhibit both GAD and GABA -T, but the dosage of AOAA 
can be adjusted so th. t it effectively inhibits only GABA-T. 
At this dose level AOAA can protect a.ninals against thio- se_mi- 
carbazid e- induced convulsions (De Vanzo, Greig and Cronin, 1961; 
Roa, Tews and Stone, 1964; Schumann, Paquette, heinzelman, 
Vallach, De Vanzo, and Greig, 1962) though not against high 
pressure oxygen- induced convulsions (Wood and Watson, 1965). 
Again, the maximum protection from convulsions occurs at a differ- 
ent time from the maximum increase of brain GABA content (Kuriyama, 
Roberts and Rubinstein, 1966). The relationship between brain 
GABA concentration and seizure susceptibility is therefore a 
matter of some complexity (Baxter, 19b9) although a drop in the 
tissues levels of GABA nearly always results in convulsions. As 
Tapia et al. (19b9) have pointed out, inhibition of GAD seems 
to be constant feature of drugs which interfere with pyridoxal 
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phosphate coenzymes and also cause convulsions. The parodox of 
convulsions occurring in the face of elevated GABA levels in the 
brain might be explained by the existence of two different 
functional "pools" of GABA. GABA -T is principally a mito- 
chondrial enzyme and Kuriyama and Roberts (1969) have speculated 
that it may be located principally in post -synaptic areas and 
glia, while GAD may be concentrated in pre- synaptic nerve endings. 
Inhibition of GABA -T might then raise the tissue level of GABA 
but have very little effect on the pre- synaptic pool of GAGA 
which may be available for release at inhibitory synapses. 
There would seem therefore to be a considerable body of evi- 
dence to support a link between GABA metabolism and convulsions. 
Whether this is a causal relationship is not known. Certainly 
a causal link would be consistent with the hypothesis that GABA 
is an inhibitory transmitter in the central nervous system. 
In this section of the thesis I shall report on the develop- 
ment and application of a new micro -technique which allows the 
quantitative analysis of GABA and associated amino acids in micro- 
gram amounts of brain tissue. 
Animal Models of Epilepsy 
The most widely studied animal models for epilepsy are the 
convulsive states produced either by electroshock or by convulsant 
drugs such as pentylenetetrazole. These models have proved very 
useful in the study of anticonvulsant drugs. However the trans- 
itory nature of the convulsive states, and the fact that they are 
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being induced by agents wl.ich affect the whole brain suggest 
they may not be good models for studying the mechanisms involved 
in human epilepsy. 
It has been sdown that certain types of insult to the brain 
can produce long-lasting localised abnormalities of brain function 
very similar to those found in cases of focal epilepsy in humans. 
Openchowski in 1883 was the first to demonstrate that freezing a 
small circumscribed area of the surface of the cerebral cortex 
resulted in an "epileptic'' focus at the site where the tissue was 
frozen. The momentary freezing of the tissue may be achieved 
by placing a very cold rod of a good conducting material on the 
.surface of the brain until ice crystals are seen to form on the 
cortical surface (Keith and Bickford, 1954). Alternatively the 
surface of the brain may be cooled with an ethyl chloride spray 
(Morrell and Florenz, 1958). The lesion produced by such techni- 
ques starts to discharge within 1 -3 hours. The spike discharge 
continues at a steady rate for some 12 hours, after which time 
it becomes less frequent. Intermittent paroxysmal discharges 
may continue in the rabbit for up to weeks, and in the cat for 
up to 3 months. 
Application of alumina cream to the cortex (either topically 
or by injection into the ;grey matter) results in a different type 
of epilepto :enic lesion (Kopeloff, Barrera and Kopeloff, 1942) in 
that the seizure activity produced by this technique does not 
develop for several weeks. Once established however, the focus 
may continue to disch: =rge aonormally for a period of years. 
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Many other agents including penicillin (Walker, Johnson 
and Kallross, 1945), tungstic acid (Blum. and Liban, 1960) 
antimony, bismuth, nickel, cadmium and nickel (Chusio and 
Kopeloff, 1962) have been used to produce epileptogenic lesions 
in the brain. 
In this present study epileptogenic lesions in the cortex 
nt 
of the rat have been induced by the implantation of a small quality 
of cob .lt into the cortical grey matter (Dow, Fernandez -Guardiola 
and Manni, 1962; Fischer Holubar and Malik, 1968; Dow, Park, 
Pryor and Townsend, 1971; Dow, Mcíueen and Townsend, 1972). 
With this lesion clinical seizure activity is evident within 
days, and evidence of spike discharges persists for a period of 
months. There is also evidence from electrocorticogram records 
that a secondary epileptic focus (the "mirror"' focus first des- 
cribed by Morrel and Baker, 1961) is set up in the corresponding 
area of the contralateral cortex. In this section of my thesis 
I shall report the results of the analyses of GABA and associated 
amino acids in both primary and secondary epileptic foci. 
At the outset of this work I was interested primarily in the 
rela.tionslaip between GABA and epilepsy but the method which I 
chose to measure GABA levels in the brain showed itself to be 
readily applicable to the analysis of other amino acids as well 
as GABA. Glutamate, glutamine, glycine and aspartate were there- 
fore also included in this study. Glutamate was included firstly 
on the ground that it is the immediate precursor of GABA (Fig.3:1) 
and secondly because it may have an excitatory transmitter 
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function in the central nervous system (reviews - Krnjevic, 
1970; Johnson, 1972) . Glutamine was of interest principally 
as a reservoir of glutamate (Fig. 3:1), while glycine (e.g. 
Merman and Aprison, 1968; Curtis and Johnson, 1970; Logan and 
Snyder, 1971; Iversen and Bloom, 1972) and aspartate (e.g. 
Curtis and Watkins, 1963; Logan and Snyder, 1971) have been 
proposed as candidates for, respectively, inhibitory and 
excitatory transmitter roles in the central nervous system. 
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METHODS 
Choice of method to analyse GABA levels in a model epileptic focus 
A cobalt implant in the rat cortex, such as I have used in 
this study (see pages 250 to 252), produces discrete histological 
changes in a small area of cortex surrounding the implant(1 mm 
radius 11 days after the implantation). Abnormal epileptiform 
activity arises both from the site of the cobalt implant (the 
primary focus) and from the secondary "mirror" focus in the 
contralateral cortex. It seemed possible therefore that bio- 
chemical changes cni"ht be restricted to these sites. It also 
seemed possible that only a relatively small number of cells in 
the focal area might in fact be "epileptic". If these "epileptic" 
cells were scattered over the focal area it might be very diffi- 
cult to detect any significant biochemical changes because of 
"dilution" with normal cells. However if the "epileptic" cells 
were grouped together in a distinct zone within the focus it might 
be possible to detect significant biochemical changes by examining 
that zone in isolation. To allow examination of this latter 
possibility required that I use a method of assay which would 
allow the e.3timation of GABA in sub -milligram amounts of brain 
tissue. 
Jakoby and Scott (1959) have reported a higlBy specific 
enzymic assay procedure for GABA, and this has been employed by 
Baxter and Roberts (1959, 1960) and Fahn and Côté (1968) in 
studies of GABA levels in different brain areas. The method, as 
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applied by Fahn and Cóté, has a detection lirait of about 1 nano - 
mole of GABA and therefore might allow the estimation of GABA 
in about 1 mg of cortical tissue. Since I intended eventually 
to examine even smaller areas of tissue within the focal area 
this method was not considered suitable. 
A more sensitive enzyme assay for GABA is that reported by 
Otsuka, Obata, Miyata and Tanaka (1971). This technique combines 
the method of Jakoby and Scott (1959) with the enzymic cycling 
tecïlni,yue of Lowry, Passoneau, Schulz and Rock (1961), and per- 
mits the measurement of as little as 2 x 10 -14 moles of GABA. 
Using this method Otsuka et al. (1971) carried out GABA analyses 
on single isolated nerve cell bodies. However this method has 
the disadvantage of requiring five different highly purified 
enzymes and several highly purified substrates. It was there- 
fore excluded on the grounds of high complexity and cost. An- 
other factor in its exclusion was that cobalt in the primary focal 
area might interfere with the enzymes involved in the assay. 
Use of either of these two methods for GABA estimation would 
also have required the parallel development of entirely separate 
techniques for the other amino acids in which we were interested, 
namely glutamate, aspartate,glutamine and glycine. The standard 
techniques for automatic amino acid analysis using an ion -exchange 
column separation followed by a colorimetric reaction with 
ninhydrin were too insensitive. For instance a recent study of 
amino acid levels in human brain samples used about 100 mg of 
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tissue for a satisfactory analysis (Perry, Berry, Hansen, 
Diamond and Mok, 1971) . 
In 1970 Neuhoff and Weise reported a method for the prepara- 
tion, separation and detection of dansyl derivatives of amino 
acids in brain tissue. This method was said to have a potential 
sensitivity for the estimation of amino acids in the picomole 
range, although as applied by Neuhoff and Weise it was only semi - 
quantitative. 
Weber (1952) had first demonstrated that dansyl chloride 
could produce a stable, fluorescent, covalently-bonded conjugate 
with protein. Hartley and Massey (1956) attempted to use dansyl 
chloride as a fluorescent label for the amino acid group at the 
active centre of the enzyme chymotrypsin. In 1963 Grey and 
Hartley reported on the use of dansyl chloride as a reagent for 
end -group analysis of Qroteins and peptides. It was found to be 
100 times more sensitive than the original fluorodinitrobenzene 
reagent introduced by Sanger (194=). The usefulness of dansyl 
chloride as a reagent for end -group analysis de,sends on three 
factors: the high yield of dansylated products; the stability 
of the dansyl -amino acid bond during acid hydrolysis of the 
protein; and the high quantum yield of dansyl -amino acid fluo- 
rescence within the visible range of the spectrum. Since Grey 
and Hartley's original report the technique has become a standard 
method of end -;group amino acid analysis (review; Hartley, 1970). 
As the dansylation ülethod appeared to be potentially suit- 
able for estimating GABA and other amino acids with the required 
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sensitivity it was studied further. 
Dansyl Chloride 
Dansyl chloride (Fig. 3:2), or to give it its full title 
1- dimethylaminonapthalene -5- sulphonyl chloride, behaves as a 
typical aromatic sulphonyl chloride, reacting with a wide variety 
of bases such as primary or secondary amines, phenolic hydroxyls, 
thiols and imidazoles. Tertiary amines do not react with dansyl 
chloride but catalyse the reaction with primary and secondary 
amines. The bonds formed between dansyl chloride and thiol and 
imidXzole groups are unstable. The reaction between the primary 
amino group of an amino acid and dansyl chloride is highly depend- 
ent on the pKa of the amino acid and the pH of the solution in 
which ':.he reaction takes place. When the pH is low and the 
amino group protonated,dansyl chloride preferentially hydrolyses 
water. As the pH rises howeverf hydroxyl ions become strongly 
competing nucleophiles. Hartley (1970) has prepared a graph 
showing theoretical yields of different amino acids with dansyl 
chloride at different pH. The optimal range for dansylation of 
most amino acids lies between pH 9 and 10. Grey and Hartley 
(1963) found that carrying out the dansylation of end -group 
amino acids in 50% aqueous acetone produced solubilisation of 
the dansyl reagent and suppressed the ionisation of the amino 
groups on the amino acids. 
The important reactions in respect of the dansylation of 
tissue amino acids are shown in Fig. 3:3. The first reaction 
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1- DIMETHYL AMINO NAPTHALENE -5- SULPHONYL CHLORIDE 
(DANSYL CHLORIDE -- ArSO2C1) 
FIG. 3:2 The structure of dansyl chloride. 
ArSOtCR + MHCOOH 
NHz 
ArS01C.l, + I-1z0 
ArSO,CJt + l2CHCOOH + Hi0 
ÑHSO,F1, 
R CHCOOH + HCA 
NH i01Fir 
ArSOOH + HCQ 
(I) 
(n) 
RCHO + Ar SOtNHz + Ar SOLO H ( 1ÌL 
1 
+ CO + Hu 
FIG. 3:3 Reactions of dansyl chloride 
The three reactions illustrated occur in buffered 
(pH 8.5 - 10) aqueous acetone (50¡o) solution between: - 
I Dansyl chloride and an amino acid 
II Dansyl chloride and water 
III Dansyl chloride and a dansyl -amino acid. 
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is that between dansyl chloride and the primary amino group of 
an amino acid. At a pH between 9 and 10 the dansyl chloride 
attacks the amino group of the amino acid forming a dansyl amino 
acid and hydrochloric acid. In the case of an aromatic amino 
acid any phenolic hydroxyl groups or imidazole groups may also 
be dansylated. 
the hydroly,is oj- by 
The second reaction showsLdansyl chloride hydLolyaing water 
with the formation of dansyl hydroxide (l-dimethylaminonapthalene- 
5-sulphonic acid) and hydrochloric acid. 
The kinetics of these first two competing reactions have 
been studied by Spivak, Shcherbukhin, Orlov and Varsha.vsky (1971). 
The third reaction betweendansyl chloride and dansyl amino 
acids was first reported by Neadle and Follit (1965). In this 
reaction a dansyl amino acid derivative is degraded with the 
formation of: an aldehyde derived from the amino acid; dansyl 
amine from the dansyl moiety; and carbon monoxide from the 
carboxyl group of the amino acid. 
This last reaction introduces a complicating factor in the 
establishment of conditions which will give the optimum yield of 
dansyl amino acid since both reactions I and III are favoured by 
an excess of dansyl chloride (Spivak et al., 1971). 
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Equipment used in the extraction, dansylation and quantitative 
estimation of amino acids in brain. tissue. 
Stage I - Homogenisation, protein precipitation and dansylation. 
1. Conical polypropylene reaction tubes, capacity 
1.5 ml (Eppendorff). 
2. Glass homogenisation pestle, ground at one end to fit 
into the above tubes. 
3. High speed centrifuge, capable of producing 20,000 g 
(Mistral, Tßî. S. E. , fitted with high speed head) . 
4. 2, 5 and 10 ßz1 microcapillaries (Drummond). 
5. Glass micro- reaction tubes, capacity approximately 
100 pa, length approximately 20 mm (prepared from 
glass capillary tubing, internal dameter 2.5 mm, 
external diameter 3.5 mm). 
0. Rubber caps for micro- reaction tubes (the rubber washers 
from the plunger heads of 1 ml polyethylene syringes 
(Becton, Dickinson and Co. Ltd) ). 
7. Heating block, 37 °C (Eppendorff). 
8. Source of nitrogen gas. 
9. Calcium chloride drying tower. 
Stage II - Chromatography 
10. Polyamide micro -chromatography plates (3.5 x 3.5 cm) 
prepared from 15 x 15 cm polyamide plates (a layer of 
poly- E- ca.prolactam applied to both sides of a solvent- 
-212- 
resistant polyester base). The plates obtainable 
from Carl Schleicher and Schull. were found to give 
slightly better resolution of the dansyl derivatives 
than tho-3e obtainable from B.D.H. 
11. Fine glass micro -capillary with flamed tip (tip 
diameter 0.05 - 0.15 mm), prepared from standard 
melting -point tubes. 
12. Stereo microscope (Zeiss). 
13. Micro -chromatography tanks (Uickfit glass weighing 
bottles, 4.7 cm diameter, 5 cm depth). 
Stage III - Identification and assay of dansyl amino acid spots. 
14. Source of short wavelength uu. light (254 nm). 
15. Liquid scintillation counter (Nuclear Chicago, Mark II). 
Materials used in the development and application of the dansyl- 
ation method for the quantitative estimation of amino acids in 
brain tissue. 
iadiochemicals from the Radiochemical Centre - Amersham 
3H - dansyl chloride 
14C - glutamic acid 
14C - aspartic acid 
Specific Activity Activity as despatched 
5600 ci /mole 
260 " 
227 " 
250 Aci in 500 Al benzene 
50 p.ei in 800 7.11 
2% ethanol solution 
50 }zci in 1000 pl " 
14 
C - glutamine 45 50 p.ci in 800 1,11 " 
14 C - GABA 204 " 50 pci in 500 ptl " 
14C 
- glycine 108 " 50 pei in 1000 Al " 
14C 
- hydroxyproline 38 " 10 )Zci (solid) 
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Chemicals 
Dansyl chloride, dansyl glutamic acid, dansyl glutamine, 
dansyl glycine, and dansyl GABA were obtained from B.D.H. 
dl- á -alanine, dl -2- amino -n- butyric acid, 1- arginine monohydro- 
chloride, dl- aspartic acid, 1- cysteine hydrochloride, 1- cystine, 
di -3,4- dihydroxyphenylalanine, 1 -g lutamic acid, glycine, 1- histidine 
monohydrochloride, 1- hydroxyproline, 1- leucine, dl -iso- leucine, 
dl- nor -leucine, 1- lysine monohydrochloride, dl- methionine, 
dl- ornithine monohydrochloride, dl- P -phenylalanine, 1- proline, 
dl- serine, dl- threonine, dl- tryptophan, dl- tyrosine, dl- valine, 
and d- amino -n- butyric acid (GABA) were all obtained from B.D.H. 
2- aminoethanol (ethanolamine), 1- homocarnosine sulphate, 
dl- norvaline, glutathione (reduced form), taurine, and n- acetyl- 
dl-aspartic acid were obtained from Sigma Chem. Co. Ltd. 
Solutions 
0.48 N perchloric acid 
1.5 M potassium carbonate solution 
0.2 M potassium bicarbonate solution 
24x10 dansyl chloride solution in redistilled acetone 
(only used in preliminary experiments) 
5.69x10 -3 M dansyl chloride solution in redistilled acetone. 
3H - dansyl chloride in benzene (250 pei /ml). 
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Stock solution of 14C - amino acids 
The 10 .ci of 
14 
C - hydroxyproline (solid) was taken up in 
200 pl water. 
Using this solution of 14C - hydroxyproline and the 
solutions of the other 14C - amino acids as delivered from the 
Radiochemical Centre the following stock solution was prepared. 
C14 - Glutamate solution 
C14 - Aspartate " 
20 volumes 
20 
Activity of each amino 




C14 - Glutamine " 15 23.4 " 
C14 - Glycine " 10 12.5 " 
C - Hydroxyproline " 10 12.5 " 
C14 -GABA " 5 ( 12.5 " 
Scintillant Solution 
1,4 -di- 2 -[(4- methyl- 5- phenyloxazolyl)] benzene (dimethyl 
POPOP) and 2,5- diphenyloxazolyl (PP0) were obtained from Koch - 
Light Co. Ltd. 
Scintillant solution was prepared by adding 0.112 g dimethyl 
POPOP and 4.25 g PPO to 1 litre of toluene. 
Solvent Systems 
1. formic acid : water (1.5 : 98.5) 
61j volume 
2. benzene : glacial acetic acid (9 : 1). 
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Development of techniques for dansylation and quantitative 
estimation of amino acids in sub -milligram amounts of brain tissue. 
The separation of dansyl amino acids 
In the early work on the end group analysis of proteins 
the dansylated amino acids were separated by paper electro- 
phoresis (Grey and Hartley, 1903). Subsequently thin -layer 
techniques were introduced and Deyl and Rosmus (1965) studied 
the separation of dansylated amino acids in several different 
solvent systems using either silica Gel or alumina as a carrier. 
In 1967 Woods and Wang reported excellent separation of dansylated 
amino acids on polyamide chromatography plates. Micro- plates 
of this material measuring 3 x 3 cm have been employed by Neuhoff 
and Weise (1970) and Bruton and Hartley (1970). In both these 
studies the plate was first run in a 1.5 (v:v) aqueous solution 
of formic acid. The plate was then carefully dried and re -run 
at 900 to the original direction in a mixture of benzene and 
glacial acetic acid (9:1, v:v). Crowshaw, Jessup and Ramwell 
(1967) and Hartley (1970) have reported the use of a third solvent 
system of ethyl acetate : methanol : glacial acetic acid (20:1:1, 
v:v:v) to achieve better separation of some poorly defined pairs 
of dansylated amino acids. 
Neuhoff and Weise (1970) stated that as little as 10-32 moles 
of dansylated amino acids could be separated on polyamide micro - 
chromatography plates. This was the method used in this present 
study. 
- 216 - 
Polyamide chromatography plates (15 x 15 cm) were obtained 
from B.D.H. These plates consist of a layer (50 microns thick) 
of poly- -caprolactam applied to both sides of a solvent 
resistant polyester base. Neuhoff and Weise (1970) used these 
plates cut into 3 x 3 cm squares but I found that a size of 3.5 x 
3.5 cm squares was more easily handled during chromatography. 
Quickfit glass weighing bottles (see page 212) were found 
to make very satisfactory micro - chromatography tanks for these 
3.5 x 3.5 cm micro - chromatography plates. 
Standards of dansyl - glutamic acid, dansyl- glutamine, dansyl - 
GABA and dansyl--- glycine were made up in 0.2 M potassium bicarbonate 
solution to dive 10-47M solutions of each of these four dansylated 
amino acids. The chromatographic separation of these dansyl 
amino acids was then investigated. 
Application of very small volumes (0.1 - 0.3 microlitres) 
of these standard solutions to the polyamide micro -plates was a 
major problem. Because of the small total area of the plate the 
spot size had to be kept below a diameter of 0.5 mm. Also one 
had to avoid physical damage to the surface of the plate during 
the application procedure. The procedure eventually used was 
application of the solution from a fine glass capillary. For 
satisfactory working the tip diameter had to be within the range 
of 0.08 - 0.12 mm. To prevent damage to the plate surface the 
tip of the capillary was slightly flamed. By manual manipulation 
in the visual field of a stereo -microscope the capillary (filled 
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by capillary attraction) was lightly touched onto the surface of 
the plate causing a very small volume of fluid (less than 0.01 µl) 
to run out of the capillary. It was found helpful to have a 
blower (operated by a variable foot switch) blowing a stream of 
cold air over the working area. 
Homogenisation and extraction of free amino acids from tissue 
Neuhoff and Weise (1970) homogenised 20 mg of brain tissue 
in 0.05 M sodium bicarbonate solution and then precipitated 
protein with trichloroacetic acid (TCA). This agent cannot be 
readily removed from the supernatant after the precipitation of 
protein. Since the dansylation of the amino acids requires an 
alkaline pH (between pH 9 -10) the TCA must first be neutralised 
with alkali. As a result the final dansylated TCA extract 
contains a considerable amount of TCA salts. When this dansylated 
extract is applied to the plate the spot rapidly becomes "loaded" 
with these TCA salts. These salts cause streaking of the 
chromato :ram. 
It was decided that this problem made TCA an unsuitable 
protein precipitating agent. Three protein precipitating agents 
which can readily be removed from the supernatant extract are 
ethanol, acetone and perchloric acid. Of the three, perchloric 
acid gives the most efficient protein precipitation. Saifer 
(1971) has recommended perchloric acid extraction as the best 
method overall for the quantitative estimation of free amino 
acids in brain tissue. 
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It was therefore decided to homo enise the tissue in 
perchloric acid and subsequently neutralise the solution with a 
strong solution of potassium carbonate, thus precipitating 
perchlorate as its highly insoluble potassium salt. It was found 
that this technique resulted in a lower concentration of inorganic 
salts in the final dansylated extract. This allowed the appli- 
cation of a greater volume of dansylated extract to the plate 
without causing streaking of the chroLnato raya. 
Conditions of 3ansylation 
Gray and Hartley (19b3) reported that a 50% solution of acetone 
in bicarbonate buffer (pH 9) was a suitable medium for the dansyl - 
ation of end-groups in proteins. The presence of the acetone 
achieved stabilisation of the dansyl chloride and inhibited the 
protknation of the amino acid. Spivak et al. (1971) studied 
the dansylation of glycine, serine, 1Jroline and leucine. Using 
50. acetone bicarbonate buffer they found that a 100 -500 fold 
excess of dansyl chloride over amino acid resulted in optimal 
yields. For the quantitative estimation of amino acid mixtures 
they recommended adding one volume of 30 x 10 -3M dansyl chloride 
solution in acetone to one v )lume of the buffered mixture of amino 
acids (amino acids 10 -3:úl or below). The occurrence of reaction 
III (Fig. 3:3), namely the degradation of a dansyl amino acid 
by äansyl chloride, could be minimised by carrying out the dansyl - 
ation at room temperature and limiting ths reaction time to 
40 minutes. 
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It was decided to use these conditions in the present study. 
However it was found that dansyl chloride solutions (in acetone) 
of above 24 x 10 -3M resulted in precipitation of dansyl chloride 
when they were added to equal volumes of aqueous buffer solutions. 
A 24 x 10 -3L solution of dansyl chloride in acetone was there- 
fore used in preliminary investigations. 
preliminary separation and concentration of dansyl amino acids 
The possibility of extracting dansyl amino acids from the 
final acetone /buffer mixture has been investigated. It was 
found that the carboxyl groups on the dansyl-amino acids prevented 
their extraction into orJanic solvents. However it was noted 
that dansyl chloride (strong yellow coloration) was extracted into 
di -ethyl ether. 
A mixture of amino acids was dansylated and the final dansyl- 
ated mixture was extracted with 2 volumes of di -ethyl ether, giving 
a yellow coloured ether extract and a colourless aqueous residue. 
An aliquot of the ether extract was spotted onto a polyamide 
micro -plate which was then developed as described on page 222 
Under short wavelength u. v. light the developed chromatogram 
showed only two discrete spots. One of the soots was identified 
as dansyl hydroxide by its strong blue fluorescence. The other, 
a very much fainter yellow -green spot, was identified as dansyl - 
amine. The extracted dansyl chloride yiroduced a strong diffuse 
fluorescence principally at the head of the second solvent front 
directly above the origi 
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Following the ether extraction the residue containing the 
dansyl -amino acids was taken to dryness under dry nitrogen at 
37 °C. The dansyl - amino acids were glen extracted with ethanol. 
Ethanol wa.s chosen to extract the dansyl-amino acids for three 
reasons: firstly because these compounds are soluble in ethanol; 
secondly because inorganic salts are relatively insoluble in 
ethanol and therefore much of the buffer salt was left behind as 
a solid residue; and thirdly because the application of an 
ethanol solution to the polyamide chromatography plates was more 
easily controlled than was the application of an aqueous acetone 
solution. When the ethanol extract was spotted onto a polyamide 
plate and chromatographed as described on page 222 examination 
of the developed plate under u.v. light showed that the ether 
wash and the ethanol extraction had resulted in several improve- 
ments. In the first place the ether wash removed much of the 
dansyl -hydroxide qnd dansyl- amine, neither of which I was interested 
in. In the ,second place the ethanol extraction allowed more of 
the dansyl amino acids to be spotted onto the plate without the 
danger of applying too much salt. As a result the developed 
chromatogram showed dote intense and discrete spots with an 
absence of streaking (Fig. 3:5 ). Another important action of 
the ether wash was to remove excess reagent (dansyl chloride) thus 
preventing continuing degradation of dansyl -amino acid by attack 
with dansyl chloride (reaction III, Fig. 3: 3 ) 
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Preparation of map of separated dansyl amino acids 
Before progressing to the analysis of amino acids in tissue 
it was necessary to prepare a map showing the relative positions 
of the dansyl derivatives of the amino acids after chromatography 
on a polyamid e plate. 
The principal amino acids likely to be encountered in brain 
tissue, along with a few unnatural synthetic amino acids, (see 
check list for Fig. 3:4) were made up individually in 0.2 M 
potassium bicarbonate buffer and then aliquots of the individual 
solutions were mixed so that the final mixture was 2 x 10-4M with 
respect to each individual amino acid. 
For locating the position of an individual amino acid 
derivative, a 1 ml aliquot of the above mixture was placed in a 
15 ml glass centrifuge tube. A small volume of the stock solu- 
tion of the amino acid under study was then added to the 1 ml 
aliquot of the mixture to give a ten -fold excess of that particular 
amino acid over the others in the mixture (i.e. 2 x 10 -3M as 
opposed to 2 x 10 -4M). The mixture was then dansylated with an 
equal volume of dansyl chloride solution in acetone (24 x 10-3M), 
for 40 minutes at room temperature in the dark. After this 
period excess dansyl chloride reagent was removed by washing 
with 2 volumes of di -ethyl ether. The aqueous residue was then 
evaporated under dry nitrogen at 37 °C and extracted with 1 ml of 
ethanol. 0.1 pl of the ethanol extract was then spotted onto 
the corner of a polyami..e plate. The plate was first run in 
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ascending fashion in 1.5ic formic acid solution (solvent I). It 
was then carefully dried and re -run at 900 to the original 
direction in benzene : glacial acetic acid (9:1, v:v) (solvent II). 
After drying, the plate was examined under u.v. light. The spot 
pertaining to the amino acid under study stood out from all the 
others by its more intense fluorescence. 
This procedure was repeated with all the amino acids and 
from these studies the map shown in Fig. 3:4 was prepared. It 
was apparent from these early studies that modifications would 
have to be made to the conditions of the chromatography in order 
to separate firstly dansyl glutamine from dansyl serine and dansyl 
threonine; and secondly dansyl aspartate from dansyl glutamate. 
It was not considered necessary.to attempt to separate dansyl GABA 
from dansyl oc- amino -n- butyric acid since only traces of this 
latter compound can be detected in the brain (Perry, Hansen, 
Berry, N1ok and Lesk, 1971) . 
Several different solvent systems were tried in an attempt to 
improve the separation of dansyl- glutamine, dansyl-aspartate and 
dansyl -glutamate. The solvent systems are shown below:- 
(1) water : formic acid (98.5 : 1.5) 
(2) benzene : glacial acetic acid (9 : 1) 
(3) ethyl acetate : methanol : glacial acetic acid (20 : 1 : 1) 
(4) n- heptane : n- butanol : glacial acetic acid (3 : 3 : 1) 
(5) n- butanol :pyridine : glacial acetic acid : water(30 : 20 : b : 
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FIG. 3:4 Dansylated Amino Acid Map 
Acid 
: Glacial Acetic Acid. 0:1) 
Solvent 1 : 1.5iL Formic 
Solvent 2 : Benzene 
1. á -Amino Butyric Acid 18. DL- P- Phenyl Alanine 
2. Glycine 19. L- Proline 
3. L- Glutamine 20. DL- Serine 
4. L- Glutamic Acid 21. DL- Threonine 
5. DL- Aspartic Acid 22. DL- Tryptophan 
b. L- iìydroxy Proline 23. L- Tyro3ine 
7. DL- Alanine 24. DL- Valine 
8. DL-d,-Amino Butyric Acid 25. L- Homocarnosine 
9. L- Arginine 26. Taurine 
10. L- Cysteine 27. Glutathione 
11. L- Histidine 28. Aminoethanol 
12. L- Leucine 29. DL- Norvaline 
13. DL- Isoleucine 30. Dansyl -Hydroxide 
14. DL- Norleucine 31. Unknown 
15. L- Lysine 32. Starting Point 
16. DL- Methionine 
17. DL-Ornithine 
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(7) chloroform : benzyl alcohol : glacial acetic acid (70 : 30 : 3) 
(8) chloroform : ethanol : glacial acetic acid (38 : 4 : 3) 
Solvent systems (5) to (8) gave poor separation and defini- 
tion of the dansyl -amino acid spots and were not investigated 
further. Solvent system (3) which has been reported by Hartley 
(1970) to separate dansyl -glutamate from dansyl- aspartate was no 
.pore successful in this respect than solvent system (2). Solvent 
system (4) was more successful in separating dansyl -glutamate from 
dansyl- aspartate but it carried both dansyl -GAGA and dansyl-glycine 
almost at the solvent front where they became mixed with other 
dansyl derivatives. It was found that developing the chromato- 
gram in solvent system (2) with the lid of the tank off for 9 
minutes resulted in separation of dansyl- glutamate from dansyl - 
aspartate. Under these conditions the solvents evaporated about 
half -way up the plate and as a result the dansyl derivatives with 
a lbw Rf value continued to advance up the plate while the deriv- 
atives with a high Rf value remained half -way up the plate at the 
solvent front. The lid of the tank was replaced after 9 minutes 
and the solvent front allowed to reach the top of the plate. 
Fig. 3:5 shows a mixture of dansylated amino acids which have 
been chromatographed in this way following an initial separation 
in solvent system (1) . The extended run in solvent system (2) 
separated dansyl -Glutamate from dansyl- aspartate, and dansyl - 
serine from dansyl- glutamane and dansyl -threonine. 
aft* amine / threonine 
° __--dns-glutamate o 
d s-serine 
ó dns-aspartate 
AffiliiiMMOBOMMM6 MUM F- SOtven¡' ! J 
FIG. 3:5 : Chromatogram of a mixture of dansyl -amino acids 
after a normal development in Solvent (I) and an 
* 
extended development in solvent system (2). 
Shows separation of 
(a) dansyl- glutamate from dansyl -aspartate 
(b) dansyl- glutamine /threonine from dansyl -serine. 
*See text page 221for explanation. 
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Recovery of 1¢C -amino acids through the method 
iNeuhoff and Weise (1970) had shown that the amount of dansy- 
lated amino acid on a plate could be quantified by using a radio- 
actively- labelled dansyl chloride of known specific activity and 
counting the activity of the dansylated amino acid spot. How- 
ever before such information could be applied to estini:.ting the 
amount of amino acid originally present in a,sample one would 
also have to estimate the recovery of amino acid through the 
various procedures of dansylation and crromatography. Two 
methods of accomplishing this have been investigated. 
The amino acid hydroxyproline is found principally as a 
constituent of collagen and gelatin; its occurrence in brain 
has not been reported. The dansyl derivative of hydroxyproline 
can be readily separated from other dansyl-amino acids (Figs. 3 :4, 
5). It was intended to add a known amount of hydroxyproline to 
a brain tissue extract and then dansylate the extract with radio- 
actively- labelled dansyl chloride. Following chromatography of 
the dansylated extract the recovery of hydroxyproline through the 
method could be calculated from the activity of the dansyl- hydroxy- 
proline spot. However before the recovery figure for hydroxy- 
proline could be applied to the other amino acids, it would have 
to be shown that the recoveries of the other amino acids varied 
in constant proportion to the recovery of hydroxyproline. 
This question, along with other basic questions as to the 
effect of various parameters on the yield of the 14C- dansylation 
- 227 - 
reaction, was investiated, using 14C -amino acids. 14C- glutamic 
acid, 14C- glutamine, 14C- aspartic acid, 140 -glycine, 14C -GABA, 
and 
14 C-hydroxyproline were obtained from the Radiochemical Centre, 
Amersham. 
An alijuot (5 or 10 tzl) of a mixture (see below for composi- 
tion of mixture) of these 140 -amino acids in 0.2 M potassium 
bicarbonate buffer was carefully placed inside a small glass micro - 
reaction tube (see list of apparatus, no.5, page 211). An equal 
volume of a 24 x 10 -3M solution of dansyl chloride in acetone was 
added to the tube which was then thoroughly agitated, capped, and 
left in the dark at room temperature for 40 minutes. After this 
time the dansylated mixture was washed with two volumes of di- 
etIy]_ ether, taken to dryness under dry nitrogen at 37 °C, and 
extracted with 10 pl of ethanol. Using a 1 pl Drummond micro - 
capillary (calibrated by length on the basis of its having a uni- 
form internal diameter) a known volume of ethanol extract (between 
0.1 and 0.5 pl) was transferred to a fine glass microcapillary for 
application to a polyamide chromatography plate. After chromato- 
graphy the various dansylated amino acid spots were identified 
under u.v. light and ringed with a soft pencil. The ringed spots 
were then cut from the plate, using small sharp scissors, and 
placed in standard 20 ml glass scintillation vials. 1 ml of 
ethanol was added to each of the vials which were then violently 
agitated (`dhirlimix). 10 ml of a toluene -based scintillant 
solution (see page 214) were added to the vials which were then 
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counted in a liquid scintillation counter (Nuclear Chicago, 
Mark II) at 14C settings. The efficiency of counting was 
determined by a channels -ratio method (Baillie 19b0). 
If, after counting, the small portions of polyamide plate 
were carefully removed from the vials and the vials then re- 
counted it was found that there was no detectable drop in the 
counting rates. This demonstrated that the 14C- dansyl -amino 
acids had been eluted from the polyamide layer by the ethanol and 
were homogeneously distributed throughout the scintillant solution. 
Toluene scintillant solution alone did not elute the dansyl -amino 
acids from the polyamide layer. 
The composition of the 14C -amino acid mixtures used in these 
recovery experiments was such that after dansylation and chromato- 
graphy, the spot pertaining to each individual amino acid was 
both visible under u.v. light and sufficiently radioactive to be 
readily counted in a 20 minute counting time (i.e. greater than 
10 times the background level of activity). 
Table 3:1 shows the results of an experiment in which the 
amount of 14C- labelled dansyl -amino acid actually recovered has 
been compared with the theoretical 100'¡:, recovery assuming complete 
dansylation of amino acid and no manipulative losses of 14C -label 
throughout the method. Glutamate and aspartate have been shown 
together because the fluorescence of their spots on this occasion 
was so weak that it was not possible to tell clearly where one 
stopped and the other started. The joint recovery of both (5.7)x) 
was very poor compared with that of the other amino acids (> 25iß). 
This finding was repeated in other similar experiments. 
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TABLE 3:1 : Dansylation experiment with 14C -amino acids 
demonstrating low recovery of aspartate and glutamate. 
D.p.m. expected 
1 
D.p.m. obtained c» Recovery 
Hydroxyproline 7840 5670 72.5 
GABA 15680 8 927 57.0 
Glutamine 19600 6881 35.1 




1 The expected d.p.m. have been calculated on the assumption 
of complete dansylation and no manipulative losses through 
the method. 
-230- 
The other important finding of these early recovery experi- 
ments was that the recovery of one particular amino acid could 
vary independently of the others. This may have been due to 
slight differences in the pH at which the dansylation was carried 
out, since among other factors governing the degree of dansylation 
are the pKa of the amino acid and the pH of the reaction mixture. 
Whatever the reason,these experiments demonstrated that hydroxy- 
proline could not be used as an internal standard to give a 
general figure for the recovery of amino acids through the dansyl- 
ation procedure. 
In attempts to improve the recoveries of glutamate and 
aspartate it was found that a reduction of the time of dansylation 
to 30 minutes almost doubled the recoveries of these two amino 
acids to 107. This suggested that some of the dansyl- glutamate 
and dansyl- aspartate formed was subsequently being degraded 
(reaction III Fig. 3:3). 
Another step in the method which was investigated was the 
ethanol extraction of dansyl glutamate and dansyl aspartate from 
the evaporated dansylation mixture. The residue remaining after 
an ethanol extraction was completely taken up in 5(» acetone and 
water. The ethanol extract and the aqueous acetone solution 
were spotted onto separate polyamide plates. These were then 
developed in solvent systems (1) and (2) as before. 
By counting the activity of the dansylated amino acid spots 
it was found that ethanol satisfactorily extracted dansyl -GAGA, 
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dansyl -glycine, dansyl -glutamate and dansyl- hydroxyproline but 
failed to extract more than 3O of the dansyl- .glutamate and 
dansyl -aspartate. 
Because of this shortcoming in the ethanol extraction 
technique I considered simply spotting up the final aqueous acetone 
mixture but this had the disadvantae of being difficult to apply. 
It also resulted in a heavily salt -laden chromatoraphy plate. 
It was decided to try the acetone : glacial acetic acid (3:2, v:v) 
extraction which had been used by Woods and Siang (1967). This 
solution was found to leave some of the salts undissolved and 
was very readily applied to the chromatography plates. It was 
also decided to reduce the dansyl chloride concentration to 
5.7 x 10-3M (Briel, Neuhoff and Maier, 1972). These two steps 
resulted in a much improved recovery of glutamate and aspartate 
(Table 3:2). 
i=tecovery of 14C -amino acids from a homogenate of rat cortical tissue 
having established satisfactory dansylation techniques for 
pure solutions of amino acids I then investigated the dansylation 
of 14C- amino acids added to samples of brain tissue (rat cortex). 
Much of the methodology for these experiments was similar to that 
currently used in the analysis of tissue amino acids (full descrip- 
tion pages 239 to 23). Therefore at this stage I shall only 
outline the approach to these experiments. 
A small piece of rat cortical tissue, approximately 1 mg in 
weight, was placed on the inside wall of a glass micro- reaction 
- 232 - 
TABLE 3:2 : Dansylation experiment with 1¢C -amino acids 
demonstrating satisfactory recovery of six amino acids. 
D.p.m. expected 
1 
D.p.m. obtained % recovery 
Hydroxyproline 587 405 69.0 
GABA 1175 689 58.6 
Glycine 1175 683 58.1 
Glutamine 1470 565 38.5 
Aspartate 3525 1257 35.7 
Glutamate 4410 1442 32.7 
Footnotes : (1) See Footnote (1) Table 3 :1 (page 229 ) 
(2) The levels of activity in this table are 
much lower than in Table 3 :1. This merely 
reflects the use of lower levels of activity 
in the light of experience gained from 
earlier experiments. 
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tube. It was then homogenised in 15 }il of 0.48 N perchloric 
acid using a small rod of perspex (1.8 mm diameter) shaped to 
fit the micro- reaction tubes. A 5 pl aliquot of a 140 -amino 
acid mixture was then added to the tube which was left at 4 °C 
for 20 minutes to complete the process of protein denaturation. 
The tube was then centrifuged at 20,000 g and a 10 pl aliquot of 
the protein -free supernatant was removed to another micro - 
reaction tube and neutralised with 2 pl 1.5 la potassium carbonate 
solution. The insoluble potassium perchlorate was spun down and 
a 10 jil aliquot of the supernatant was placed in another micro - 
reaction tube. An equal volume of dansyl chloride solution in 
acetone (5.7 x 10I) was added to this tube which was then left 
for 30 minutes at room temperature in the dark. The contents 
of the tube were then taken to dryness under dry nitrogen at 37 °C 
and extracted into 10 pl acetone : glacial acetic acid solution 
(3:2, v:v). A known volume (0.1 - 0.5 }xl) of this extract was 
then spotted onto a polyamide plate and chromatographed as before. 
The plate was then examined under u.v. light. An example of a 
"tissue" plate is shown in Fig. 3:6. As the photograph shows, 
certain of these dansylated amino acid spots are very intense 
compared with others, reflecting the fact that certain amino 
acids are present in tissue in a free form at much higher concen- 
trations. In this study it has not been possible to spend time 
in identifying all the dansyl derivatives present on a "tissue" 
plate. Only the dansyl -amino acid spots in which I was interested 
have been positively identified as in Fig. 3:6. 






FIG. 3:6 Chromatogram of dansylated- extract of tissue 
from rat cortex (control). 
Solvent (I) normal development 
Solvent (II) extended development. 
See text page 22 for explanation. 
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The spots pertaining to the amino acids under study were 
marked and removed for counting of 
14 
C-activity. It was found 
that the recoveries of the 14C -amino acids from the tissue 
homogenate were in the same range (30 -80 %) as the recoveries 
from pure solutions. 
quantitative assay of amino acid levels in tissue 
Two methods have been used to assay separated dansyl -amino 
acid derivatives. Neuhoff and Weise (1970) dansylated tissue 
extracts with 14C- dansyl chloride of known specific activity 
and then counted the activity of the separated dansyl amino acid 
spots. By this means they were able to calculate the amount of 
dansyl amino acid in the spot. 
Fluorescence assay has also been used (Needle and Follit, 
1965; Seiler and Weichmann, 1966; Crowshaw, Jessup and Ramwell, 
1967; Spivak, Shcherbukhin, Orlov and Varshaysky, 1971). How- 
ever elution of a dansyl -amino spot and subsequent fluorescence 
assay of the dansyl -amino acid in solution is only possible with 
amounts of the order of 1 x 10 -9 moles or hiker (Crowshaw et al., 
1967). Spivak et al. (1971) have reported a method for the 
assay of the fluorescent dansyl -amino acid "in situ" on a silica - 
gel chromatography plate. This method, as described, has a 
sensitivity of 1 x 10 -11 moles. However it is based on the 
assumption that the dansyl derivatives are symmetrically distrib- 
uted in their spots. Also, since the fluorescence of the dansyl- 
amino acids is strongly quenched by water, it requires very strict 
- 236 - 
control of humidity. Because of these exacting constraints this 
method was not considered to be suitable as a routine micro- method. 
It was decided to combine the radioactive- labelling technique 
of Neuhoff and Weise (1970) with a tecinique for estimating the 
recovery of amino acid through the dansylation procedure. Use 
of hydroxyproline as an internal standard proved to be unsatis- 
factory. It was therefore decided to use added 14C -amino acids 
as internal standards and carry out the dansylation with 3H- 
dansyl chloride. Counting the spot of separated dansyl -amino 
acid for both 14C and 3H activity would then provide the following 
information : firstly, how much dansylated amino acid was present 
in the spot (from the 3H activity); secondly, how much of the 
exogenously added 14C -amino acid had been recovered (from the 
14C activity); and finally, how much of the amino acid was 
derived from the tissue. The 14C activity could then be used 
to estimate the recovery of amino acid through the method, and 
this figure could then be applied to the amino acid derived from 
the tissue. The theory of the method (isotope dilution assay) 
and the actual mathematical analysis are described below. The 
practical aspects of the method as it is currently being used will 
be described later (pages 239 to 248 ). 
Theory of method and mathematical treatment of results 
The principle of the method, which forms one of the general 
class of isotope dilution assays, can be represented in four 
stages. 
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(1) Addition of known amount of 14C- labelled amino acid, of 
known specific activity, to the "pool" of endogenous amino 
acid. 
( ) Subsequent isolation of combined pool of endogenous and 
exogenous (14C- labelled) amino acid. 
(3) Measurement of specific activity of combined pool. 
(4) Calculation of dilution of 14C- labelled amino acid by non- 
radioactive endogenous amino acid, leading to calculation 
of the amount of endogenous amino acid originally present. 
The method involves the basic assumption that there are no 
significant isotope effects at any of the various steps such as 
dansylation or chromatography. The specific activity (w. r.t.14C) 
of the combined pool of exogenous and endogenous amino acid there - 
fore 'remains unaltered throughout the method. 
Symbol Jefinitions 
AAext = moles of exogenous 14C- labelled amino acid added to 
SAa a 
each aliquot of perchlorate extract of tissue. 
specific activity of exogenously added 14C- labelled 
amino acid (curies 14C /mole amino acid). 
AAA = curies of exo en.ous 14C- labelled amino acid added to 
each aliquot of perchlorate extract of tissue. 
AA = SAaa x AAext 
AAint = 
SAd c = 
N = 
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moles of endogenous amino acid present in each aliquot 
of perchlorate extract of tissue. 
specific acitivity of dansyl c;.loride (curies 3t /mole 
dansyl chloride) 
number of d.p.m. per curie. 
For the six amino acids studied (glutamate, aspartate, 
glutamine, hydroxyproline, GABA and glycine) the conditions of 
dansylation were such that the reaction between dansyl chloride 
and the amino acid was equimolar. Therefore considering a spot 
of a dansyl -amino acid which has been removed from a chromatogram 
and counted for and 1¢C activity : - 
Total no. of moles of amino acid present in 
spot (as dansyl derivative) = 3ri dpm x 1 
SA dc N 
with respect to 14C, the specific activity 
of the amino acid present in soot (as 
dansyl derivative) = 14C dpm x 7 
moles of amino acid in spot N 
= 1¢7Cdp2 x SA dc 
H dpm 
However as explained earlier the specific activity (w. r. t.14C) 
of the amino acid in the spot (present as dansyl derivative) is 
the saine as specific activity of the combined pool of endogenous 
and exogenous amino acid. 
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The specific activity of the combined pool 
of exogenous and endogenous amino acid = 
- 
AA 
AAint + AAext 
AA = 14 C dpm x 3Ad c 
AAint + AAext 3iï dpm 
AAint = 3H db m x 1 - AAext 
* 14 
C dpm ìAd c AA* AA 
AAint = AA* H dpm x 
140 
V 
1 - 1 
3Ad c SAaa ) 
Current method for the extraction, dansylation and quantitative 
estimation of free amino acids in rat cerebral cortex. 
Tue scheme of the current uietaod has been summarised in 
Fig. 3:7. 
Equipment and materials - as described on pages 211 to 211, with 
the exception of the 3H- dansyl chloride preparation which is 
described below. 
Stock solution of 14C- amino acids 
The composition of this solution (shown on page 214 ), an 
aliquot (2 ,µl) of which was used as an internal standard in the 
dansylation procedure, was adjusted so that:- 
(1) After dansylation and chromatography of a tissue extract 
(+ an aliquot of the 140- amino acid mixture) the dansyl- 
amino spots pertaining to these particular amino acids would 
be visible under u.v. light even if none of the amino acids 
were present in the tissue sample. 
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FIG. 3:7 General scheme for the quantitative estimation of amino 
acids in brain tissue by the dansylation method. 
14C 
-amino acids added to 
extract to act as markers 
for recovery through the 
method 
Tissue sa:Tol e isolated 
homogenised and protein precipitated 
Supernatant 
Protein precipitating agent removed 
Extract dansylated with 3h- dansyl 
chloride in buffered (pH 9-10) 
aqueous acetone solution. 
Dansylated extract dried under 
nitrogen at 37 C. Dansylated amino 
acids extracted into acetone : glacial 
acetic acid (3:2, v:v) 
Dansylated extract spotted onto 
3.5 x 3.5 cm polyamide chromatography 
plate and developed in 
(1) 1.5i,, formic acid 
(2) benzene : glacial acetic 
acid (q:1, v:v) 
Dansylated amino acid spo ;s identified, 
olated and counted for H and 
C activity. 
Amino acid content of tissue sample 
calculated 
Residue 
Protein in sample 
estimated 
Amino acid content of sample 
in umoles amino acid /100 mg protein 
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(2) the dansyl -amino spots contained sufficient 1¢0 activity 
for them to be readily counted. 
After allowing for requirements (1) and (2) the levels of 
exoenously - added amino acids were kept as low as possible. 
Preparation of tubes for dansylation of tissue extracts with 
3H- dansyl chloride. 
The specific activity of the 3x- dansyl chloride solution 
was adjusted so that the 3h- activity in each dansyl- amino acid 
spot was at least four times greater than the 140- activity. 
This reduced the error involved in estimating 3h- activity in the 
presence of 140-activity. 
20 Al of 3H- dansyl chloride solution in benzene (250 pci /ml, 
0.048 x 10 -3M) and 5 Al of non -radioactive dansyl chloride solution 
in acetone (5.689 x 10- 31',x) were added to a glass micro- reaction 
tube. The contents of the tube were then taken to dryness at 
37 °0 under dry nitrogen. The tube was then capped and kept in 
a dry place until use. A batch of such tubes was freshly pre- 
pared before each experiment, the number in the batch depending 
on the number of tissue extracts to be dansylated. 
The specific activity of this preparation of 3H- dansyl 
chloride was 170 ci /mole. 
2rocedure 
Stage (1) 
The rat was stunned and immediately decapitated. The 
skull was rapidly opened and the cortex rapidly frozen 
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"in situ" with a dichlorodifluoromethane spray (Polar Spray, 
Medical Aerosols Ltd.). With a metal cork borer (diameter 
3.5 mm) a small plug of frontal cortex was removed and the 
white matter trimmed off. The sample of cortical grey 
matter (between 20 and 30 mg wet weight) was immediately 
placed in a small plastic centrifugation tube (1.2 ml 
capacity, Eppendorff) containing liquid nitrogen. The 
liquid nitrogen was allowed to evaporate and the tube con- 
taining the now frozen tissue was placed in a deep -freeze 
at -,20 °C for 18 hours, until assay. This procedure took 
between two and three minutes. 
Stage (11) 
The tube containing the deep frozen sample of cortical 
tissue was removed from the deep- freeze. 200 µl ice -cold 
0.48 M perchloric acid solution were added to the tube and 
the tissue was homogenised by hand for 5 minutes using a 
small ground glass pestle shaped to fit the tube. The 
homegenate was then allowed to stand at 4 °0 for 20 minutes 
to allow further fragmentation of tissue. The small poly- 
propylene tube containing the homogenate was then centrifuged 
at 20,000 g for 20 minutes (2 °C) using the high speed head 
of a Mistral centrifuge (M.S.E.). During centrifugation 
the small polypropylene tube was cushioned inside a poly - 
carbonate cen6rifuge tube (capacity 7 ml) with tightly 
packed cotton wool. After centrifugation the supernatant 
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was carefully removed leaving a pellet of denatured protein 
in the bottom of the tube. The tube with the protein 
residue was deep frozen at -20 °C until a later stage when 
the protein content was analysed. 
.stage (III) 
A 10 ),11 aliquot of the protein -free perchlorate extract 
was transferred to a small glass micro-reaction. tube (descrip- 
tion, page 211 ) to which was then added 2 Al of a stock sol- 
ution containing known amounts of 14C- labelled amino acids. 
(As listed earlier on page 214 this solution contained 
14 
C- 
glutamic acid, 14C- aspartic acid, 1¢C- glutamine, 14C -GAGA, 
14C- 
glycine and 14C- hydroxyproline). 2;11 of 1.5 M potassium 
carbonate solution were added to the tube (with vigorous 
mixing) causing the evolution of CO2 and the precipitation of 
perchlorate as its insoluble potassium salt. On a scaled - 
up experiment this addition of potassium carbonate adjusted 
the pH of the extract to 9.7. With the small volumes used 
in the actual assay it was not possible to measure the final 
pH but it was assumed to lie within the range 9.3 - 9.8. 
The extract was left to stand for 10 minutes at 4 °C to assist 
the precipitation of potassium perchlorate (this salt is 
noticeably less soluble at low temperatures). The potassium 
perchlorate was then spun down by centrifuging the tube 
(placed inside a small polypropylene reaction tube (Eppendorff)) 
at 10,000 g for 2 minutes. 5 jil of the alkaline supernatant 
was then dansyla.ted as described in Stage (IV). 
-244- 
Stage (IV) 
5 Al of redistilled acetone were added to a pre - 
prepared (page 241 ) glass micro -tube containing 3H- dansyl 
chloride (specific activity 170 ci /mole) and the tube was 
vigorously agitated (Whirlim.ix) to ensure that all the solid 
dansyl chloride was taken up into the acetone. 
To this tube containing 5 p.1 of H3- dansyl chloride 
(5.88 x 10- 3M)were then added 5 Al of the alkaline super- 
natant from the potassium perchlorate- precipitation step 
described in Stage (III). The tube contents were thoroughly 
mixed and the tube capped (with the rubber seal from the 
plunger of a 1 ml polyethylene syringe) and left in the dark 
at room temperature for 30 minutes. The contents of the 
tube were then taken to dryness (370C) under dry nitrogen. 
At this point the tube could be capped and stored in the 
dark, in a dry atmosphere, until the chromatography step 
(Stage V). 
Stage (V) 
The dry contents of the micro- reaction tube were 
extracted with 10 Al acetone : glacial acetic acid (3:2, 
v:v) mixture. The tube was vigorously agitated and then 
centrifuged at 10,000 g for 2 minutes (micro -reaction tube 
placed inside an Eppendorff polypropylene reaction tube) to 
concentrate the undissolvol .salts at the Dottaa of the tube. 
Using a fine glass .:iicro- capillary with a flamed tip a small 
-245- 
volume of the supernatant (between 0.1 and 0.2 pl) was care- 
fully applied to the corner of a 3.5 x 3.5 cm polyamide 
plate (0.5 cm in from each edge). This procedure was 
carried out in the visual field of a stereo- microscope. 
A gentle flow of cold air was blown over the plate during 
the application of the acetone: glacial acetic acid mixture. 
lith experience it was possible to tell when the spot was 
becoming saturated with salt. The application of material 
to the plate was stopped at this point (usually after the 
application of 0.1 to 0.2 µl). 
Stage (VI) 
The bottom of a micro -chromatography tank was just 
covered with 1.8 ml (v /v) formic acid solution (solvent 
system 1). Using fine tweezers the prepared plate was then 
carefully lowered into the tank and developed in the ascending 
direction with the lid of the tank on. When the solvent 
front was within 3 mm of the top, the plate was removed and 
dried in a stream of warm air. It was then examined under 
short wavelength u.v. light. In the event of evidence of 
severe streaking (too much salt applied to plate), or insuffi- 
cient fluorescence (too little of the dansyl derivatives 
applied to plate) the plate was discarded at this stage. If 
satisfactory (a large blue spot of dansyl hydroxide set two - 
thirds of the way along an almost continúous line of yellow - 
green dansyl amino acid spots), the plate was then run in 
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ascending fashion in solvent system (2) (benzene : glacial 
acetic acid, 9:1) , at 900 to the direction. of the first run. 
For the first 9 minutes of this run the lid of the tank was 
left off (see page 224 ). After this period the lid was 
placed on the tank and the solvent front run up to within 
3 mm of the top of the plate. The plate was then removed 
from the tank, dried in a stream of warm air, and examined 
under u.v. light. 
Under u.v. light the dansyl -GAGA, dansyl -glycine, dansyl- 
glutamate, and dansyl -glutamate spots were very obvious by 
their strong fluorescence and characteristic positions on 
the plate (Fig. 3:6). The dansyl- hydroxyproline spot was 
very faint but it was always characteristically isolated from 
all other spots. i)ansyl- aspartate formed a relatively faint 
spot between the prominent dansyl -glutamate and dansyl - 
hydroxide spots. 
The spots reciuired for counting were carefully ringed 
with a soft pencil. In the calculation of the endogenous 
amino acid levels the absolute activity of the spot was not 
used but rather the ratio of to 14C activity. For this 
reason it was unnecessary to remove the whole spot for 
counting. Isolating and counting only the central intensely 
fluorescent zone of a dansyl -amino acid spot reduced the 
danger of contamination by neighbouring spots, thus increasing 
the specificity of the assay. A spot on the plate showing 
no fluorescence was rinsed to serve as a background sample. 
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The marked spots were then carefully cut from the plate 
with a pair of fine scissors and placed in scintillation 
vials containing 1 ml ethanol. To assist the elution of the 
dansyl derivatives from the plate into the ethanol the vials 
were agitated vigorously for 10 seconds on a Whirlimix. 
10 nil of toluene scintillant solution were added to the vials. 
These were then counted in a li.ÿuid scintillation counter 
Nuclear Chicago, Mark II) in two channels set to give maxi- 
mum differentiation between 14C and 3ïß activity (Nuclear 
Chicago Mark II manual). The efficiency of counting in 
each of these channels was determined by an external standard 
quench correction procedure (Hetenyi and Reynolds, 1967). 
The concentrations of endogenous amino acids in the 
perchlorate extract were calculated from the ratio of to 
14C 
activity in the dansyl -amino acid spots as described in 
the mathematical analysis of the technique (pages 23d to L39 ). 
By determining the amount of protein originally precipitated 
from the brain sample by the erchloric acid extraction, 
it was then possible to calculate the amino acid content 
of the sample in terms of pinoles amino acid per 100 mg 
protein. 
In the technique which has been described it has been 
assumed that 14C activity in the spots counted was specific 
to da,nsyl amino acids. The validity of this important 
assumption was proved by showing that 14C amino acids them- 
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selves when chromatographed in solvent systems (1) and (2) 
ran at the first solvent front. There was therefore no 
possibility that the non- dansylated 14C amino acids in the 
final mixture applied to the plate could have contaminated 
any of the dansyl -amino acid spots. 
Estimation of protein. in samples of brain tissue 
_Protein was estimated by the method of Lowry, aosebrough 
Farr and Randall (1951). 
Materials 
0.75 N sodium hydroxide solution. 
(w /v) sodium carbonate in 0.1 N sodium hydroxide solution. 
(w /v) sodium potassium tartrate solution. 
1. (w /v) copper sulphate solution. 
Folin -Ciocalteau reagent (E.D.H.). 
Stock solution of bovine serum albumin (Sigma) (2.5 
Distilled deionised water. 
Initial preparation of samples and standards 
The pellet of denatured protein remaining after the perchloric 
acid extraction of brain tissue (approximately 20 mg wet weight 
of brain) was solubilised in 1.0 ml 0.75 N sodium hydroxide 
solution. This process was accomplished in a period of one to 
two hours by placing the small polypropylene reaction tube 
(Eppendorff) in a shaker (Eppendorff) . 0.1 ml of the alkaline 
protein d i e st (vigorously mixed just prior to sampling) was 
- 249 - 
diluted to 2.2 ml with seater. The protein estimation was per- 
formed on a 0.1 ml ali4uot of this dilution. 
A stock solution of bovine serum albumin (2.5 mg/ml) was 
diluted to give standard protein solutions of 25, 50, 100, 150 
and 200 »g/ml albumin. 0.1 ml aliquots of these solutions were 
used in the reaction. 
Reaction 
Reagent solution A was freshly prepared; i.e. 0.2 ml of a 
2iL solution (w /v) of sodium potassium tartrate and 0.2 ml of 1; 
(w /v) copper sulphate solution were added to 20 ml of a 2;- solu- 
tion (w /v) of sodium carbonate in 0.1 N sodium hydroxide. 
0.5 ml of solution A was added in turn to : 0.1 ml of each of 
the 1/22 sample dilutions; 0.1 ml of each of the standard protein 
solutions; 0.1 ml of water. These tubes were allowed to stand 
for 10 minutes. 
0.5 ml of freshly prepared solution B (1.0 ml Folin- 
Ciocalteau's reagent + 1.5 gill of water) was then added (with 
vigorous mixing - Whirlimix) to all the tubes in the assay, namely, 
the samples, the standards and the reagent blank. The tubes 
were then allowed to stand for 30 minutes. 
After this period the optical density of the solutions at 
750 mµ was read in a spectrophotometer (Perkin- Elmer) against the 
reagent blank. Over the standard range the optical densities of 
the final solutions were linearly related to their protein concen- 
tration. Appropriate dilution factors were used to calculate the 
amount of protein in the orihinal sample of brain tissue. 
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Animal Methodology 
The operative technique for the implantation of cobalt into 
the cortex of the rat, and the insertion of stainless steel 
screw electrodes into the skull., has been described in detail by 
Dow, Mc,cueen and Townsend (1972). 
I am very much indebted to Jr. J. K. -Lc ueen and .Dow 
for the preparation and electrocorticogram recording of the three 
"cobalt" rats used in this study. 
Male Piebald Virol Glaxo (PVG) rats, approximately 220 g in 
weight (a-e 3 months) were anaesthetised with a halothane /oxygen 
mixture. A halothane (Fluothane, I. C.I. Ltd.) mixture was 
used during induction while 2 -2.5y6 mixture was used to maintain 
anaesthesia. A curved incision was made in the scalp, starting 
close to the left eye and extending 2 -3 cm backwards. The soft 
tissues were retracted. The skull was trephined on both sides, 
3 mm out from the midline, at points 3 mm anterior to, and 3 mm 
posterior to, the coronal suture (Fig. 3:8). These drill holes 
(2 mm diameter) allowed approach to the underlying cortex and 
prepared the skull for the insertion of the four stainless steel 
recording electrodes. The dura. over the right frontal cortex 
was split with the tip of a 23 gauge needle. A cube of cobalt 
gelatin (1 mm3), prepared as described by Fischer, Holubar and 
Malik (1967), was inserted vertically into the cortex so that its 
top was flush with the cortical surface. The specially -constructed, 






Diagram of rat skull /brain showing the positions of the 
extradural recording electrodes and the mbalt implant. 
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served as extract url electrodes were then inserted into the four 
drill -holes. The collar of each screw was secured to the bone 
with cold curing acrylic resin (Simplex). Holes were then 
punched in the skin flap so that this could be fitted neatly around 
the electrodes. The incision was closed with Michel clips. 
Electrocorticogram (ECoG) recordings were made from the 
unrestrained conscious rat (Fig. 3:9) within 24 hours of the oper- 
ation. Spring connectors (Amphenol) fitted into the hollow 
screws allowed the brain potentials to be recorded on a Grass 
Model 7 polygraph. Fig. 3:10 shows an ECoG recording taken from 
one of the three cobalt rats at 11 days post- operation, one hour 
before it was killed. The ECoGs were similar in all the three 
animals. The record from the ''cobalt" animal shows high ampli- 
tude left -sided polyspikes. An -JCoG from a control animal is 
shown above the "cobalt' animal record. 
FIG. 3:9 
Photograph showing the recording of a rat's electrocorticogram. 
The sprint; connectors attached to the recording leads have been 
inserted into the permanently implanted electrodes in the rat's 
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FIG. 3:10 aectrocorticogram (E Co G) recordings from 
control (top) and "cobalt" (bottom) rats. 
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RESULTS 
Presentation of Glutamine Data 
With the present solvent system it has not been possible to 
separate the dansyl derivatives of glutamine and tbreor,ine. It 
has been assumed that the recovorj- cf threonine through the 
method is similar to the recovery of 
14 
glutamine and on this 
basis I have calculated a composite figure expressing the sum of 
glutamine and threonine activity in terms of }moles /100 mg protein. 
Mcllwain and Bachelard (1971) have collected together data 
on brain amino acids from a number of sources and it would appear 
from these data that the level of threonine in the bcain is be- 
tween and 10: of the level of glutamine. The assumption, 
stated above, of a similar recovery for threonine to that of 
glutamine is tie :eforeunlikely to have led to serious errors in 
the estimation of their combined activities. 
Amino acid analyses on the frontal cortices of control rats 
Glutamate, GABA, glycine, hydroxyproline, aspartate and 
glutamine in combination with threonine, have been estimated 
in samples of frontal cortex from three rats. From the Perchlor- 
ate extract of each cortical sample two separate aliquots were 
removed and analysed. A standard mixture of 140 -amino acids was 
first added to each aliquot. The aliquots were then dansylated, 
and the dansyl derivatives separated by chromatography on poly - 
amide plates. The spots representing the dansyl derivatives of 
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the amino acids under study were identified, and counted for 3H 
and 14C activity. 
The results of the analyses are shown in Tables 3:4 -6. 
Comparison of the 14C activity recovered from each dansyl amino 
acid spot with the amount of each 14C -amino acid taken through 
the dansylation procedure (Table 3:3) reveals that the final cal- 
culations have been based on the "recovery" of only a small fraction 
of the amino acids originally present. Three factors were res- 
ponsible for this apparent low recovery. 
Most important was the fact that only about 1-5 of the final 
dansylated extract was actually spotted onto a chromatogram 
(0.1 -0.5 pl out of a volume of 10 »1). The actual volume spotted 
on has not been measured, because a knowledge of this volume is 
not essential in the calculations and the calibration of micro - 
capillaries is a difficult and time -consuming task. 
Another factor which tended to produce a low apparent recovery 
was the practice of partial removal of the dansyl -amino acid spots 
whereby only the central intensely -fluorescent zone of the spot 
was actually removed for 14C and 3H counting. This technique 
avoided contamination from neighbouring spots. In fact because 
of the generally excellent resolution of the spots (Fig. 3:6) and 
the small distances over which the dansyl derivatives were chrom- 
atoraphed the losses of dansyl amino acid in this way were normally 
very slight. 
The final factor influencing the recovery of 14C -amino acids 
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TABLE 3:3 : Exogenous 14C -amino acids in that portion of each 







C -amino acid in each 
5 ).l aliquot of alkaline 
tissue extract prior to 
dansylation 
(Ci /mole) (nci) (d.p.m.) 
Glutamate 260 11.16 24775 
Glutamine 45 8.37 18 581 
GABA 204 4.46 9901 
Glycine 108 4.46 9901 
Hydroxyproline 38 4.46 9901 
Aspartate 227 8.93 19825 
71 These figures have been arrived at by multiplying the 
amounts present in a 2 jzl aliquot of the stock solution of 
these 14C -amino acids (page 214) by a factor of 5/14 to 
allow for the fact that only this proportion of each aliquot 
was actually taken through the dansylation step. The 
corrected figures shown constitute the AA terms described 
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- 261 - 
was the yield of the dansylation reaction. Apart from the in- 
complete dansylation of the amino acids (reaction I, Fig. 3:3), 
almost certainly some of the dansyl -amino acids formed were broken 
down through further attack by dansyl chloride (reaction III, 
Fig. 3:3). The improvements in the recovery of glutamate and 
aspartate which were brought about by reducing the time of dansyl- 
ation and decreasing the concentration of dansyl chloride in the 
reaction mixtures suggest that dansyl- glutamate and dansyl - 
aspartate may be particularly vulnerable to attack by dansyl 
chloride. 
In recovery experiments where I measured the volume of the 
final dansylation mixture applied to a plate the yield of dansylated- 
GABA, glycine, glut amine and hydroxyproline was between 40 and 
90'. Glutamate and aspartate gave a l0 -40¡ yield of dansylated 
product (Table 3:2). 
Estimation of aspartate in brain tissue 
The dansylation techniques were not entirely satisfactory 
for aspartate. The agreement between duplicate estimates was 
not always good for this amino acid. Two factors would seem to 
have contributed to the variability of the aspartate results. 
Firstly, under the present experimental conditions the 
dansylation of aspartate gave a poor yield of dansylated product 
(Table 3:2). 
Secondly, the dansyl -aspartate spot was very close to the 
large dansyl- glutamate spot. Almost certainly the dansyl- 
- 262 - 
aspartate spot on some occasions was contaminated with dansyl- 
glut ama t e . 
Because of the degree of variability of the aspartate results 
they were not included in the analysis of the data. In order 
to assay aspartate levels satisfactorily one would have to prepare 
a separate chromatogram for this amino acid and continue the 
extended run in solvent system (2) until the dansyl -aspartate was 
clearly separated from dansyl- glutamate. 
Hydroxyproline 
As can be seen in Table 3:5 the analysis of hydroxyproline 
sometimes gave a ne,,ative figure for the level of this amino acid 
in cortical tissue. Hydroxyproline is an important constituent 
of collagen and gelatin but no reference could be found describing 
its detection as a free form in brain. If it was present in the 
cortical tissue of the rats it was below the detection limits of 
the dansylation technique. In these studies therefore the 
variance of the hydroxyproline results about zero gave an estimate 
of the variance of the method. 
Glutamate, glutamane and threonine, GABk and gli cine levels in 
the frontal cortices of control rats. 
These amino acids were satisfactorily measured by quantita- 
tive dansylation techniques. The agreement between independent 
estimates (independent at least after the initial homogenisation 
















































































































































































































































































































































































































































































































































































































- 2b4 - 
As an index of the likely error limits of the technLiue, 
the deviation of the duplicate estimates from their mean has 
been calculated for each amino acid. The re5ults of this analysis 
are ,summarised in Table 3:8. This analysis showed that for 
these four amino acids the technique has a good degree of reproduc- 
ibility (average deviation approximately 
± 
56A). 
Because the variation between the mean amino acid levels 
in the left and right cortices was greater than the variation 
between the mean cortical levels in the three rats (i.e. between 
cortices variation greater than between rat variation), the 
results from the left and right cortices of the three rats have 
been treated as independent estimates of the mean amino acid con- 
tent of rat cortical tissue. Control amino acid levels in rat 
cortical tissue, as determined in the present studies, are shown 
in Table 3:9, along with previously published values. 
In many previous studies of brain amino acids the results 
have been expre :3sed in terms of micromoles of amino acid per gram 
of tissue weight. There are however considerable difficulties 
in weighing small amounts of frozen tissue, both in respect of 
getting an accurate figure and in keeping the tissue frozen. 
In this present study therefore the level of free amino acids 
in each tissue sample has been related to the weight of protein 
in the sample. 
Battistin, Gcynbaum and Lajtha (19b9) found that 1 gram 
(wet weight) of cortical tissue contained 83.5 
± 
4.0 (mean ± s.d.) 
-265- 
TABLE 3:8 : Variability of Assay Technique 
Variation of duplicate estimates 
Glutamate 5.8 
± 
4.9 ¡ö (11) 
Glutamine + Threonine 4.8 
± 
3.5 (11) 
GABA 6.3 ± 5.4 (11) 
Glycine 4.6 ± 5.2 ;- (11) 
Mean deviation of the individual values of duplicate 
estimates from the mean of the duplicates, exJressed as a 
percentage of that mean; mean ± S.D. (no. of duplicates). 
The assays on the left cortex of rat 3 have been excluded 






































































































































































































































































































































































































































































































































































































































































































































































































































































































mg protein. The data of Fahn and Côté (1968) indicate a 
slightly higher figure of 89.5 m; for the protein content of 
1 gram of cortical tissue. On this basis 100 mg of protein 
WOUld therefore be" e.juivalent" to between 1.05 and 1.20 g of 
cortical tissue (wet weight). 
To allow direct comparison between the present data. expressing 
amino acid content of tissue in terns of poles per 100 mg protein 
and previously published amino acid data in terms of pmoles per 
g wet weight tissue, the present data have been multiplied by 
a factor of 0.865 to convert to Wholes amino acid per gram wet 
weight. This conversion factor was based on a mean figure for 
the relationship between wet weight of tissue and protein content 
taken from the studies of Fahn and Cóté (1968) and Battistin et 
al. (1969). Study of Table 3:9 reveals that the present data 
are entirely comparable with previously published data for amino 
acid levels in rat cortex. 
Amino acids in the . jrimary and secondary foci of rats with a 
cobalt- induced esile to, <enic lesion. 
Tables 3:10 -12 show the amino acid analyses from the frontal 
cortices of rats which 9 days pr.viously had cobalt implanted 
into tige right frontal cortex. The sample of cortex taken on 
the right side was centred on the site of the cobalt implant and 
was considered to be a sample from the primary epileptic focus. 
A sample was taken from the corresponding area of the left fr ,ntal 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































- 271 - 
(Dow, McQueen and Townsend, 1972) . 
As in the control studies there was good agreement between 
the two estimates of each amino acid in each tissue sample. 
Because of the small number of animals involved (3) and the 
necessary differentiation between the results from the left and 
ri<Jht cortices, the data has been analysed in terms of individual 
values. From the data on control rats (Table 3 :9) fiducial 
limits were calculated for the amino acid content of rat frontal 
cortex. 
i.e. 
Amino acid content 
of rat (control) 
frontal cortex 
(mean estimate (standard 
from sample ) (t) (deviation of sample) 
where t is the "t" value at any specified level of 
probability. 
On this occasion the sample was compared at six values, 
therefore "V had five degrees of freedom. 
Once the fiducial limits had been calculated for given levels 
of probability, the individual values from the "cobalt" rats were 
compared with these limits to see whether they were inside or 
outside the range of concentrations expected in control animals. 
The results of this analysis are shown in Table 3 :13. 
It can readily be seen that rats 2 and 6 showed an identical 
series of amino acid changes in the area of the secondary epil- 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(p< 0.001) and glutamine /threonin.e (p < 0.005). Glutamate and 
GÁ3á both tended to be lower. In neither of these two rats 
were any changes observed in the area of the primary focus. 
In rat 4 on the other hand there was a significantly increased 
glutamine /threonine level (p< 0.001) and an increased glycine 
level (p<.0.05) in the primary focal area with no changes in the 
secondary focal area. 
There was no satisfactory explanation why rats 2 and b dis- 
played a different spectrum of amino acid changes from rat 4. The 
ECoG's recorded from each rat an hour before they were killed 
showed epileptiform spikes. The vast majority of the discharges 
arose from the secondary focus. These were associated with 
twitching of the vibrissae. Those spikes which were seen on the 
primary side always occurred in synchrony with discharges from the 
secondary focal area. There was no difference in the manner of 
milling, or in the sampling of brain tissue from, the three animals. 
Because of the small numbers of animals studied (3) and the 
lack of a consistent pattern of amino acid changes in the three 
animals it has not been possible to draw any firm conclusion 
regarding the effect of the cobalt implant in the cortex. There 
was however evidence of major changes in the levels of glutamate, 
glutamine / threonine, glycine and GAGA, particularly in the region 
of the secondary epileptic ( "mirror") focus. It is highly un- 
likely that the observed changes arose by chance. Thus it would 
seem that epileptic processes are associated with disturbances 
of certain amino acids. 
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DISCUSSION 
The study reported here would seem to establish the appli- 
cation of dansylation techniques to the quantitative micro- 
analysis of tissue amino acids. The evidence for the success 
of the method lies firstly in the good agreement between duplicate 
estimates from the same tissue sample and secondly in the fact 
that the data from the control rats are comparable to previously 
published data for cerebral amino acids (see Table 3:8). Although 
aspartate was not satisfactorily estimated in this particular 
study there seems no reason why the techniques evolved should not 
be applicable to many other amino acids (Fig. 3:4). 
There have been several previous reports of semi -quantitative 
amino acid analyses by dansylation techniques. In the first of 
these Crowshaw, Jessup and 3amwell (1967) dansylated extracts of 
cortical superfusate, chromatographed the products, eluted the 
separated dansyl -amino acid spots and assayed the fluorescence 
of the eluates. The fluorescence of the eluates was compared 
with the fluorescence of known amounts of dansyl -amino acid 
standards which were chromatographed, separated, eluted and 
assayed in a similar manner. The method gave no indication of 
the recovery of amino acids through the actual dansylation 
process. A similar shortcoming is to be found in the study of 
Neuhoff and Weise (1970) , in which the final dansylated products 
were estimated by a radioactive method. 
- 275 - 
Briel, Neuhoff and Maier (1970) have recently published a 
comprehensive report on their studies of the analysis of tissue 
amino acids using dansylation techniques. Their method however 
requires very strict control of reaction conditions and an extra- 
polation from standard calibration curves. Also, the estimation 
of any one amino acid requires that all the dansyl derivatives in 
the mixture be estimated. The method is therefore highly involved, 
requires strict control of reaction conditions and makes too many 
assumptions to be termed quantitative. 
The techniques outlined here therefore represent the first 
reliable use of dansylation to calculate absolute levels of amino 
acids in tissue.. However there does remain room for investiga- 
tion and further improvement of the present method. 
In the present study 14C -amino acid recovery standards were 
not added until after the protein precipitation step. It was 
assumed that there were no serious amino acid losses during 
protein precipitation. This may have introduced a slight error 
which would tend to underestimate the values for tissue amino 
acid content. However in many other amino acid studies it has 
been standard practie to assume complete extraction of amino acid 
from tissue (e.g. Okumura, Otsuki and Aoyama 1959; Johnson and 
Aprison, 1971). Also it has been shown previously (Yates, 1967) 
that addition of exogenous standards to brain homogenate prior to 
perchloric acid extraction may result in a variability in the 
recovery of the standard which is not a reflection of the recovery 
of the endogenous material. In future studies where it is intended 
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to work with smaller volumes of tissue the 140 -amino acid 
standards will be added before the homogenisation and this 
problem will be examined with reference to these particular amino 
acids. 
Perhaps the greatest scope for improving the method lies in 
the final chromatography stage. At present because of problems 
of loading the polyamide plate with inorganic salts only about 
1 -2 of the final dansylated extract (0.1 - 0.2 jzl from 10 pil) 
can be actually chromatographed. If a way could be found of 
extracting the dansylated amino acids from the final solution, 
the sensitivity of the techni`iue would be greatly increased. 
As a first step towards a lower salt content in the final 
extract it might be possible to use a volatile protein precipitant. 
The fact that an agent such as acetone or ethanol can be completely 
removed from the solution after the protein precipitation step 
may outweigh the disadvantage of less efficient precipitation than 
that achieved by perchloric acid. 
It would also be extremely useful to investigate further 
solvent systems and chromatography conditions which would allow 
the separation of dansyl-glutamine from dansyl- threonine. 
Amino acid results 
Glutamine /Threonine 
The fact that the sum total of these two amino acids was 
altered significantly in the area of the secondary epileptic focus 
in two out of three rats makes it particularly important to find 
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separation techniques for the dansyl derivatives of these two 
amino acids. At present one can only speculate as to which of 
the two amino acids were in fact increased in the secondary focal 
area of the "cobalt" rats. 
Threonine is an essential amino acid which cannot be synthe- 
sised by mammals. As far as is known ,its principl* role in 
metabolism is to serve as a constituent of protein. The break- 
down products of threonine enter the general metabolic pools of 
acetyl -CoA and pyruvate. There is also a pathway converting 
threonine to glycine. 
In contrast to threonine,glutamine is a non -essential amino 
acid being readily synthesised from glutamic acid and ammonia. 
It is a constituent of protein, and has an important function as 
a source, or acceptor, of nitrogen in many transamination reactions. 
The low levels of threonine in rat brain (Table 3:9) and the 
fact that it cannot be synthesised by the rat suggest that major 
changes in the brain content of this amino acid would be unlikely 
unless there was considerable catabolism of protein in which case 
all free amino acid levels would be raised. The significant 
changes in the glutamine /threonine levels in the "cobalt" rats 
have therefore been attributed to glutamine. 
Measurement of GABA in Brain Tissue 
In the estimation of GABA levels in the brain one might be 
well advised to invoke the Heisenberg uncertainty principle, since 
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in obtaining a sample of tissue for biochemical analysis one is 
forced to alter the physiological state of the tissue. Such 
procedures as decapitation or immersion in liquid nitrogen are 
almost certain to induce intense, if only momentary, electrical 
activity in the brain. If indeed GABA is a transmitter sub- 
stance then one might well expect such activity to lead to an 
alteration in its level at these sites where it has a transmitter 
function. One cannot even predict whether levels obtained with 
the use of any one particular metnod of killing the animal are 
any more representative of the "normal" physiological levels than 
levels obtained with any other method of killing. 
Lovell Elliot and Elliot (1963) were the first to study this 
problem in detail. They found that rats killed by immersion in 
liquid air had a cerebral GABA level of 1.64 }zmoles /g wet weight. 
witl, talung 
Rats killed by decapitation of the head /straight into liquid air 
had a cerebral GABA level of 1.78 pmoles /g wet weight. When the 
rats were decapitated and the brains left at room temperature 
for 2 minutes before homoenisation in ethanol the GABA level rose 
to 2.39 pmoles /g wet weight. Minard and Mishawer (1964) have 
reported that after the first two minutes the post -mortem rise in 
GABA levels slows down considerably. They suggested, on the basis 
of their glutamate and GABA data, that the immediate post -mortem 
increase was due to continued conversion of a small highly active 
"pool" of glutamate to GABA. 
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Qualitatively similar post -mortem changes in cerebral GABA 
levels have been observed in human studies. A comparison of amino 
acids in autopsy tissue (Perry, Berry, Hansen, Diamond and Mok, 
and. 
1971) whioh amino acids in biopsy tissue (Perry, Hansen, Berry, 
Mok, and Lesk, 1971) demonstrated significant post -mortem increases 
in many amino acids including glutamate, glycine and GABA. It 
is interesting that the GABA and glutamate levels (0.42 and 5.96 
jzmoles /g wet weight cortex) reported for the biopsy samples fall 
well below the range of values collected together by Mcllwain 
(1971) from a variety of studies in different species. This may 
be significant in that only a few seconds elapsed between removal 
of the biopsy sample and immersion in liquid nitrogen. 
It can be seen therefore that measurement of GABA in cerebral 
tissue is not a straightforward operation. When looking for diff- 
erences between control and treatment animals one must standardise 
the conditions of sampling. In this particular project I was inter- 
ested in isolating and analysing a small amount of cortical tissue 
(20 -30 mg). For this reason I did not consider freezing the decap- 
itated head before removing the samples of cortical tissue since 
deep- freezing a head in liquid nitrogen makes subsequent isolation 
and removal of a particular brain area a difficult operation. How- 
ever before carrying out more extensive follow -up studies on amino 
acids in "epileptic" tissue I shall require to develop techniques 
which will allow the accurate sampling of brain tissue under condi- 
tions which preclude or minimise continuing metabolism in the tissue. 
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Studies on epileptogenic tissue 
In this study three rats with 11 day -old cobalt- induced 
epileptogenic lesions were sacrificed and analyses were made on 
the levels of glutamate, glutamine and threonine, GABA and glycine 
in both the primary and secondary foci. The fact that only three 
such rats were examined, and the fact that two of these rats 
Showed amino acid changes very different from those observed in 
the third rat (without any electro- corticographic evidence of a 
marked difference between the electrical disturbances produced 
by the lesions) make it very difficult to draw any firm conclusion 
about the effect of the cobalt lesion. Nevertheless the similar- 
ity of the pattern of amino acid changes seen in rats 2 and 6 on 
the side contralateral to the lesion (an increase in glutamine and 
glycine levels, a decrease in glutamate and GABA levels) suggest 
that the generation of an epileptic focus in neural tissue may 
involve changes in amino acid metabolism. 
It was perhaps rather surprising to find no significant 
chan =es at the site of the primary focus (except for a raised 
glutamine level inrat 4), particularly since associated with the 
cobalt lesion there is marked gliosis and capillary proliferation 
in the adjacent tissue (McQueen - unpublished results). However 
it should be noted that at the 11 day stage epileptiform dis- 
charges from the primary site were less, both in number and ampli- 
tude, than those from the contralateral "mirror" site. If the 
results observed here in two of the "cobalt" rats (rats 2 and b) 
were to be repeated in further experiments, one might speculate 
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that the establishment of a secondary epileptic focus was associated 
with alterations in either the synthesis, storage or utilisation 
of certain amino acids. 
With reference to changes in the tissue levels of glutamate 
and GABA it should be noted that glutamate and GAGA are formed 
principally by operation of the "GABA shunt" in which x -keto- 
glutarate ) glutamate --H> GABA > succinic semialdehyde 
succinate --' citric acid cycle. It has been estimated (Balázs, 
Machiyama, Hammond, Julian and Richter, 1970) that 8% of the 
general oxidative metabolism of neural tissue may be by way of 
the "GABA shunt". One can radily see therefore that quite apart 
from any postulated role as neurotransmitters, GABA and glutamate 
are very important metabolic intermediates. Any alterations in 
the levels of these compounds in tissue therefore may not necessarily 
reflect increased or decreased transmitter release but rather a 
general alteration in tissue metabolism. 
In fact however, while one may speculate whether decreased 
GABA and glutamate levels mean decreased availability of these 
compounds, or increased turnover with a resetting of the tissue 
stores at a lower level; for further interpretation of the meaning 
of the absolute tissue levels one requires some idea of the 
dynamics of the system. For this reason in further studies on 
epileptogenic tissue it would seem essential to carry out precursor 
labelling experiments which might give a clue as to the rate of 
turnover of these amino acids. The most one can say at present 
is that the observed changes in GABA and glutamate levels in 
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epileptogenic tissue might be related to the neurotransmitter 
roles postulated for those compounds (review; Krnjevic, 1970; 
Johnson, 1972). 
It is tempting to link the increase of glutamine levels in 
the region of the secondary epileptic focus in two of the "cobalt" 
rats with the concomitant decrease in glutamate levels. This 
link seems particularly attractive in view of the report by Berl 
and Clarke(1969) that uptake of glutamate from the intraneuronal 
space is associated with glutamine synthesis. Watkins (1972) 
has hypothesised that the enzyme glutamine synthetase may be 
located principally in glial cells and post -synaptic neuronal 
elements. A very naive and completely speculative explanation 
of the increased glutamine levels and decreased glutamate levels 
in the secondary epileptic focus would be that there is an 
increased release of the excitatory transmitter glutamate, associ- 
ated with increased uptake and glutamine synthesis by the post - 
synaptic elements. In the present state of knowledge however it 
would be difficult even to test such a hypothesis. 
The increase in the glycine level in the secondary focus of 
two of the "cobalt' rats might be indicitative of increased 
protein synthesis at this site since it has been shown that glycine 
levels in the brain are highest while the brain is actively 
maturing (Agrawal, Davis and Himwich, 1966; Bayer and McMurray, 
1967; Levi and Morisi, 1971). However an investigation of the 
rates of protein synthesis in the primary and secondary epileptic 
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foci of these rats found no difference between control and 
"cobalt" rats (Dewar, Dow and McQueen, 1972) . 
Since the amino acid studies reported here were envisaged 
there have been two other reports on amino acid levels in epilep- 
togenic cortical tissue. 
Van Gelder, Sherwin and Rasmussen (1972) have reported amino 
acid analyses on samples of "focal epileptic" tissue from the 
frontal or temporal lobes of cases of human focal epilepsy. The 
region which demonstrated most epileptiform activity was sampled, 
as well as, whenever possible, an area of cortex far -removed from 
the focal area. They reported that there was a generalised 
decrease in the levels of GABA and aspartate throughout the 
cerebral cortex of these patients. It is not clear however how 
they arrive at this conclusion since the only control human data 
they quote (Perry et al., 1971) showed very much lower GABA and 
aspartate levels in biopsy samples of cerebral cortex. The 
results of Van Gelder et al. (1972) do suggest that "focal 
epileptic" tissue hasaa lower content of glutamic acid and taurine 
and a very much higher content of glycine than "control cortical" 
tissue from the same patient. The authors suggested that their 
findings indicated an uncoupling between glucose oxidation and 
anino acid metabolism in epileptogenic tissue. 
The studies reported by Koyama (1971) are more comparable to 
our own in that he examined amino acid changes in cortex 24 hours 
after the application of cobalt powder to exposed pre -cruciate 
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cortex of the cat. At that time these cats with cobalt-induced 
epileptogenic lesions displayed clonic convulsions affecting 
all four extremities. In the tissue immediately caudal to the 
primary lesion site Koyama observed a 79% decrease in the GABA 
level, a 54% decrease in the glutamate level, and a 45% increase 
in the glycine level. The changes observed in the corresponding 
area of the contralateral cortex were a 56% decrease in the GABA 
level, a 10% decrease in the glutamate level and a 15% increase 
in the glycine level. Glutamine, threonine and aspartate levels 
were unchanged in both areas of cortex. In a qualitative sense 
these changes (apart from the lack of change in glutamine levels) 
resemble the changes seen in the secondary epileptic foci of rats 
2 and 6 of the present study. 
Several factors may have contributed to the rather different 
results of my own and Loyama's study. In the first place a 
different species of animal was used, and in the second place a 
different method of cobalt application was used to produce the 
epilepto;enic lesions. The lesions and their effects may there- 
fore have been radically different in the two studies. For 
instance in the present study one never saw the clonic convulsions 
affecting all four limbs which have been reported by Koyama. In 
the rats the characteristic seizure pattern was intermittent 
forelimb and whisker twitching. A further important factor which 
varied in the two .studies was the time after cobalt treatment at 
which the amino acid analyses were carried out; it being 24 hours 
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in the case of the cats and 11 days in the case of the rats. 
For all these reasons it would perhaps be naive to expect to find 
identical amino acid chan'es in the two studies. 
The important point to emerge from these three studies 
(Ko,rama, 1971; Van Gelder et al., 1972; present study, 1972) 
is that despite the differences in the form of epilepsy studied 
there was evidence that the levels of certain amino acids were 
altered by epileptic processes. 
The development and further refinement of the present 
analytical technique for quantitative micro -determination of the 
amino acids involved in these processes may signal a new phase in 
the elucidation of the basic biochemical mechanismswhich are 
concerned in the development of epilepsy. 
- 286 - 
SUMMARY 
A new isotope dilution assay technique was developed for the 
micro -determination of GABA and associated amino acids in sub - 
milligram amounts of brain tissue. The method depends on the 
preparation, separation and measurement of the dansyl derivatives 
of the free amino acids in a perchlorate extract of brain tissue. 
Values for GABA, glutamate, glutamine /threonine and glycine 
levels in rat cortex obtained by use of this technique were 
highly reproducible and in good agreement with previously published 
values. 
These amino acids were studied in tissue samples from the 
primary and secondary epileptic foci of rats with an 11 day -old 
cobalt- induced epileptogenic lesion in the right frontal cortex. 
There was evidence that the levels of GABA and glutamate were 
lowered, and the levels of glycine and glutamine /threonine raised, 
in the region of the secondary epileptic "mirror" focus. 
It was concluded that epileptic processes may be associated 
with disorders in amino acid metabolism. 
The general problems of amino acid studies in the brain are 
discussed as is the significance of the findings inthe rats with 
the cobalt -induced epileptogenic lesions. 
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GENERAL :DISCUSSION 
This short closing discussion will attempt to consider the 
findings of the three investigations against the general back- 
ground of epilepsy and indicate further lines of research arising 
from them. 
The important and surprising finding of the folate studies 
was that large oral doses of folic acid do not have any effect 
on the level of folate activity in the c.s.f. If, as seems 
reasonable, this can be taken as evidence for unaltered levels 
of folate activity in the central nervous system after oral folic 
acid, then Reynold's hypothesised link (Reynold's et al., 1966) 
between the folate- depleting effects of certain drugs (diphenyl- 
hydantoin, phenobarbitone and primidone) and their anticonvulsant 
action must uz :uferiously challenged. A major argument in favour 
of this link was that folic acid replacement therapy in patients 
on chronic anticonvulsant treatment occasionally caused an 
increase in the severity and frequency of fits. The present 
findings argue against this being a direct "convulsant" effect 
of folic acid but rather support the contention that this effect 
results from more efficient metabolism of the anticonvulsant drug 
leading to subtherapeutic plasma.concentrations of the anti - 
convulsant drug. 
The other major argument in Reynold's hypothesis was that 
proloned treatment of epileptics with diphenylhydantoin, pheno- 
barbitone or primidone can lead to an effective folate deficiency 
- 288 - 
state. This action however, has never been satisfactorily 
related to the efficacy of the drug treatment and it seems 
likely that it is merely a side-effect of prolonged treatment 
with these particular anticonvulsant agents. 
Undoubtedly, further research on the role of folic acid 
derivatives in cerebral function, both normal and abnormal, should 
be directed towards examining basic problems namely: which folic 
acid derivatives are present in brain and c.s.f.? is the folate 
activity in the c.s.f. derived from brain or plasma? which folic 
acid derivatives are transported across membranes, both at the 
tissue and cellular levels? and finally what are the effects of 
anticonvulsant drugs on the metabolism and transport of folic 
acid derivatives? 
The potassium studies revealed that thiopentone, pentobarbi- 
tone and diazepam may reduce the c.s.f. potassium fluxes. This 
was interpreted as being due to an action of these drugs to 
decrease potassium exchange across the neuronal membrane. With 
diphenylhydantoin there was evidence for a slightly decreased 
potassium influx into the c.s.f. while paraldehyde increased 
c.s.f. potassium fluxes. There was therefore, no uniformity of 
action on potassium transport among these various agents, all of 
which have been used in the treatment of status epilepticus. 
This fact however does not disprove the hypothesis that an 
abnormally raised potassium level in the extracellular fluid is 
one of the factors contributing to epileptic discharges in some 
cases. 
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Direct testing of this hypothesis is made very difficult 
by virtue of the fact that sampling of brain extracellular fluid 
is impossible because of the smallness (several hundred angstroms 
across) of the intercellular spaces. Also in view of the small- 
ness of the contribution which extracellular potassium makes to 
total brain potassium it is difficult to derive much useful 
information from total brain potassium levels. The most promising 
approach to this problem would seem to be to use glial membrane 
potential as a measure of extracellular potassium (review - 
Orkand, 1969). It is possible that this technique might allow 
direct analysis of the effect of anticonvulsant drugs on epileptic 
phenomena (w.r.t. extracellular potassium) at the neuronal level. 
Of the three investigations perhaps the one with the greatest 
potential for application to the study of epilepsy in man is that 
concerning the role of amino acids. Preliminary results from 
the rats with the induced epileptic foci suggest that GABA, 
glutamate, glutamine and glycine may all be involved in epileptic 
processes. Similar investigations could be readily carried out 
on biopsy samples of epileptogenic tissue from patients undergoing 
operations for surgical removal of the focus. 
However, for interpretation of simple amino acid levels in 
tissue it will be necessary to carry out further detailed studies 
in animals at the cellular level. Such studies should be directed 
towards elucidating the turnover of the amino acids, and investi- 
gating the possibility of separate and distinct pools of amino 
acids available for release as transmitter. 
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These investigations would be particularly relevant in view 
of the interest which is being shown in the use, as anticonvul- 
sants, of drugs which specifically affect GAdA metabolism. 
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Summary The administration of folic acid, which has been reported to cause 
alterations in mood and seizure threshold, was found 
to be without effect on the concentration of homo- 
vanillic acid, 5- hydroxyindol- 3- ylacetic acid, and even 
the folate activity in the cerebrospinal fluid of dogs. 
The findings are against the central toxic actions which 
have been proposed for folic acid. 
INTRODUCTION 
UNCONTROLLED trials reporting that folic acid 
produces " mental changes " in volunteers 1 and that 
when given concurrently with vitamin B.2 it alleviates 
mental retardation in epileptic patients on drug 
therapy ' have received much criticism.' -' There 
have also been several trials,4,e0-10 some of them 
carefully controlled, which have shown that pharma- 
cological doses of folic acid do not appear to influence 
mood or behaviour in epileptic patients or volunteers. 
In spite of this, there is some recent support for the 
thesis 11 that folic -acid metabolism influences mental 
function, in that certain metabolic errors causing low 
folate concentration are associated with mental 
defect.16,16 It is also claimed that " there is a signi- 
ficant association between a variety of psychiatric 
diagnoses in epileptic patients and disturbed folate 
metabolism " 14 and that " there was a definite, 
though diagnostically indeterminate, relationship be- 
tween low serum folate and mental illness in epileptic 
patients ".' 
Pteridine derivatives are the coenzymes for tyrosine 
hydroxylase 10 and tryptophan hydroxylase,18 the 
rate -limiting steps in the synthesis of dopamine and 
of 5- hydroxytryptamine (5- H.T.), and alterations in 
these biogenic amines in brain have been found to be 
associated with mood changes. It has been suggested 1 
that these now well- documented findings provide a 
4 
rational basis for the influence of the administration 
of folic acid on mood and behaviour. While it may be 
naive to consider that folate activity as measured by 
bacteriological assay may indicate the availability of 
pteridine coenzyme in a suitably reduced form, it 
nevertheless seemed worth while to examine more 
closely the relationship of these pathways in brain 
in the in -vivo situation. 
METHODS 
Cerebrospinal fluid (c.s.F.) was withdrawn from the 
lateral ventricle and cisterna magna of beagle dogs 17 
twice weekly at approximately 10 A.M. These samples 
were assayed for folate," 5- hydroxyindol- 3- ylacetic acid 
(5- H.I.A.A.) (the acid metabolite of 5- H.T.), and homo- 
vanillic acid (H.v.A.) (the main acid metabolite of dop- 
amine)." Samples of plasma which were obtained con- 
currently had portions subjected to ultrafiltration,90 and 
folate activity was estimated Ie in both whole plasma and 
ultrafiltrate of plasma. Once a control baseline had been 
established for each dog, 2.5 mg. folic acid was adminis- 
tered orally at 9 A.M. and 5 F.M. each day throughout the 
next month, and further samples were taken throughout 
the treatment period. (This dose on a weight- for -weight 
basis is equivalent to a daily intake in man of 30 mg., 
twice the normal pharmacological dose used in most 
studies.) The dogs were fed a constant amount of a 
batch -prepared diet for three weeks prior to the start of 
the control period and throughout the entire experiment. 
RESULTS 
It has been demonstrated that there is a gradient 
TABLE I- HOMOVANILLIC ACID (H.V.A.) AND 5-HYDRO%YINDOLYL- 
ACETIC ACID (5- H.I.A.A.) BEFORE AND AFTER CHRONIC FOLIC -ACID 
ADMINISTRATION 
Sample Dog 
5- H.I.A.A. (ng. /mI.) H.V.A. (ng. /Inl.) 
Before After Before After 
C.S.F. from 
lateral 
ventricle 1 297±53 (9) 250±45 (7) 1768±215 (10) 1977±542 (7) 
2 297±43 (6) 159±111 (6) 1137±446 (7) 1019±477 (6) 
3 131 ±47 (5) 137 ±47 (5) t279±223 (6) 1211 ±670 (5) 
C.I.F. from 
cisterna 
magna 1 41±7 (7) 35±6 (5) 114±33 (9) 103±41 (6) 
2 19±6 (5) 2015 (4) 36±8 (6) 39±18 (3) 
3 37±8 (4) 34±25 (2) 99±35 (5) 114±48 (2) 
Mean ±s andard deviation (number of samples in parentheses). 
t Abnormally low initial values due to contamination with blood, 
contro values taken three months after stopping folic -acid adminis- 
tration 1501±I009 (16). 
5 
in the concentrations of the acid metabolites, 5- H.1.A.A. 
and H.V.A., from lateral ventricle to cisterna magna," 
and that this is due to a localised transport system 
for the removal of the metabolites in the region of the 
fourth ventricle." The results (table 1) confirm the 
presence of this gradient. The administration of folic 
acid did not alter the concentration of 5- H.1.A.A. or 
H.V.A. in C.S.F. from either the lateral ventricle or 
cisterna magna. 
The folate activity of the C.S.F. from lateral ventricle 
and cisterna magna did not differ significantly (paired 
t test on 38 control values). The mean c.s.F: folate 
is shown in table ix together with the corresponding 
concentrations found in whole plasma and plasma 
ultrafiltrate. Control samples showed that, as in 
man,"-a' the folate activity was considerably higher 
in C.S.F. than in plasma. However, in contrast to pre- 
vious studies,'4. 86, 97 there was no significant correlation 
between plasma -folate activity and the comparable 
C.S.F. values, thus confirming the findings of a recent 
extensive study of 491 paired samples in man.S6 It 
would appear that, as in man," much of the folate 
activity in dog plasma is protein -bound, since in the 
control period the plasma ultrafiltrate has only 
43 ±3% of the folate activity of whole plasma. There 
was no significant correlation between folate activity 
in paired samples of c.s.F. and plasma ultrafiltrate. 
Following the administration of folic acid, the folate 
activity in whole plasma showed a tenfold rise. The 
proportion of plasma -folate activity which was filter- 
able decreased to 21 ±2%; thus there was only a 
TABLE II- FOLATE ACTIVITY BEFORE AND AFTER CHRONIC FOLIC -ACID 
ADMINISTRATION 
Sample Dog 
Folate (ng. /m1.)" Signifi- 
tante 
(t test) Before After 
c.s.F. 1 20 ±4 (11) 22 ±2 (8) .. 
2 14±5 (9) 17±5 (8) .. 
3 18 ±4 (7) 29 ±4 (7) .. 
Plasma ultrafiltrate .. 1 3.7 ±0.8 (8) 16 ±8 (3) <0.01 
2 3.4 ±0.8 (6) 18 ±5 (6) <0.001 
3 3.3 ±0.3 (7) 14 ±7 (5) <0.01 
Plasma .. .. .. 1 9.3 ±4.1 (8) 83 ±33 (3) <0.001 
2 8.1 ±4.8(6) 91 ±27(6) <0.001 
3 7.1 ±2.4 (7) 62 ±17 (5) <0.001 
Mean ± standard deviation (number of samp es in parentheses). 
0 
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Folate activity in plasma ultrafiltrate (interrupted Line) and 
C.S.F. (continuous line) before and after folic -acid admini- 
stration. 
fivefold increase in folate activity in plasma ultra - 
filtrate. These changes were significant in all the dogs 
(table n). Despite the considerable increases in folate 
activity in plasma and its ultrafiltrate, there was only 
a small increase in C.S.F. folate, and in view of the slight 
positive regression of folate in C.S.F. during the control 
period (see accompanying figure), no change in C.S.F. 
folate activity can be attributed to the folic -acid 
supplements. 
DISCUSSION 
Alterations in cerebral metabolism of the biogenic 
amines are reflected in the concentrations of their 
acid metabolites in c.s.F." It has been said 80 that 
administration of folic acid caused a significant lower- 
ing of H.V.A. levels which related to raised serum - 
folate concentrations. This is at variance with our 
results and those from a trial of patients with senile 
dementia," where in both instances folic -acid adminis- 
tration caused no alterations in the concentrations of 
H.V.A. or 5- H.I.A.A. in C.S.F. Indeed, it seems that oral 
administration of folic acid, although increasing folate 
activity markedly in plasma and plasma ultrafiltrate, 
does not do so in C.S.F., and may therefore not be 
expected to alter folate activity in brain. The studies 
confirm the lack of effect of folic -acid administration 
on C.S.F. folate activity found recently in epileptics 
on anticonvulsant therapy " and in patients with 
senile dementia. 27 
The lack of increase of folate activity in C.S.F. may 
well be explained by the finding that an oral dose of 
7 
folic acid does not appear to cause a rise of 5- methyl- 
tetrahydrofolate in plasma," and this is apparently 
one of the forms of folate that is rapidly transferred 
to c.s.F. ea Indeed, it has been suggested 86 on the basis 
of in -vitro enzyme studies that a high plasma con- 
centration of folic acid in its fully oxidised form will 
cause a pronounced inhibition of dihydrofolate reduct- 
ase, thus impairing the conversion of dihydrofolate to 
tetrahydrofolate (the other form of folate rapidly 
transferred to c.s.F.ss) and thus possibly even reducing 
the amount of methyltetrahydrofolate present in 
plasma. This suggestion agrees well with our present 
data and with studies in man of the absorption and 
metabolism of different forms of radioactively labelled 
folate as indicated by the correlations found between 
radioactivity and assay of folate activity with both 
Lactobacillus casei and Streptococcus fcecalis.e9,85 
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Effect of drugs used in status-epilepticus on the potassium fluxes of cerebrospinal fluid 
in the conscious dog 
' J. HALLIDAY* and A. T. B. MoIR 
rM.R.C. Brain Metabolism Unit, Pharmacology Department, Edinburgh University, 
' 1 George Square, Edinburgh, EH8 9JZ 
Zuckerman & Glazer (1968) demonstrated that localized high concentrations of 
potassium in the region of the inferior horn of the lateral ventricle could cause con- .: 
vuisions originating in the hippocampal system. 
The potassium concentration in the cerebrospinal fluid (C.S.F.) is maintained within 
narrow limits independent of large alterations in plasma concentrátions (Kemeny, 
Boldizsar & Pethes, 1961). The mechanisms whereby this is achieved have been in- 
vestigated and characterized by ventriculo- cisternal perfusion techniques (Heisey, 
Held & Pappenheimer, 1962; Cserr, 1965; Katzman, Graziani & Ginsberg, 1968; 
Bradbury & Stulcova, 1970). In the experiments described here, drugs useful in the 
treatment of status epilepticus were investigated for their effect on the potassium fluxes 
of C.S. F. 
Ventriculo- cisternal perfusions were performed in adult beagle dogs with chronically 
implanted guide tubes, using inulin and 42K contained in a sterile salt solution which 
was comparable to dog C.S.F. The perfusion fluid was pumped into one lateral ventricle 
and out of the cisterna magna at a rate of 0.3 ml /min using two equally calibrated 
modules of a multichannel pump. The experiments were carried out while the animals 
were conscious and free moving, and pressure alteration within the cerebrospinal 
fluid system still appeared to be governed by normal physiological variables such as 
head movement, respiration and blood pressure. The effluent from the perfusion 
system was collected by means of a fraction collector and the samples were sub - 
sequently analysed for inulin, 42K and total potassium. This data, in conjunction 
with the results of comparable analyses on the inflowing fluid, allowed calculation of 
bulk flow of C.S.F. from the system and the appropriately corrected rate constants 
(mcq /min) governing the influx and efflux of C.S.F. potassium. All these parameters 
' could thus be assessed on a continuous basis throughout the experiments. 
. When a stable base line of control values had been established after a period of at 
least 90 min, the drug under study was administered by either intravenous or intra- 
muscular injection. Of the drugs investigated, the barbiturate anaesthetics, sodium 
thiopentone and sodium pentobarbitone, when given in doses sufficient to achieve 
light anaesthesia, had the most striking effects, producing highly significant decreases 
of up to 40% in both potassium rate constants. Phenytoin and diazepam both pro- 
duced significant decreases of between 6-14% in efflux and influx rates of C.S.F.' 
potassium in subanaesthetic doses while paraldehyde, even when given in sufficiently 
high doses to produce light anaesthesia, had no significant effect on potassium fluxes. 
' These preliminary results would seem to indicate that while the potassium fluxes of 
British Pharmacological Society, 15th -17th September 449P 
C.S.F. can be reduced by drugs with anaesthetic or anticonvulsant action, these states ,'' 
can be induced by paraldehyde without any significant alteration in C.S.F. potassium. 
3.Ii. is in receipt of a grant from the MacRobert Trust. 
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